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CHAPTER 1
BIOPHYSICAL METHODS FOR STUDYING PROTEIN-MEDIATED
INTERACTIONS

Understanding biological processes in living organisms ultimately means
understanding the atomic-level molecular recognition events between the primary
biomolecules—proteins, nucleic acids, carbohydrates and lipids—that take place
at the cellular level. To these participants can also be added the endogenous
array of organic metabolites, inorganic salts and metals, and—last but certainly
not least—water, which not only serves as universal host for all the binding
interactions among all the aforementioned, but can be an explicit participant as
well. The presence of these naturally occurring molecular components, in both
static and dynamic roles, results in all the structures and process we associate
with cellular function.
Although all the biomolecular classes are involved in generating and
maintaining higher-level molecular organization on the cellular level, the
formation of macromolecular complexes is predominately the responsibility of
proteins. To elucidate the function of this diverse group of biomolecules, it is of
central importance to reveal their structure. Empirically solving the threedimensional structure of a protein represents a key step in the determination of
its structure-activity relationship (SAR). X-ray crystallography and nuclear
magnetic resonance (NMR) spectroscopy are the methods of choice to
accomplish this. To these can be added other methods that aid in characterizing
protein structures, circular dichroism (CD) and mass spectrometry (MS). In
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combination, all these techniques contribute to assembling a more complete
picture of a protein structure, as well as the protein-drug, protein-inhibitor, and
protein-protein complexes that it can engage in. Computer-aided visualization
and manipulation (e.g., molecular modeling and dynamics), while not strictly
empirical techniques, are often invaluable additions to the study of protein
structure and behavior.
Despite the enormous amount of knowledge gained from the use of these
experimental approaches regarding the structure of a protein (either alone or in a
complex), they do not ensure accurate prediction of its function and, by
extension, its biological activity. The first step to functional analysis is in fact the
understanding of a protein's binding behavior, since the binding of a protein to
one or more ligands (broadly defined from small metals and organic molecules all
the way to other large proteins) is what will immediately or eventually result in a
'biological activity'. The first rigorous step towards this understanding is to then
examine the biomolecular associations themselves, and this at the level of
thermodynamic binding parameters. Thermodynamics provides information on
the forces that drive biomolecular interactions, providing a detailed energetic
foundation to the analysis of the basic behavior of a protein.
In brief, then, a complete understanding of a protein's cellular role means
that both structural and thermodynamic properties need to be characterized. In
this dissertation, I present research based on both approaches, directed towards
two different proteins: the peptide-binding PDZ domains of PSD-95, and ironbinding frataxin. Specifically, the two primary methods utilized in the in vitro
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characterization of the protein complexes presented here are isothermal titration
calorimetry (ITC) and X-ray crystallography. What follows is a brief overview of
the techniques themselves and their theoretical foundations, beginning first with
thermodynamic binding parameters and their measurements by ITC, followed by
structural analysis as determined by X-ray crystallography.
1.1 Isothermal Titration Calorimetry (ITC) as a Method for Measuring
Thermodynamic Parameters.
1.1.1 Basic thermodynamic parameters. There are four basic thermodynamic
parameters that govern all biomolecular interactions; these are (1) change in
Gibbs free energy (ΔG); (2) change in enthalpy (ΔH); change in entropy (ΔS);
and (4) change in heat capacity (ΔCp).
1.1.1.1 Gibbs free energy change (ΔG). By definition, the Gibbs free energy of
a system is the enthalpy of the system (all molecular participants, including
solvents) minus the product of the temperature times the entropy of the system
(1). Therefore, the change in free energy that occurs during a chemical process
(such as a binding interaction or an actual transformation or reaction) is equal to
the difference in enthalpy change and the change in entropy at the given
temperature (2).

G = H − TS

(1)

ΔG = ΔH − TΔS

(2)

€
The change in free energy in a chemical process is also related to the
€
association or dissociation equilibrium constants through equation (3).
ΔG = −RT lnK a = RT lnK d

€

(3)
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Thus, by combining equations 2 and 3, it is clear that there is a direct correlation
between the key thermodynamic parameters of enthalpy and entropy, and the
affinity of a binding interaction as represented by the equilibrium constant.
1.1.1.2 Enthalpy change (ΔH). Enthalpy change of a chemical process can be
assessed in a single ITC experiment. By definition, change in enthalpy between
products and reactants for a chemical transformation represents heat released or
absorbed during the reaction. Exothermic reactions, in which the heat of the
system is emitted, have negative ΔH whereas the reactions in which heat is
absorbed (i.e. endothermic) have a positive ΔH. Regarding the relations in
equation (2), a negative value of ΔH is favorable for the interaction and a positive
ΔH is unfavorable. In terms of molecular interactions, changes in enthalpy are
most closely linked with actual atomic-level interactions, such as those based on
hydrogen bonds, electrostatic (charged, ionic, or dipole) forces, or Van der Waals
forces. To a first approximation, the changes in enthalpy are often attributed to
the making and breaking of specific interactions, between the binding molecules
themselves as well as with (and between) solvent (i.e., buffered water, in both
cellular and ITC environments).
1.1.1.3 Entropy change (ΔS). The change in entropy between the products and
the reactants for a chemical process is defined as a change of degree of freedom
at a molecular level. Theoretically, this can be expressed as the difference in the
number of accessible energetic states, before and after a binding interaction.
Specifically, this is associated with several processes, such as the net increase
or decrease in conformational mobility, as dictated by the changes in rotatable
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bonds. Also, the restriction or immobilization (or release) or water molecules is
also a major biomolecular process that is linked to changes in entropy.
Spontaneous changes occur with an increase in entropy and negative values of
ΔS indicate decrease in the number of accessible states during the
transformation. In regards to the free energy change given in equation (2), a
positive ΔS is favorable for the association and negative ΔS has an opposite
effect.
1.1.1.4 Heat capacity change (ΔCp). The net change in heat capacity between
chemical transformation reaction products and reactants, at constant pressure,
can be calculated using equations (4) and (5).
ΔC p =

d(ΔH)
dT

ΔC p = T
€

d(ΔS)
dT

(4)
(5)

In many regards ΔCp is considered a subtler and more complex parameter than
€ and entropy, since it is not as easy to assign to it specific molecular
enthalpy

processes. But it is considered by some even more fundamental than the other
parameters, since it places limits on what the values of enthalpy and entropy can
be at a given temperature, as equations 3 and 4 demonstrate. Nonetheless,
there are processes, such as the extent of burial of polar or nonpolar surface
area when a ligand binds a protein, that have been correlated to the sign and
magnitude of ΔCp.
1.1.2 ITC as a biophysical technique.
1.1.2.1 General aspects of ITC. Calorimetry, derived from the Latin word calor
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(heat) and the Greek word metria (a measure), is, as the combination implies, a
method that quantitatively determines the heat absorbed or released during
physicochemical transformations. Calorimetric methods have proven very useful
in characterizing biomolecular interactions. However, only recently with technical
improvements in instrumentation that have given rise to several highly sensitive
titration calorimeters that are increasingly accessible to researchers, has the
method became highly valued and widely used. The increased popularity of ITC
as a tool for studying biomolecular interactions in vitro has been addressed in
many review articles lately [1-9]. In order to summarize the wide landscape of
applications of the method, Ladbury and coworkers have published yearly
surveys on calorimetry from 2002-2005 [10-13].
1.1.2.2 Advantages of ITC. Compared to other methods applied in
thermodynamic studies of biomolecular systems, the ITC technique offers some
important and unique advantages. The particular aspects involving the interaction
of proteins with peptides and metal ions is addressed in Chapter 2 of this
dissertation, and the following is a broader survey of ITC as pertaining to five
basic attributes of ITC.
1. ITC is the only technique that directly provides the thermodynamic binding
constants. van't Hoff analysis of temperature-dependent affinity values from
other assay methods has been used to provide ΔH and ΔS parameters (see
1.1.2.4), but there is concern that this does not yield optimal or valid results.
In addition, ITC provides those values in the course of a single experiment.
2. ITC relies on the 'universal' signal of heat transfer, which is not restricted to
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molecular class or type, and consequently can be used to study almost any
type of biomolecular binding process. A detailed list of all the possible
applications is given on the official MicroCal website [14]. Further, reliance
on a heat signal avoids the need to prepare chemically-modified versions of
one or more participants in the process (e.g., as with fluorescently-labeled
ligands). All the reagents are used in their ‘native’ form.
3. Experimental conditions can be easily varied without adversely affecting the
binding analysis. Typical perturbations of interest for a particular biological
interaction include, but are not limited to, component concentration;
temperature, ionic strength, pH and buffer composition. As part of a
systematic and thorough study of a particular protein-ligand system,
conditions like the nature and concentration of salts used can be altered as
well as mutational changes in the protein itself (site-specific or group
mutagenesis). [2, 15]
4. ITC is a true solution method, and unaffected by artifacts that can arise in
other assays that involve chemical modification (e.g., affects of fluorescent
spectral labels) or when heterogeneous surface immobilization (e.g., as with
surface plasmon resonance (SPR), such as Biacore) of interacting species
is required. This is an important property, since attachment of different
reporting groups can alter the binding properties of the system. In addition,
unlike the ELISA (enzyme-linked immunosorbent assay) and related
methods, the equilibrium state of the interaction is not perturbed since it is
not necessary to separate bound from free species.
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5. Assuming the appropriate fitting model is used, ITC can also generate the
binding stoichiometry (n, the number of equivalents of ligand per protein) in
a single experiment. This is also a particularly important factor in this
dissertation research, as the issue of multivalency is central to the reported
PDZ domain and frataxin studies. The reproducibility of ITC measurements
regarding molar binding ratios (i.e., n) is claimed to be within 1% [16].
1.1.2.3 Limitations of ITC. No experimental method is perfect, and like any
other analytical technique, ITC has its own set of disadvantages. But as noted
below in the four challenges that can be encountered, most of them can be
overcome in one way or another.
1. A large sample requirement still remains the principal limitation of the ITC
technique. The actual differences are highly case- and volume-dependent,
but ITC may require, for example, hundreds of micrograms of a protein,
whereas a fluorescence method or SPR might consume material in the
nanogram range [2]. Thus, as currently practiced ITC requires upwards of
102-103 more material than the most sensitive methods currently available.
It is possible, however, to recover the protein sample used, since ITC is a
non-destructive method. Also, the next generation of microcalorimeter from
MicroCal is reported to use considerable less material (only 200 µL of
protein sample) than the current series.
2. A primary requirement for all ITC experiments is that there should be a
measurable heat signal. Although noncovalent macromolecular interactions
are associated with intrinsically small heat changes (typically 5 to 10
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kcal/mol), experimental conditions can be manipulated in order to obtain
valid data. However, it is occasionally possible to encounter an entropicallydriven high affinity interaction with an insignificant ΔH contribution [17]. For
example, a case where ΔG = -8 kcal/mol can be due to TΔS ≈ +8 kcal/mol,
and ΔH ≈ 0 kcal/mol (see equation 2). In such a case, it is possible to
perform the same experiment using a different buffer system with a higher
heat of ionization, or at a higher temperature (if stability of macromolecule is
not jeopardized). Such changes can often move the enthalpy change further
from zero.
3. ITC experiences a relatively narrow range for the direct determination of
binding affinity (Kd), from 10 mM to 0.1 µM. However, a common
workaround solution is to conduct a competitive titration experiment with a
known binding agent of differing affinity. [1, 18, 19]
4. The buffer system might also be a restriction for some proteins that have a
requirement for a specific buffer. Protonation and deprotonation reactions
result in change of the overall enthalpy, and therefore corrections need to
be made [2, 20]. This requires that ITC titrations be performed in buffers
with different ionization enthalpies (at least three for reliable data analysis),
and if there is any change in the enthalpy values due to proton exchange,
these should be adjusted. Otherwise, the observed ΔH values may not be
interpretable in terms of only the protein-ligand interactions involved.
1.1.2.4 Indirect estimation of ΔH without ITC: the van’t Hoff analysis. In the
van’t Hoff method, temperature dependence of the equilibrium constant is used
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for calculations of ΔH and ΔS; lnKa is plotted against 1/T, multiplied by (-R) and
used to determine ΔH. This method is potentially valuable since it does not
require a calorimeter, and can rely upon much less material, and that of lower
purity. This latter aspect alone makes the method attractive for analysis of
membrane proteins, such as receptors, which are difficult to access in large
quantities in pure form [21]. However, there are significant differences amongst
authors as to the accuracy of this approach. There are three major points that
van’t Hoff omits: (1) the assumption is made that ΔH is constant over the entire
experimental temperature range; (2) enthalpy-entropy compensation is not taken
into account; and (3) the thermodynamic parameters cannot be determined
independently. The matter is not fully resolved. Based on the specific
experimental setup, some researchers obtained good agreement in enthalpy
values determined by by both ITC and van’t Hoff analysis [22, 23], while others
that demonstrated significant differences [16, 24].
1.1.3

ITC

instrumentation.

Not

long

ago,

investigators

conducting

biocalorimetric analyses did so on custom-made instrumentation specifically built
for the purpose in their respective laboratories. Few calorimeters were
commercially available with the required sensitivity. The breakthrough period in
the

field

came

with

the

commercial

availability

of

newly

developed

microcalorimeters (both ITC and DSC (differential scanning calorimetry)) in the
beginning of the 1980s. Today, two companies, MicroCal (acquired in 2008 by
GE Healthcare) [14] and Calorimetry Sciences Corporation (acquired in 2007 by
TA Instruments) [25] dominate the field of ultra-sensitive microcalorimeters
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suitable for biomolecular analysis.
The most common type of differential power compensation isothermal
titration calorimeters consists of twin coin-shaped cells composed of a highly
efficient conducting material (Hastelloy® Alloy C 276 in the case of the VP-ITC,
which is the calorimeter used for all measurements reported in this dissertation)
surrounded by an adiabatic jacket. [6, 8] A schematic diagram of the VP-ITC is
shown in Figure 1.1. Sample cell volumes vary with instrument type; in the case
of the VP-ITC the cell volume is exactly 1.4154 mL [26]. Operationally, this
requires a (bio)macromolecule sample of approximately 1.8 mL ,even though the
working volume of the cell is only 1.4 mL [26]. In addition to the sample cell filled
with the macromolecule solution, a reference cell is also present that contains
either water or buffer, and plays no direct role in the titration. The titrating agent
or ligand is loaded into an injection syringe with a volume of 290 µL.
A thermoelectric device measures the temperature difference between the
sample and reference cells, and a second device measures the temperature
difference between the cells and the adiabatic jacket. During the experiment,
very low constant power is applied to the reference cell and a variable power to
the sample cell in order to preserve the temperature difference. The power added
to the sample cell to maintain this fixed difference is the experimentally measured
quantity related to the heat of reaction [27]. A constant power (< 1mW) is applied
before the injections start and represents the baseline signal [6]. The noise level
of the VP-ITC instrument is 1 ncal/sec (4 nW) and the baseline constancy is ± 5
ncal/sec (± 20 nW) [26].
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In an ITC experiment, the signal actually presents time dependence of the
electric power (µcal/sec) necessary to maintain constant the temperature
difference between the reaction in the sample cell and the reference cell, after
each injection of reactant [8]. The area under each peak is the area associated
with the process. Depending on the reaction type, exothermic or endothermic,
heat is released or absorbed. For an exothermic reaction, with the temperature
increase, feedback power will be deactivated in order to preserve equal
temperatures between the cells, resulting in a negative signal. The situation is
reversed for the endothermic reaction, where the recorded signal is positive [6].
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Figure 1.1 A schematic diagram of the ITC instrument. Reproduced from the VPITC MicroCalorimeter user’s manual [26].
1.1.4 Designing the ITC experiment. There are many different aspects that
need to be taken into account before performing an ITC experiment. A critical
factor is correct sample preparation, both in terms of purity and concentration
determination of both the macromolecule and the ligand. The solutions of the two
interacting species must be prepared carefully using the same exact buffer in
order to avoid a false heat signal that such solution mismatch can generate. In
the experiments described in this dissertation two different techniques were
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employed in order to achieve this. For the PDZ domain protein-peptide
interactions, both solutions were prepared in the same buffer, and the ligand
solution was usually titrated to adjust the pH value to within acceptable limits. A
difference of ±0.02 pH units was considered acceptable [1, 2]. For frataxin
protein-iron interactions, that procedure was impossible since all sample
preparation had to be conducted anaerobically. It was determined in a separate
study that dissolving iron salt in the buffer that the protein was dialyzed in did not
change the pH significantly.
Accurate concentration estimation of both macromolecule and the ligand
is important since it directly affects the calculation of all thermodynamic
parameters. Protein concentration can be determined using different assays: UV
reading at 280 nm wavelength; Coomassie Plus Assay (modified Bradford
assay); and the Advanced Protein Assay, among others. Ligand concentration
need also be precisely determined. For both PDZ domain -peptide and frataxiniron studies, ligand was in the solid form: lyophilized peptide powder or inorganic
iron salt, respectively. In both cases, careful weighing of the compound yielded
sufficient accuracy for the concentration determination. Ligand concentration
affects all the thermodynamic parameters (stoichiometry, Ka, ΔH) obtained from
ITC experiments, while the concentration of the macromolecule affects the
stoichiometry (n) of the reaction [26].
For the PDZ domain-peptide interactions, thorough degassing along with
thermo stating was needed. The thermovac is an ITC accessory device used for
this purpose, prior to loading protein and peptide samples into the sample cell
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and injector [26]. Degassing of the solutions is also important, since the presence
of released air bubbles can interfere with the signal that is recorded during the
ITC run. In order to accelerate the degassing process stirring the macromolecular
sample can also be employed. However, stirring can lead to protein denaturation
and precipitation, and therefore it was avoided in all the experiments described in
this dissertation. During thermo stating the temperature species is usually kept at
few degrees lower than the actual working temperature. This is preferred since
the time required for the instrument to heat up is much less than the time
required to cool down. For frataxin-iron interactions all these preparations were
avoided, due to the anaerobic preparation of samples.
In a typical ITC experiment, the macromolecule solution is added to the
sample cell using a long needle glass syringe with a blunt end [6]. Slowly
releasing liquid is followed by two or three rapid spurts of at least 2.3 mL solution
to ensure the removal of air bubbles from the bottom of the cell. Any excess
solution remaining in the reservoir is removed.
ITC experiments are fully automated, and can be designed in several
different ways. One key parameter that can be changed easily is the
temperature, which is kept fixed throughout the duration of a single experiment.
The range of temperatures available with the VP-ITC varies from 2 °C to 80 °C
[26]. This is fairly broad, and the very low and high ends assume that the protein
remains stable (either avoiding precipitation or denaturation), which is of course
case dependent. Other adjustable parameters include injection volume, injection
number, spacing between the injections, stirring speed, baseline position, and
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feedback mode. At the outset of a study with a new protein, several pilot
experiments are performed in which these settings are systematically varied.
Once optimal conditions are found, they are employed for all future experiments.
Control ITC experiments are another necessary factor in characterizing
the system under study. Usually referred to as blank experiments or blank
titrations, they can be designed in different manners. Titrating ligand solution into
the matching buffer in the sample cell is a control experiment with the most
pronounced impact. Highly concentrated ligand solution (volume = 290 µL) is
diluted several fold when added to the sample cell (volume = 1.41 mL) and can
lead to the release or absorption of a considerable amount of heat. This effect
must be separated from the heat of the macromolecular interaction by running
this control experiment and correcting for the ligand dilution effect.
Another variant of the dilution effect involves that of the protein. Buffer
from the injector is added to the protein solution in the sample cell. The heat
change is usually insignificant, since during the course of the experiment the
sample solution is only diluted ca. 10-20%. This type of blank titration is usually
only needed when starting a new protein study, or switching to a new buffer
system. Finally, the last type of blank titration is buffer into buffer. Assuming care
is taken to prepare the protein and ligand in matched buffers to begin with, this is
not a required control, as the heat associated is usually negligible under normal
circumstances. it may be important, though, if the experiment is performed at
more than ±10°C of the environment temperature (since the ligand is in the
external syringe at ambient temperature) [26].
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Another control experiment that can be useful in investigating errors or
artifacts in ITC experiments is reverse titration. Here the interacting species
switch places: protein is used as a titrating agent, and ligand is placed in the
sample cell. The concentration of both components needs to be adjusted
accordingly (since the titration typically proceeds to saturation), while keeping all
other parameters the same as in the standard “direct titration”. Theoretically, in
case of 1:1binding, if the correct model is used for data fitting, the same values
for the thermodynamic parameters should be obtained from both experiments.
If desired, ITC experiments can also be designed to obtain the enthalpy
change (ΔH) alone, or the complete set of binding parameters (n, Ka, ΔH, ΔS). In
the first case, introducing ligand in a single injection into the protein sample is
sufficient. Enthalpy change can be determined at concentrations when the
binding partners are fully associated and the saturation is still low, i.e. full
saturation at partial saturation [28]. In order to obtain all binding parameters, a
complete isotherm needs to be recorded. Usually, ligand is added in ca. 3-4
molar excess to ensure complete saturation of the macromolecule at the end of
titration. Another important point is the limiting sensitivity of 0.1 µcal/s of the VPITC instrument [26]. Therefore, experiment should be designed in such a way
that in each injection at least 1-2 µcal/s heat change is produced [9]. The most
recent version of the software for VP-ITC has an option for Single Injection
Method (SIM) [29] as a separate, innovative ITC technique.
1.1.5 Data analysis. The method of data analysis depends on the system under
study. Detailed explanations about the data treatment are given in Appendix A.
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ORIGIN software supplied by MicroCal comes preloaded with different models of
curve fitting; they include: “One Set of Binding Sites”, “Two Sets of Binding Sites”
and “Sequential Binding Sites” models. The latest version of the ORIGIN
software

offers

additional

data

fitting

equations

that

include

“Enzyme/Substrate/Inhibitor Assay”, “Dissociation Model” and “Competitive
Binding Model”.
Before peak integration, the heats of binding are normalized as a function
of ligand concentration. Additionally, a volume correction is also performed due
to the dilution of the macromolecule during each injection (also explained in
Appendix A). The area of each peak is then automatically integrated using the
routines of the ORIGIN software. Experimentally obtained data is normalized as
kilocalories per mole of ligand injected, and plotted against the ratio of the ligand
to macromolecule concentration. The derived sigmoidal titration curve is further
fitted to yield the final binding isotherm. The final figure obtained characterizes
the interaction of the macromolecule and the ligand, and includes the
thermodynamic parameters of binding, i.e. n, K and ΔH.
The quality of the experimental data fitting procedure is usually judged by
the value of the χ2 (chi squared) parameter [30]. The standard manner of defining
the best fit is to choose the parameters so that the sum of the squares of the
deviations of the theoretical curve from the experimental points for a range of
independent variables is at a minimum. The χ2 parameter is equal to the sum of
the squares of the deviations of the theoretical curve from the experimental
points, divided by the number of degrees of freedom.
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If a set of experimental data is treated with different models, the most
meaningful thermodynamic parameters are obtained from the model that results
in the minimum χ2 value—provided, of course, that they do not violate what is
biochemically known about, or reasonable for, the protein under study.
1.1.6 of the ITC c value. The critical parameter that determines the shape of the
binding isotherm is the unitless constant c. The value c is defined as product of
the binding constant Ka and the total starting macromolecule concentration of the
macromolecule in the sample cell, Mtot, times the stoichiometry n, as shown in
the equation (6).
c = KaMtotn

(6)

Tight binding (i.e., small Kd) as a consequence has a very large c value
and lower values are signature for weak binding (high Kd). Figure 2.2 depicts
shape variants of the binding isotherm as a function of the c value.

Figure 1.2 Schematic diagram of simulated binding isotherm for different values
of c. Picture reproduced from VP-ITC user’s manual [26].
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Close inspection of these isotherms reveals that their shape is reasonably
sensitive to the binding constant only when the c value is between 1 and 1000
[26]. Often times this range is referred to as the “experimental K window”. Curve
fitting of the experimental data should allow reliable determination of all
thermodynamic parameters (n, Ka, ΔH,). Therefore, the binding isotherm should
have at least a few data points corresponding to the initial phase of the
experiment, additional points for the transition from the unsaturated to the
saturated state of the macromolecule, and finally, a few points towards the end of
the experiment that demonstrates complete saturation. Each of these parts of the
experiment is valuable, and the absence of any makes data interpretation
difficult.
Values for binding affinity (i.e., Kd) that can be reliably measured by ITC
are typically between 10-3 and 10-8 M. Very tight binding cannot be determined,
since in order to satisfy the c value and generate a continuous, fittable curve with
all the regions discussed above, the concentration of the macromolecule should
be very small, which will result in a very low heat signal. Even with the most
recent ITC instrumentation these measurements cannot be accurately made.
Similarly, very weak binding cannot be studied. For the good data fitting and an
acceptable c value, macromolecular concentration would need to be so high that
sample aggregation and other effects would preclude the accurate determination
of the thermodynamic parameters. However, there is a way to extend the range
of such applications by designing appropriate competitive experiments [18, 19].
The most recent version (2004) of the ORIGIN software tutorial [31] includes
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complete descriptions of this method, based on the contributions of Sigurskjold
[19].
In brief, a competitive displacement experiment can be executed by
titrating a very tight binding ligand into a solution of macromolecule already
saturated with a weak binder of known affinity [3]. Obtaining thermodynamic
parameters is possible only if two ligands have significant differences in binding
enthalpy [18, 32-35]. Detailed calculations and fitting routine are provided in
Appendix B. Another approach to overcoming this problem in the case of a weak
affinity system is to saturate the macromolecule in a single injection of ligand.
The obtained enthalpy change is fixed during data fitting in ORIGIN.
1.1.7 Calculating thermodynamic binding parameters in ITC experiments.
ITC records the heat signal during a biochemical interaction. The heat released
or absorbed during each injection is proportional to the change in concentration
of the bound species. The overall heat content during the experiment is related to
the total macromolecule concentration, and used to calculate the enthalpy
change of binding. Utilizing the volume change in the course of the titration, the
software calculates the heat released or absorbed in each injection. Calculated
values from the model and experimental values for data fitting are then compared
by standard Marquardt methods. Iterations are performed until no further
improvement in the data fitting finally gives values for the stoichiometry (n),
association constant (Ka), and enthalpy (ΔH). From this ΔG is calculated. The
change in entropy (ΔS) is obtained using ΔG and ΔH from the standard
thermodynamic equation (equation 2). It is in this manner that ITC provides all
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the thermodynamic parameters from a single experiment [7]. Detailed
calculations are given in the Appendix D.
1.1.8 Thermodynamic data interpretation. Binding affinity is an exponential
function of the energy of association, as shown in equation 7.
Ka = e −

ΔG
RT

(7)

Therefore, ΔG is considered the most important thermodynamic parameter of
€ that determines the stability of a biomolecular complex. Free energy is
binding

often used to characterize structure-function relationships [9]. In various studies it
was noted that, compared to thermodynamic parameters measured by ITC, ΔG
has the lowest signal to noise ratio (values close to one another) [7]. Enthalpyentropy compensation (explained in section 1.1.8) is the reason why free energy
change is relatively insensitive to the change in molecular details of interactions
[36-38]. Since two different parameter contribute to the value of ΔG, many
combinations of ΔH and ΔS can result in the same binding affinity [8].
The enthalpy change measured by ITC is a property of the net change of
the whole system. Therefore, the total heat released or absorbed in the cell upon
adding the ligand represents the cumulative effect of many components. These
include, for example, the enthalpy of association of molecules, the heat due to
mixing and the heat of dilution (especially that of the ligand). Due to contributions
from nonspecific effects, what is measured is actually the apparent enthalpy
change [3]. For these reasons it is important to correct the calculated heat and
accurately determine the intrinsic ΔH of the reaction.
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The enthalpy change has the highest signal-to-noise ratio in an ITC
experiment [7]. This parameter reflects the formation of discrete noncovalent
interactions [9]. During the binding of the ligand to the macromolecule, old
interactions are broken while new ones are formed. The interactions that are lost
include hydrogen bonding and van der Waals interactions between the protein
and the solvent (water in most cases) and ligand and the solvent. New bonds
formed are protein-ligand interactions that also typically involve hydrogen
bonding and van der Waals forces, but can also include hydrophobic interactions
and salt bridges, and solvent reorganization near protein surfaces. All these
interactions can be favorable or unfavorable, but since ITC measures the net
change, the overall effect is usually smaller than the individual specific
contributions [17]. Specific interactions, however, can be evaluated through
alanine scanning [39] and mutational studies [40], by removing specific amino
acid functionality from the binding site of the macromolecule.
The entropy change is calculated indirectly from ΔG and ΔH based on
equation (2). Entropy change is less precisely determined than these other two
thermodynamic parameters because of error propagation [7]. Several factors
contribute to ΔS, but the main one is generally considered the solvation
(hydration) effect. Complex formation is often coupled with the release of ordered
water from the binding regions of the protein surface and the ligand, which enters
into the bulk water phase, which is less ordered (higher entropy). The net result
for this specific process is a large and positive entropy change upon binding. The
factors that affect unfavorably the entropy change of binding are any reductions
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of rotational, translational and conformational entropy when free protein and
ligand associate. Standard errors within experiments for the ΔH, ΔS and ΔG
parameters are typically around 1 kcal/mol [7].
Stoichiometry is calculated from the molar ratio of the interacting species
at the equivalence point of the titration curve. In order to obtain an accurate value
for n, the concentration of the interacting species should be known very precisely
[2]. The potential factors that can affect the n value are experimental errors in the
concentration measurement. For example, if a solid ligand is weighed out in
order to prepare the desired concentration solution, any error in weight
measurement will be transferred to the error in concentration. If the concentration
of the macromolecule (in the sample cell) is lower than what is determined as a
result of misfolding, inactivation, or degradation, then the n value will be smaller
than expected, and vice versa. Similarly, the presence of an impurity in the ligand
will cause the n value to be larger than expected. For this same reason ITC can
be applied as a quality control tool for analyzing the protein stability where the
stoichiometry is already known [2].
1.1.9 Enthalpy-entropy compensation. As mentioned earlier (section 1.1.8)
compensation between ΔH and ΔS is a common phenomenon observed in many
biological systems [37, 38]. This is a result of a linear relationship between the
two parameters (i.e. any increase in favorable enthalpy is often matched by an
unfavorable entropy and vice versa), resulting in no noticeable improvement in
affinity. In such a case, any increase in the bonding that produces a highly
favorable enthalpy will be at the expense of freezing rotations and increasing
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order, leading to more unfavorable entropy. Enthalpy-entropy compensation has
been considered a general consequence of weak intermolecular interactions [41].
1.1.10 Heat capacity change. Since the working temperature range for the VPITC is quite wide (2-80 ºC), it is suitable for the experimental calculation of ΔCp
during complex formation. Heat capacity change can be calculated from a plot of
ΔH versus temperature (T) using equation (3). The correlation between ΔCp and
the change in surface area buried upon binding of the macromolecular complex,
has been very well studied, and forms a link between structural and
thermodynamic information.
1.2 X-ray Crystallography as a Method for Structural Determination. Proteins
are defined as amino acid heteropolymers, whose exact sequence is defined by
their corresponding gene sequence. The amino acid sequence determines its
three-dimensional tertiary structure, which dictates its function [42]. Structural
information reveals design principles of the molecular foundations of living
systems. It not only answers basic mechanistic questions of protein function, but
it can also provide insight into evolutionary relationships between cellular
components [43].
There are several methods used to determine structural information: X-ray
crystallography; electron microscopy (EM); small-angle X-ray scattering (SAXS);
and nuclear magnetic resonance (NMR). Among them, X-ray crystallography has
historically proven to be the preferred method, judging by the more than 40,000
structures deposited in the official protein structure repository, the Protein Data
Bank (PDB; http://www.rcsb.org). Although protein NMR methods have increased
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in popularity, X-ray crystallography is still the major source of protein structures
since it routinely yields the highest resolution data, and can solve structures that
are considerably larger than those solvable by any other current technique. The
number of structures in the PDB has increased exponentially over the last few
years [44], a trend that will certainly continue with the development of "structural
proteomics" as a field of research [45-47].
X–ray crystallography is a powerful technique in resolving the threedimensional structure of biological macromolecules [48-50]. Details of covalent
and noncovalent interactions during protein-ligand complex formation are
frequently revealed by this type of analysis [51]. Thus far, it is the only method
that can routinely reach atomic resolution, and in addition to providing information
to basic questions about protein behavior, it has proven invaluable in the applied
biomedical sciences. Data obtained using this method has been instrumental in
structure-based design efforts [52, 53] that ultimately led to the discovery and
development of many drugs, including HIV protease inhibitors, neuramidase
inhibitors, rennin inhibitors [53] and anticancer agents [54], to cite only a few
examples.
X-ray crystallography was first used as a method in structural biology in
1934, when Bernal and Crowfoot (later Hodgkin) [55] produced the first diffraction
pattern of a protein, pepsin. The real breakthrough in the field came with the work
of Perutz [56] and Kendrew [57] on the structures of hemoglobin and myoglobin,
respectively, in the 1950’s. Technological advances brought many improvements
to instrumentation, sample preparation, data collection and processing. However,
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the methods and mathematical approaches that were developed to solve those
first protein structures represent the core of the methodology that is used even
today.
In the process of solving a protein structure by X-ray crystallography, a
series of steps, each with its own difficulties, is required. In brief, these include
(1) crystal formation; (2) data collection; (3) solving the structure. Each of these
steps is summarized below.
1.2.1 Crystal formation. The first requirement is a reliable method for producing
a good supply of protein crystals. Protein crystals are, unlike mineral or small
molecule crystals, mostly made of water (30%-80%), and as a result are
extremely fragile due to the relatively weak interactions that hold the lattice
together. For determining crystallization conditions and effecting subsequent
growth of crystals of suitable quality for structure determination, at least 2 mg of
pure protein is needed, in a highly concentrated form of 5–30 mg/mL [43].
Although this amounts is considered high for certain proteins, only a few
microliters (1 – 3 µL) of this concentration sample is required for a 'screening set
up'; thus, a 1 mL sample can be used to screen for hundreds of different
crystallization conditions [58]. In the early days of protein crystallography,
experiments were carried out on proteins obtained from natural sources (usually
cow and pig organs or blood). Recent advances in recombinant DNA technology
[59] and newly developed bacterial expression systems, principally those based
on E. coli [60, 61], routinely allow overproduction of properly folded target protein
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[62]. A wide array of bacterial expression plasmids is nowadays available from
commercial vendors (e.g., Novagen and Invitrogen).
However, not only protein quantity, but also quality is important for
crystallization [63]. Protein samples need to be chemically pure; that is, having
only one type of macromolecule or complex in the tube. It should be folded into
its native conformation and not contain covalently heterogeneous features (such
as partial glycosylation or phosphorylation, or mixtures of truncation products).
Methods

like

gel

electrophoresis,

protein

chromatography,

and

mass

spectrometry should be employed in order to provide and confirm a chemically
pure sample [63, 64]. The sample must also be conformationally pure, which is
usually assessed with size exclusion chromatography or with light scattering
measurements [65-67].
Protein crystallization is a phase transition that consists of nucleation and
crystal growth [63, 68]. The basic idea is to transfer the concentrated protein of
interest into a solution of precipitants that will trigger crystal formation.
Precipitants act by promoting the formation of intermolecular interactions by
affecting macromolecular hydration, molecular crowding, solubility, hydrophobic
interactions, and electrostatics. Unfortunately, the same components that push
proteins towards crystallization can also promote the common (and undesired)
phenomenon of amorphous precipitation. It is impossible to predict in advance
which conditions, if any, will cause a protein or protein complex to crystallize. The
list of possible factors is a long one: precipitant type; pH; salt concentration;
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detergents; temperature; and the inclusion of cofactors and ligands are the most
common variables. The variables are endless.
A prudent route to take involves screening sets of already established
'good' protein crystallization agents. Crystallization screens often focus on a
limited set of concentrations of various sizes of polyethylene glycols (PEGs),
salts, and alcohols that have been successful for protein crystallization in the
past [68-71]. Commercially available crystallization screening kits (e.g., those of
Hampton Research, Wizard, and Nextal), especially if the experimental set up is
performed utilizing microcrystallization robotics, makes it possible to test
thousands of initial conditions. The newest trend that appears to be emerging in
the field is to have screenings conducted in a dedicated 'crystallization centers'.
Although there are other techniques available, vapor diffusion is the most
frequently used method of setting up crystallization experiments. Protein and
precipitant are usually mixed in a 1:1 proportion, in volumes from 50 nL to 1 µL,
depending on the type of instrumentation used. A solution drop that is formed in
such a way is then placed in a sealed chamber that contains a large volume
relative to the drop of precipitant, also termed the mother liquor solution. The
imbalance in vapor pressure slowly draws water from the protein/precipitant drop
into the mother liquor, and gradually concentrates the protein solution. Crystals
can be formed if the process proceeds through a supersaturated protein solution.
Crystal formation time is highly variable. They may form within a few hours
(sometimes even only minutes), or, quite commonly, they may require weeks or
months, depending on the protein and the particular conditions used.
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Vapor-diffusion can be performed in two modes: the hanging-drop method
and the sitting-drop method. In the hanging-drop method, each drop is prepared
by mixing the protein sample with the buffer. A small slide with the droplet is
inverted over a prepared well with the buffer. The drop is kept on the slide by the
surface tension forces. This kind of setup is usually performed in a multiwell plate
format, with 4 x 6 wells per plate. The sitting drop method utilizes the same
principle, only in this case the drop sits on a microbridge over the precipitant
reservoir, in the same well.
Another interesting method used for crystallization of proteins is known as
the microbatch method. Using this technique a small drop of concentrated protein
solution, combined with the crystallization reagent of choice, is pipetted under a
layer of oil. All of the reagents involved in the crystallization are present at a
specific concentration and no significant concentration of the protein or the
reagents occurs in the drop. This method is simple and efficient for screening for
crystallization conditions, but not for obtaining good quality crystals.
A new advancement in crystal preparation methods is the use of robotic
systems that are able to prepare and evaluate up to 40,000 crystallization
experiments per day, using this microbatch technique, or 60,000 micro-vapor
diffusion experiments per day. These technological advancements are very
important in the new field of high-throughput crystallization and structure
determination, which is expected to have a large impact in the drug discovery
process.
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1.2.2 Data collection. Unfortunately, having crystals form does not necessarily
mean that they will be suitable for obtaining a good structure. Crystals can only
diffract X-rays if they are well ordered. Since weak interactions hold the lattices
together, fragile crystals might, in some cases, have internal disorder and
therefore diffract poorly. This is impossible to determine in advance just by
visually judging the crystal appearance, The only way to be certain is to actually
expose a crystal to the X-ray beam and measure the diffraction pattern.
The question is then why some crystals lead to solvable structures and
others do not. A more detailed discussion of the nature of crystals is required.
Crystals represent an “orderly three-dimensional array of molecules, held
together by noncovalent interactions [55]"; that is, built in space from multiple
copies of the same repetitive element. These building blocks are called unit cells
and are related to each other by simple translations. There are fourteen types of
unit cells (cubes, prisms, hexagons).
The unit cell may contain a single copy of the protein or complex of
interest, but often it contains many copies, and they are related to each other by
a set of rotations and translations defined by crystallographic symmetry. The
symmetry of the unit cell is indicated by its space group. Theoretically, 230
different space groups exist, but luckily for researchers, only 65 different types of
symmetry are actually known. In the unit cell the “largest aggregate of molecules
that possesses no symmetry elements, but can be juxtaposed on other identical
entities by symmetry operations, is called the asymmetric unit [55].” The
asymmetric unit and its dimensions (coordinates) are determined in solving the
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structure. Often times this can be a biological unit, but it can also be built from
symmetrically positioned protein chains such as homodimer or homoteteramer.
These symmetry elements are depicted in Figure 1.3.

Figure 1.3 Anatomy of a protein crystal. Reproduced from Minor, DL[43] by
permission of Elsevier
1.2.3 Data collection. Actual determination of a structure begins with measuring
the X-ray diffraction from the crystal. X-rays are electromagnetic waves that have
short wavelengths, and the best range for crystallography involves wavelengths
between 0.5 Å–1.6 Å. These X-rays are able to penetrate samples of up to 1 mm
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thickness. They are also able to discern between features that have magnitudes
on the order of angstroms (1-2 Å covalent distance between atoms, and
hydrogen bonds at 2.5 Å – 3.5 Å).
X-rays can be produced by exciting a metal (usually copper or
molybdenum) with high energy electrons produced by a heated filament, and
accelerated by an electric field. X-rays are emitted by excited copper electrons,
making a L→ K transition at λ = 1.54 Å. In order to produce monochromatic
radiation, usually a nickel filter of 0.015 mm thickness is used.
In an X-ray diffraction experiment the intensity of the coherently scattered
X-rays is measured. The diffraction pattern is an array of “reflections” in which
the pattern and spacing is set by the unit cell parameters (Figure 1.4).
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Figure 1.4 Scheme of diffraction experiment. Reproduced from Minor,
DL[43] by permission of Elsevier
Each reflection carries information about the entire asymmetric unit. There
is an inverse relationship between the position of a reflection in a diffraction
pattern and the resolution of the information. Near the center of the diffraction
image, close to the position of the incident beam, are where the low-resolution
reflections found, while high-resolution data are found at larger scattering angles
(Figure 1.4B). High-resolution reflections determine the resolution limits of a
given experiment. These limits are a result of the quality of the internal order of
the crystal. Once the crystal parameters (i.e., space group and unit cell size) are
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determined from the diffraction pattern, the crystallographer knows exactly where
all the reflections at any resolution should be.
For data collection either a diffractometer or synchrotron radiation is used.
Diffractometers have three main components: X-ray source, goniometer and
detectors. The goniometer is able to rotate a crystal by a 40° angle in each of two
perpendicular planes during data collection. The steps in diffraction experiments
are described in Figure 1.4. Presently, most data collection is done at the
synchrotron radiation sources, although for the studies reported in this
dissertation, an in-house Rigaku instrument was used. The main advantage of
synchrotron radiation is that the intensity of X-rays generated is much higher, so
the crystal exposure time can reduced. This is very important since most
molecular crystals lose the ability to diffract X-rays within a few seconds of
exposure, due to the high energy imparted by X-rays. In order to preserve
crystals, they have to be flash frozen before the exposure, usually using liquid
nitrogen [72]. As already explained, this is important for crystal lifetime and
quality of data [73, 74]. Nearly 90% of all crystallographic data is performed at a
temperature of 100 K or lower [73]. During the whole expose time, the crystal is
placed in a cryostream of nitrogen gas, which keeps it frozen throughout the
experiment.
The X-ray crystal reflections are recorded by detectors. These can be of
different types depending on their specific design. Image plate detectors and
area detectors are most commonly used for X-ray crystallography. Image plates
are plastic sheets with a coating of small crystals of phosphor material, like
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BaF:Eu2+. By hitting the detector surface, X-ray photons excite the electrons in
the material. Laser is then used to scan the detector surface and record the
signal. The pixel size depends mainly on the reading system and varies from
100x100 to 200x200 µm. The image plate detectors have a wide dynamic range
and can be used indefinitely.
Area detectors are based on either a gas filled ionization chamber or an
image intensifier coupled to a video system. The X-ray photons cause ionization
of gas atoms. The disadvantage of this type of detector is the limitation of
counting rate due to the build up of charges in the chamber and the processing
electronics. The maximum counting rate is about 105 Hz. Another disadvantage is
the lower sensitivity at shorter wavelengths due to poor absorption, if used in
combination with synchrotron radiation.
1.2.4 From diffraction data to electron density. In order to obtain an atomicscale image from crystallographic data, a computer simulates the action of a lens
[55]. Electron density is computed from the list of indexed intensities obtained,
which is the final outcome of the X-ray data collection. Each intensity has an
index hkl assigned corresponding to its position in the reciprocal lattice. This
diffraction pattern can be mathematically related, very precisely, to the object
using a Fourier transform [55]. A Fourier-series description of the reflections is
converted into Fourier-series description of electron density. A reflection can be
described by a structure-factor equation, containing one term for each atom in
the unit cell.
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Crystallographers use Fourier transforms to convert structure factors to an
electron density equation. However, one necessary piece of information is
missing. A description of a diffracted wave includes knowing its amplitude,
frequency and phase. For each reflection, we can only measure its intensity, Ihkl
not the complete structure factor Fhkl. The amplitude of structure factor Fhkl is
actually proportional to square root of the measured intensity. Unfortunately, its
phase still remains unknown. In an analogy that was mentioned before, in
focusing reflected light from the object, a lens maintains all phase relationships
among the rays constructing an image accurately. Recorded diffraction
intensities do not carry that necessary information. This is often referred to as the
phase problem of X-ray crystallography. This problem can be overcome,
however, and phases can be obtained using different indirect approaches, as
explained in the following sections.
1.2.4.1 Heavy atom derivative. This method was developed when solving the
first protein structures in the 1960s. It is based on modifying the protein in the
crystal with a “heavy atom”, such as in the form of a mercury or platinum
complex. Because proteins are made of “light atoms” (C, H, O, N, S), the
selective addition of a heavy atom or atoms with a large number of electrons
(e.g., 80 electrons in Hg) to precise binding sites on the protein causes
perturbations to the intensities of the reflections in the diffraction pattern. The key
objective is to produce modified crystals in a way that the unit cell is not altered,
and possessing the same dimensions and crystal symmetry group. This condition
is also known as isomorphism. Obtaining phases from only one crystal derivative
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is called the single isomorphous replacement (SIR) method; if two or more
derivatives are required then the method is termed multiple isomorphous
replacement (MIR).
At the same time, the presence of heavy-atom should result in detectable
changes in the reflection intensities. If that is the case, than these atoms can be
easily located and the phases can be calculated by different computational
programs that are available. Phase estimates are further used for refinement and
structure solution. For producing the right crystals two methods are employed:
soaking of native crystals with heavy atom derivatives solutions, and
cocrystallization of the protein and heavy atoms.
MIR requires a lot of material, since many crystals often need to be
screened to yield the appropriate derivatives. Just like the search for
crystallization conditions, it cannot be known a priori which derivatives will be
useful. Often derivatization alters the unit cell parameters in such a way that the
isomorphism is not maintained
1.2.4.2 Anomalous Scattering Method. This second method of solving the
phase problem takes advantage of having a heavy atom incorporated into the
protein. Three very important technical developments make this method possible:
variable wavelength of synchrotron radiation, cryocrystallography, and the
production of proteins that contain selenomethionine instead of sulfur-containing
methionine [55]. For proteins that naturally contain a heavy atom, such as the
iron in globin or cytochtrome, the native heavy atom provides the source of
anomalous dispersion.
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Proteins lacking functional heavy atoms, but which naturally (or through
introduced point mutations) encode for methionine, can be expressed in E. coli
containing exclusively selenomethionine. Selenium atoms serve as heavy atoms
in a protein that is essentially identical to the “native” form. Isomorphism does not
represent a problem since same protein serves as both native and derivative
form. This method requires a tunable X-ray source, generally provided by a
synchrotron X-ray beamline. The incorporation of selenium allows a special type
of experiment to be done in which data are collected at the wavelength at which
the selenium atoms absorb X-rays as well as at wavelengths at which they do
not. This sort of experiment is known as a multiwavelength anomalous dispersion
or single wavelength anomalous dispersion (MAD and SAD, respectively) [7577]. Selenium atoms are located based on differences in the intensities of the
reflections, just as similar differences allow the determination of heavy atom
positions. The advantage over MIR, which requires multiple crystals, is that in
this case the experiment can be conducted with a single crystal. Also, for MIR the
treatment of the crystals with the heavy atoms frequently causes serious
degradation in the diffraction quality. This issue is completely avoided with the
MAD or SAD experiments. The quantity of selenomethionine residues allowed in
a single protein or protein complex can vary, but the largest number in a structure
solved by MAD was six per protein subunit, in the dimeric enzyme DsbA [55].
1.2.4.3 Molecular replacement: related proteins as phasing models. The
third method of solving structures is by molecular replacement. This technique,
developed by Rossman and Blow [78], takes advantage of the fact that the basic
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backbone architecture of many proteins of interest is similar to other proteins or
protein domains for which there are already solved, high resolution structures. In
this case the known structure of the macromolecule is referred to as the phasing
model. The model and the molecule of interest should share at least 40%
homology. This method is extremely useful in examining a series of mutations to
see how they perturb a structure or to see how drugs might bind and interact with
a target. In general, the target and the model backbone atoms must be within
~2.0 Å root mean squared deviation (RMSD).
If the model and the new protein are isomorphous, then the phases for the
new protein can be calculated directly, after which they are improved during an
iterative process. If they are not isomorphous the problem is more complicated,
and the position and the orientation of the phasing model in the unit cell are
searched [55]. One of the best ways to do this is through calculating the
Patterson map. The Patterson function P(u,v,w) is a Fourier series used to
calculate ρ(x,y,z) from structure factors. The coordinates (u,v,w) locate a point in
the Patterson map in the same way that coordinates (x,y,z) locate a point in an
electron density map. A Patterson map shows peaks at locations corresponding
to vectors between atoms, and is independent of the position of the structure in
the unit cell. But if the structure is rotated in the unit cell, the “Patterson map
rotates around the origin, changing the position of Patterson atoms in a single
Patterson unit cell”[55]. This has important implications for the use of the
Patterson map in determining the best orientation of the model in the unit cell of
the new protein.
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Different programs are available that perform a combination of rotational
and translational searches, or both. For the orientation search, which is also
known as rotational search, the program is looking for large values of the model
Patterson function Pmodel(u,v,w) at locations corresponding to peaks in the
Patterson map of the desired protein. The resolution range used for rotational
searches is usually within 10–3.5 Å, with 8–4 Å being the most common. For the
location search, which is also known as translational search, the program is
looking for the “correspondence between the expected structure-factor
amplitudes from the model in a given trial location and the actual amplitudes
derived from the native data on the desired protein.”
The parameter used to determine the success of the search procedure is
the R-value [55]. For proteins, R-values of 0.3 to 0.4 for the best orientation of
the phasing model have proven successful in providing initial estimates of
phases. If they are superimposed, then the phases of the model can be used as
initial estimates and improved via an iterative process.
1.2.5. Solving and refining a structure. Once the phase problem has been
solved, than the electron density function ρ(x,y,z) can be calculated from the
measured intensities. This is only the beginning of an iterative process that
attempts to improve the quality of the initial map by different methods, which
inlcude

solvent

flattening,

noncrystallographic

symmetry

averaging,

or

introducing a partial atomic model (which is building the structure into electron
density maps). If the initial electron density maps are good, protein structural
features such as α-helices, β-sheets, side chains, and cofactors can be
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recognized. The procedure involves matching the covalent structure of the
molecule (i.e., the protein sequence) with the density.
How easy or how hard this step is depends on the resolution to which the
crystals yield good data. Different protein structural features require different
resolutions. The definition of individual atoms requires data at 1.5 Å resolution or
better. At ≤ 2.0 Å resolution, the electron density of individual side chains will be
sufficiently resolved to define specific conformers. At 3.0 Å resolution or lower,
major structural features such as α helices and β sheets are clearly
distinguishable, but many side chains may not be resolved. Another problem is
that the electron density map may not be of uniform quality, and some parts of
the protein may be poorly ordered and not visible at all.
With high-resolution data (≤ 2.0 Å) interpretation is fairly straightforward.
At lower resolutions, ambiguities may exist that require multiple rounds of model
building and refinement. In both cases the basic procedure of map fitting employs
placement of atoms for the interpretable density in the map (i.e., given 3-D
coordinates within the asymmetric unit); the positions are then refined against the
data, new maps are calculated using the new phase information from the model,
and the procedure is repeated. This iterative building and refinement process
gradually improves the phases and the quality of the maps such that features
that may not have been visible at the outset become visible. In cases where the
data are ≤ 2.3 Å, automated building and refinement programs can do much of
the work. At lower resolutions, the work still requires building and map
interpretation to be done manually. It should be noted that the precision of the
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placement of the atoms in a macromolecular structure is typically much greater
than the resolution of the data. The positional errors in the core regions (i.e.,
those that are best defined) range from 0.1–0.2 Å at 1.5 Å resolution to ~0.5 Å at
3.0 Å resolution. Why is this precision better than the diffraction limit? The
answer is chemistry. We know the average lengths and angles for all of the types
of covalent bonds that hold together a protein. These values are included as
restraints in the refinement procedure and ensure that the final structural model
makes good chemical sense.
Another important parameter that defines data quality is the R factor. It
shows how well a final model fits the experimental data. Fortunately, the data
from an X-ray diffraction experiment are redundant to some degree. Thus, 5%–
10% of the data can be actually excluded from the entire refinement procedure
and this set used (known as the Rfree set) as an unbiased metric of how correct
the structure refinement is. During the structure refinement, the crystallographer
compares how well the structural model predicts the Rfree dataset.
It is now routine to report the R and Rfree values for a crystal structure.
These two numbers serve as one metric for how correctly things have been
done. R and Rfree should be similar (Rfree is always higher by ~2%–6% for wellrefined structures). During the refinement process, the value of R may decrease,
but Rfree will stay the same (or increase). If the R values are already low, this is
one way for crystallographers to know when to stop refining. Large differences
between R and Rfree indicate that some portion of the model is incorrect and that
something needs to be corrected before the refinement can be completed.
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Examination of stereochemistry and Ramachandran analysis provide two other
good measures of the quality of a structure. In good structures, one should see
RMSD for bond lengths of < 0.02 Å and bond angles of < 2°; curiously, lower
values than these do not necessary indicate higher quality structures but may
reflect the use of too-tight constraints during refinement. Ramachandran analysis
examines which parts of conformational space the protein is in.
Although the final refined model represents the average positions of the
atoms, the structures do contain information about the mobility of different parts.
One indicator is a parameter known as the B-factor. Each atom in the structure
has a B-factor value that describes the average mean displacement from the
position seen in the structure. Low B-factors show areas of low mobility and high
B-factors show regions of higher mobility. This simple interpretation can break
down in low-resolution structures (> 2.7 Å), as these generally have higher
average B-factors that also reflect the general disorder in the lattice.
1.2.4 Finale and future: integrated studies. The methods outlined in this
chapter, which have been utilized in the research presented in this dissertation,
offer a powerful way to gain valuable molecular insight into the fine anatomy that
underlies how macromolecules look and behave. Besides the explanatory power
that such approaches offer for understanding the native structure and function
itself, they are often the first step in protein design, allowing the engineering of
variant proteins with novel function, and they also provide guidance for drug
discovery and development, as commonly employed in “structure-based design”
(or “rational design”) methodologies. Although each method offers complimentary
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information, integrated studies that use various methods to get at different levels
of

structural

questions

offer

a

great

advantage

macromolecular complexes in different functional states.

for

exploring

large
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CHAPTER 2
PDZ PROTEIN INTERACTION DOMAINS
The central theme of the thesis project is multivalency of biological
systems and the core study was done on the dual PDZ domain of PSD-95
protein. Special focus was on utilizing ITC technique for analyzing affinity of
protein–protein interactions. This lead us to design of potent molecular probes to
target these interactions. Ligand design and subsequent in vivo studies are also
described in this chapter.
Different cellular processes are regulated by proteins through their various
interactions with other polypeptides, small molecules, phospholipids or nucleic
acids [79]. Many of the associated regulatory proteins are constructed of different
protein interaction domains, or PIDs [80]. In structural biology or biochemistry the
definition of a ‘domain’ is somewhat broad, although usually they are described
as relatively independent (structurally and/or functionally) structures of 35-150
amino acids that retain their fold and binding characteristics even when they are
expressed separately. A striking but not unusual structural feature is that the Nand C- termini are often located very close, on the opposite side of the ligandbinding site. This arrangement enables the assembly of PIDs into different host
proteins while keeping their binding affinity very similar. Utilizing such “building
blocks” introduces diversity in complex proteins with a limited number of
components.
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Many protein domains are known to bind to different sequences in their
target molecules. Another interesting feature is that different interaction domains
are present in the same host molecule (single or multiple copies) thus forming a
complex protein that can mediate multiple protein-protein or protein-ligand
interactions. Based on their sequence homology or their ligand-binding
properties, domains are organized into different groups; for example, SH2 (Src
Homology 2) [81], SH3 (Src Homology 3) [82], WW (two conserved tryptophan
residues) [83], PTB (Phosphotyrosine binding domain) [84], PDZ (PSD-95, Discslarge, ZO-1), LIM (Lin11, Isl-1, Mec-3) domain, etc [80].
2.1. The PDZ Domain. PDZ domains are members of the same PID family of
proteins, and likewise are relatively small, independently folded 'modules' that
occur in longer polypeptides [85-87]. As with the other members of the PID
family, PDZ domains are largely responsible for promoting transient non-covalent
protein-protein interactions. These occur primarily within the intracellular space of
a cell, and represent a number of different signaling pathways that affect all
manner of cellular functions, from growth to death.
The PDZ domains themselves are among the youngest of the identified
PIDs. They were discovered on the basis of sequence repeats first found in three
different proteins: postsynaptic density 95 (PSD-95); Disc Large (DLG) and
zonula occludens 1 (ZO-1) [88]. Initially these regions of polypeptide were
referred to as GLGF domains [85], because of the highly conserved Gly-Leu-GlyPhe motif found within the amino-terminal sequence, or DHR domain for discs
large homology region. Later, the acronym “PDZ” rose to dominance (from PSD-
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95, Dlg and ZO-1, the initial letters of the first three proteins in which they were
identified), and was widely adopted by the scientific community. Since the
sequences of several genomes have been determined, it has been shown that
PDZ domains occur in hundreds of proteins, and are among the most abundant
protein domains in multicellular eukaryotic genomes, Caerohabitis elegans (89),
Drosophila (128) and Homo sapiens (320).
2.2 PDZ Domain Specificity and Nomenclature. PDZ domains consist of
approximately 100 amino acid residues and bind in a sequence-specific manner
to the carboxyl terminus of their protein-binding partners [85, 86]. While almost
exclusively recognizing peptides with free carboxyl termini, some PDZ domains
can also interact with internal peptide sequences, and in at least one case, with a
non-C terminal cyclic peptide [89]. PDZ domains are predominantly found in
cytoplasmic proteins, in which they occur in one or multiple copies. These protein
domains are widespread in organisms, ranging from simple bacteria to complex
eukaryotes, including humans, indicating that “they are either hyper adaptable or
that they are essential or fundamental to cellular processes” [90]. Their high
conservation level throughout the species indicates that their molecular function
has been retained since the beginning of cellular life. These modular protein
domains show no catalytic activity and preferentially bind to C-terminal
sequences of the target protein, like cytoplasmic tails of transmembrane
receptors and ion channels [91, 92]. However, it has been observed that PDZs
can bind in non-canonical fashion as well to internal sequences, cyclic peptides
or even lipid molecules [89, 93]. As stated before, PDZ domains are found in
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multiple copies in complex proteins, often in combination with other domains like
SH3, WW, LIM [94], etc. A recent search in the SMART (Simple Modular
Architecture Research Tool) database found 20,072 in 12,617 proteins. PDZ
proteins can be classified into three principal families based on their modular
organization (Figure 2.1).

Figure 2.1 Examples of PDZ domain classification according to modular
organization. Reprinted by permission [94]
The first family contains proteins consisting entirely of PDZ domains,
though their number may vary from two to more than ten in certain proteins. The
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second family is the MAGUK (membrane-associated guanylate kinase) proteins.
These are a well studied family of PDZ containing proteins, particularly the
mammalian MAGUK proteins that include PSD-95/SAP-90, PSD-93/chapsyn110, SAP-97/hdlg, and SAP-102 [94]. They are found at synapses and behave
as protein-protein interaction modules that target and cluster ion channels,
receptors, and cell adhesion proteins. MAGUKs all share a common domain
organization, consisting of (one or three) PDZ domains at the N-terminus,
followed by an SH3 domain, and at the C-terminus a guanylate kinase-like (GK)
domain. PSD-95, the focal protein of the PDZ domain research presented in this
dissertation, belongs to this family [95]. Overall it is probably one of the best
studied PDZ domain-containing proteins to date, if not the best studied. The third
family encompasses proteins that, in addition to PDZ domains, contain other
domains, such as LIM, L27, C2, PH, WW, DEP and LRR [96].
2.3 The Significance of PDZ domains
PDZ domains have been found to perform a wide variety of functions on different
cell and tissue types, and many of those occurrences are associated with
disease states. Thus, the importance of these domains spans from their basic
endogenous functions all the way to disorders that are associated with proteinprotein interactions that involve binding (or disruption thereof) of PDZ domains. A
brief overview is provided here that exemplifies the range and significance of
these domains, especially as it applies to human health.
2.3.1 PDZ domains as scaffolding proteins. A well documented property of
PDZ domain-bearing proteins is their ability to serve as scaffolding elements for
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the assembly of macromolecular complexes at specific subcellular locations,
particularly at the cell surface [97, 98]. PDZ domains have a specific fold and
interact with their binding partner proteins through the latter’s variable C-terminal
region. Along with their often being accompanied in their host protein by one or
more different PIDs, such as SH2, SH3, WW and PTB, PDZ domains are usually
present in multiple copies. This enables them to assemble and anchor large
multimeric protein complexes. A primary role of such protein assemblies is to
maintain signal transduction specificity and efficiency. Sheng et al. have
described some of the best known systems where PDZ domains are involved
[96]. A representative example of a PDZ domain protein acting as such a scaffold
in the cell is INAD (inactivation-no-afterpotential D), which contains five domains
that interact in the phototransduction network [99].
2.3.2 PDZ domains and their roles in cancer development. Numerous PDZ
domain-containing proteins have been shown recently to play a role in cancer
progression, and thus emerge as potential drug targets [100]. Syntenin, a
structurally well characterized protein that contains two PDZ domains, represents
one such example [100]. Syntenin is overexpressed in many metastatic breast
and gastric cell lines. Since syntenin is localized in the area of cell-cell contacts
that act as cell adhesion sites, it might be involved in tumor cell invasion. In
support of this mechanism, forced in vitro overexpression in MCF7 (nonmetastatic breast cancer cell line) or poorly metastatic AZ-521 gastric cancer
cells increases the invasion and migration properties of those cell lines [100]. As
shown in work by Boukerche et al [101], altering syntenin expression leads to
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modifications in phenotype and alters the metastatic capabilities of melanoma
cells.
Another PDZ domain-bearing protein, PCD1 (pancreatic cancer derived),
is found to be highly overexpressed in different types of tumor tissues, such as
colon, breast, liver, pancreas, stomach and prostate [102]. Rarely is PCD1
expressed in normal tissues. Further studies have shown that the PCD1 gene
may play a role in colorectal cancer development from adenomas [103]. The
same group has shown that PCD1 is implicated in breast cancer progression and
nodal metastasis [104]. Therefore, this protein is a potential candidate for
diagnosis and treatment of these types of cancer.
Activated in prostate cancer (AIPC) is another PDZ domain protein
containing six such domains, and is highly expressed in prostate tumor tissues
The initial immunohistochemical studies have linked accumulation of this protein
with the promotion of prostate tumorigenesis [105].
Finally, another cancer-associated protein is MAGI-3, a member of the
MAGI family of PDZ domain-containing proteins that interact with proteins from
viruses like human T-cell leukemia virus type 1 (HTLV-1) and high-risk human
papilloma-virus (HPV) types. MAGIs can be viewed as a distinct subgroup of the
MAGUK family. They have three PDZ domains, but instead of an SH3 domain
there is a WW domain and guanylate kinase (GK) is found at the N-terminus.
MAGI-3 has been shown to interact through its PDZ domain with Tax1 viral
protein in HTLV-1 infected cells. This binding event alters the cellular localization
of these proteins and might have implications for their biological activity, leading
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to continuous infection of HTVL-1 in T-cells. Therefore, MAGI-3 is a very
interesting target for understanding the mechanism of these dangerous
infections, and ultimately for the design of inhibitors that could control them.
2.3.3 PDZ domain proteins in cystic fibrosis. Cystic fibrosis (CF) is the most
common lethal genetic disease in Caucasians [106].

The CF conductance

regulator (CFTR) is a low conductance chloride channel that mediates cAMP
dependent chloride secretion [107]. Changes in CFTR function are associated
with CF, secretory diarrhea and pancreatitis. Mutation of the gene encoding
CFTR reduces its chloride transport capacity and/or its level of cell surface
expression. Another disease caused by the overstimulation of CFTR activity
through bacterial enterotoxins is secretory diarrhea, the second largest cause of
infant mortality in developing countries [106].
The mechanism of action is mediated through the C-terminal tail of CFTR
that directly binds to the PDZ domain proteins NHERF (Na+/H+ exchanger
regulatory factor) [108] and EBP50 (ezrin-binding protein) [109]. It has been
shown that binding of tandem PDZ domains to the C-terminal of CFTRs has a
modulatory effect on the channel activity, revealing a new function of PDZ
domains, which might not be limited only to this complex. It has been reported
that regulation of CFTR with the PDZ domains of NHERF involves
phosphorylation of one PDZ domain. This mechanism is under control of protein
kinase C (PKC) [110]. PKC phosphorylates PDZ2 of NHERF, which triggers a
conformational change that results in loss of affinity for CFTR and inability to
activate the channel [110].
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2.3.4 PDZ domain involvement in neurodegenerative diseases. Early studies
of PDZ domains were especially interested in a single such repeat in CASK
protein (calcium/calmoudlin-dependent serin protein kinase, a mammalian
homologue of Lin2) [111]. Through its PDZ domain, CASK is shown to interact
with parkin, a protein involved in progression of Parkinson's disease [111, 112].
Parkin is an E3 ligase responsible for the ubiquitination of protein substrates as a
tag or marker, a critical step in the protein degradation pathway. It is believed
that CASK acts as a scaffold enabling cellular trafficking and localization of
parkin. However, it remains unclear what the consequence is when this
interaction is lost. Designing ligands to selectively disrupt the interaction would
be one possible way to study the associated complex functional properties, and
subsequently might lead to developing therapeutics for this neurodegenerative
disorder.
Another very interesting example is GRIP1 (glutamate receptor-interacting
protein 1), which is shown to have a direct functional link with the Fraser
syndrome protein Fras1 [113]. GRIP1 contains seven PDZ domains, and through
them it can form a diverse network of protein-protein interactions. This adaptor
protein has been implicated in the regulation of neuronal synaptic function, but its
physiological roles have not been defined in vivo. Thus far studies in mouse
model have shown that loss of GRIP1 leads to epidermal blistering, renal
agenesis and defects in the brain, a condition similar to human Fraser syndrome
[113, 114].
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A novel protein, human like X11-like (hX11L), contains a phosphotyrosine
interaction (PI) domain and two PDZ domains [115]. Through the PI domain,
hX11-L interacts with a sequence containing the same motif found in the
cytoplasmic domain of Alzheimer’s (amyloid precursor protein APP). Further
analysis of binding to APP of different hX11-L constructs indicates that PDZ
domains at the carboxy-terminal region are essential for modulating APP
degradation [115]. These observations should contribute in the current
understanding of the molecular mechanism of APP in Alzheimer’s disease.
After reviewing all these therapeutic areas that have been summarized, it
is evident that the PDZ domain is a critical player in a variety of protein binding
interactions. What unites these incidents is a molecular recognition event
between the partner protein and the PDZ domain itself. Focusing attention on
this, what is revealed is that there is both a conformity and diversity in the peptide
sequences that different PDZ domains bind, and which gives rise to how these
structures are classified.
2.4 Classification of PDZ domains. PDZ domains predominantly bind to Cterminal sequences of their binding partners [116]. The mode of recognition
represents the basis for their derived nomenclature, describing residue position
away from the carboxy end, and which was adopted for their binding targets. Cterminal residue is referred to as the “0“ position with the subsequent residues
labeled “-1“, “-2“, “-3“, etc. Classification by Songyang et al. showed that PDZ
domains can be classified based on the preference for certain amino acid
residues at key positions “0“ and “-2“ in their sequence (Figure 2.2). Class I PDZ
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domains prefer peptides with small hydrophobic residues at the “0” position and a
β-hydroxyl group (Ser or Thr) at the “-2” position, while class II PDZ domains
prefer hydrophobic or aromatic residues at this position. Most of the PDZs fall
into these two classes, but later on novel domains were discovered that have
different preferences and that led to establishing class III and class IV categories
as well (Table 2.1).

Figure 2.2 Schematic diagram of peptide orientation in the PDZ binding site. P“0”
and P”-2” point toward PDZ binding pocket while P”-1” and P”-3” are solvent
exposed.
Class III PDZ domains bind to their partner ligands with Cys at position “0” and
any amino acid residue at the “-2” position. According to the latest classification
class IV PDZs recognize Val at the “0” position and a negatively-charged residue
(Asp or Glu) at “-2”. However, there are quite a few PDZ domains that cannot be
listed in any of these classes, since they show unique binding patters.
A different study has taken into account the nature of amino acids in two
critical positions. First would be the position that immediately follows the second
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β-strand (βB5) and another would be the first position in the second alpha helix
(αB1) of the binding pocket [117]. This method was successful for classification
for the limited number of PDZ domains, however not for all, since the criterion
based on nature of amino acids at these two positions was insufficient to classify
all PDZs.

Position “-3”

Position “-2”

Position “-1”

Position “0”

Class I

X

Ser/Thr

X

Val/Leu/Ile

Class II

X

Phe/Tyr

X

Phe/Tyr

Class III

X

X

X

Cys

Class IV

X

Asp/Glu

X

Val

Table 2.1 Classification of PDZ domains based on the preference in amino acid
sequence of their binding partners; X stands for multiple possible standard amino
acids.
The idea of Bezprozvanny’s work [117] can be utilized by expanding the
number of residues in the binding pocket of the domain that are taken into
consideration. Thus proposed classification of PDZ domains by Bezprozvanny
and Maximov was listed in SMART website (yielding 25 groups overall) [118].
Insight into structure of both class I and II PDZ domains reveals that they
have a very similar fold of six β-sheets and two α-helices despite their differences
in amino acid sequence. Protein domain structure is the property that is
conserved, not its sequence [90].
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2.4.1 Class I PDZ domains. The majority of studies on PDZ domains was done
on class I PDZs. Doyle et al. [88] pioneered the work by solving the crystal
structure of PDZ3 of PSD-95 bound with the peptide derived from C-terminal of
CRIPT (cysteine rich interactor of PDZ domain).

Figure 2.3 Structure of the PDZ3 domain (blue) from PSD-95
complexed with peptide TKNYKQTSV (golden) derived from Cterminal of CRIPT. Only four C-terminal residues (QTSV) were
resolved in the crystal structure. The picture is reprinted from Doyle
et al. with the permission from Elsevier.

59
Published crystal structure of PDZ3 (Figure 2.2) is comprised of six β
strands (βA- βF) and two α-helices (αA and αB), which fold in an overall sixstranded β sandwich.
Four residues of the ligand’s C-terminal region have been shown to
interact with the peptide binding groove between the βB strand and αB helix as
an antiparallel β strand extending one of the β sheet. The C-terminal hydrophobic
residue valine at the “0” position of the peptide binds to the hydrophobic pocket
created in the PDZ domain by several hydrophobic residues, which are Leu 323,
Phe 325, Ile 327, and Leu 379. Since this pocket is the only one present on the
binding surface of the domain, authors hypothesize that selection of biding
parthner is done based on the volume of this pocket. The tight contact of the side
chain of valine with the hydrophobic pocket explains the preference for the
sequence having a hydrophobic residue at the “0” position [88]. Another critical
interaction is the hydrogen-bonding interaction of the hydroxyl group of the “-2”
position Thr with N3 of His 372 (first residue of the αB helix). The side chain of
the “-1” Ser residue is shown pointing away from the interacting surface.
The general feature of PDZ domains to bind to C-terminal sequences is
supported by the stabilization of carboxylate through the series of H-bonds to the
so called carboxylate binding loop formed by the conserved Gly-Leu-Gly-Phe
(GLGF) and an Arg 318 through a highly ordered water molecule.
Superposition of crystal structures of the peptide-free and peptide-bound
PDZ3 domain of PSD-95 showed very little conformation change leading to
peptide binding event
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Figure 2.4 Mechanism of peptide recognition by PDZ domain.
Reprinted figure from Harris et al.[119]
2.4.2 Class II PDZ domains The class II recognition mechanism was first
studied on crystal structure of hCASK/LIN-2 PDZ domain [120]. The structure of
hCASK/Lin-2 PDZ domain is consistent with the typical PDZ fold formed by six
β–strands and two α-helices shown also for class I PDZ domains, even though
these classes only share a low percentage (20%) of sequence identity. An
unexpected feature of this structure is that the peptide binding pocket of this
domain is occupied by the C-terminal sequence of a neighboring non-

61
crystallographically related molecule. Peptide binding site consists of two
hydrophobic pockets for residues at positions “0” and “-2” which is consistent with
the class II binding sequence: X-φ-X-φ (where X is any amino acid and φ is a
hydrophobic residue). Binding pocket can accommodate smaller and larger
hydrophobic groups.
After closely examining the binding pocket, it is noted that “-2” position is
formed by residues Met 507, Val 549 (at position αB1) and Leu 552. Among
these, Val 549 is highly conserved in the class II PDZ domains. This residue is
replaced by histidine in class I PDZ domains and forms an important H-bond with
the Ser/Thr residue at “-2” position of their binding partner. Another interesting
feature of this domain is that the carboxylate binding loop is structurally very
similar with that of class I, although sequences are very different (Pro-Met-Gly-Ile
in the hCASK instead of Gly-Leu_Gly-Phe). Despite these sequence differences,
both class I and II PDZ domains are structurally similar and form H-bonding
through an ordered water molecule.; yet, they bind to completely different target
sequences.
2.4.3 Non-C-terminal PDZ domain-peptide binding Non-canonical binding of
PDZs to cyclic peptides was first discovered through the phage dislay library
containing peptides cyclized via an intramolecular disulfide bond [89]. Later
reports have shown that PDZ domains can bind to internal sequences in other
PDZ domains [121, 122]. Both these complexes are characterized by interactions
of PDZ domains with “pre-organized β-finger motifs” in their partners. This βfinger motif is formed by an extension of the canonical PDZ sequence that
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contains around 30 amino acids. The β-finger motif binds into the traditional
peptide binding site of the PDZ domain and its first strand mimics a C-terminal
peptide binding. The terminal carboxylate of a peptide ligand is replaced by the
sharp β turn at the tip of the nNOS β-finger. The loss of the important interaction
of the C-terminal carboxylate with the GLGF motif in the PDZ domain is most
probably compensated by the tertiary interactions between these two PDZ
domains. Evidence that supports this hypothesis is the calculation of the surface
area buried upon binding of the β-finger motif of nNOS PDZ domain to the PDZ
domain of syntrophin, which comes to 800 Å2. This value is twice as much as the
burial of the surface area for binding of a C-terminal peptide ligand. This type of
interaction might be typical for other PDZ domains than PDZ of nNOS if they
fulfill the requirements for the β-finger motif in their structure.
2.5 Ligand recognition by PDZ domain. As previously stated positions “0” [116,
123] and “-2” [88, 124] are the critical residues for the recognition of the peptide
sequence by PDZ domains. Evidence is emerging that other residues play role in
the specificity of the peptide recognition [116]. Structural data of PDZ domains
complexed with peptides [88, 120, 121] reveals the key components for the
molecular interaction event; (1) stabilization of C-terminal carboxylate group, (2)
binding of the “0” residue at a hydrophobic pocket, (3) hydrogen bonding of
peptide backbone with the side chain of different residues in the PDZ domain,
and (4) binding of the “-2” residue with the conserved His residue (the first
residue in the αB helix) in PDZ domain.
PDZ domains have a unique ability to stabilize the C-terminal carboxylate
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group. They do so due to the presence of carboxylate-binding loop containing the
conserved motif R/K-X-X-X-G-L-G-F. The peptide C-terminal carboxylate is
coordinated by a network of hydrogen bonds with main chain amide group of this
loop. The carboxylate group forms hydrogen bonds with conserved Arg or Lys
mediated through an ordered water molecule. A mutational study in PSD-95 and
syntrophin PDZ domains has revealed the importance of the identity of
conserved but interchangeable Arg or Lys in peptide recognition [125]. The result
also indicates that the identity of the residues at this position in the carboxylatebinding loop is critical for the interaction of one PDZ domain with another PDZ
domain. PDZ domains with Lys at this position (PDZ2 of PSD-95, PDZ domains
of both α- and β-syntrophins) dimerize with the PDZ domain of nNOS (neuronal
nitric oxide synthase) while PDZ with Arg at this position (PDZ1 and 3 of PSD-95,
PDZ of γ1-syntrophin) restricts the dimerization with PDZ of nNOS [125].
N-methyl amide scanning of the peptide backbone shows that hydrogen
bonding plays an important role in the PDZ ligand interaction [126]. The order of
affinity of the N-methyl amide peptides suggests that amide hydrogens at the “0”
and “-2” positions are more important than at other positions, consistent with the
hydrogen bonding inferred from the structural information of peptide-bound PDZ3
of PSD-95 [88]. Replacing the carboxylate group with neutral alcohol and
hydroxamide group shows that electrostatic interaction of carboxylate group
andconserved Lys (in MAGI-3 PDZ2) is more important than preserving the size
of the “0” residue.68 This study also points out that the interaction between the “2” Ser/Thr hydroxyl group and the His side chain (from αB1 of the PDZ domain)
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is strictly regulated by the approximate size of binding pocket as peptide side
chain modifications at “-2” position. Such modifications include inversion of chiral
center, branching, and elongation; all lead to abolition of binding.
Requirement of a free terminal carboxylate group for the ligand led to the
belief that electrostatic interaction of the C-terminus with the domain plays an
important role in recognition. But examining the salt dependence of both terminal
and internal ligands and the effect of mutation of a conserved basic residue
(thought to be important in electrostatic recognition) in syntrophin PDZ showed
that direct electrostatic interaction with the terminal peptide do not play a
significant part in binding specificity [127]. Binding analysis of a series of
chemically modified C-terminal peptides with syntrophin PDZ demonstrates that
steric features and hydrogen bonding complementarity are vital for recognition of
the free carboxy group.
One of the major projects in our laboratory is based on the design of
macrocyclic ligands for PDZ domain using structure-based information [128,
129]. Cyclic peptides show higher stability to proteolytic cleavage in in vivo
studies, along with significant improvement in entropic contribution to the binding
affinity[130]. Another approach utilized a peptide library containing nonstandard
amino residues at position “0” was used to improve the ligand affinity by
optimizing the size of hydrophobic group at this position to best fit the binding
cavity [131].
2.6 Affinity of PDZ domain-mediated interactions. Binding affinities for the
PDZ-mediated interactions have been reported in studies that used both solution-
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based methods (fluorescence [105, 132-135] and ITC [128, 129, 136, 137]) and
solid-phase methods (surface plasmon resonance [116, 138, 139] and ELISA
based assay [140]). Predominantly, solution methods are gaining lower values of
affinity values (in the micromolar range) as opposed to the values from solid
phase methods (in the nanomolar range). Such findings are attributed to solid
phase methods possessing artifacts that lead to overestimation of binding
affinity[141, 142]. PDZ domains are involved in transient, reversible interactions
with other macromolecular targets, these low micromolar interactions are
consistent with their regulatory function [143]. However, it is worth noting that
actual in vivo values may be affected by local concentration in the subcellular
compartments or the cellular enviroment (molecular crowding phenomenon).
2.7 Regulation of PDZ domain interactions. Regulation of protein-protein
interaction involving modular domains and their binding partners is often critical
for cell signaling [80]. Several mechanisms have been proposed for the
regulation

of

PDZ

domain

interactions.

One

is

phosphorylation

and

dephosphorylation of Ser and Thr at the “-2” position in class I PDZ domains
[144]. Specific phosphorylation at the “-2” position of β2 adrenergic receptor with
GRK-5 (G-protein coupled receptor kinase 5) abolishes its interaction with PDZ
of NHERF (Na+/H+ exchanger regulatory factor) [145]. Similarly, serine
phosphorylation at the “-2” position in the inward rectifier K+ channel Kir2.3 by
protein kinase A (PKA) disrupts Kir2.3 binding to the PDZ2 domain of PSD-95
[146] In another example, phosphorylation of the “-3” residue of the AMPA
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receptor subunit GluR2 C-terminus by another kinase PKC prevents GluR2
binding to the GRIP PDZ domain [143].
Another mechanism proposed is allosteric regulation, as seen in the case
of the Par6 PDZ domain. The binding of Cdc42 to CRIB (Cdc42/Rac interactive
binding) domain of Par6 induces conformational changes in the Par6 PDZ
domain, leading to enhanced affinity for the ligand [147, 148]. A NMR binding
analysis of the hPTP1E (human protein tyrosine phosphatase 1E) PDZ2 domain
with RA- GEF2 (Ras-associated guanine nucleotide exchange factor 2) peptide
indicates a significant change in PDZ2 dynamics upon ligand binding, and the
distal surface in PDZ2 are shown dynamically linked to the ligand binding site
[149].
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2.8 Materials and Methods.
This section describes all the materials and experimental procedures employed
in conducting the research presented in this dissertation.
2.8.1 Materials. Difco laboratories Bacto® Lennox LB Broth and granulated agar
were used to prepare the LB/amp50 plates and LB/amp50 Media. Corning® 100
mm/tissue culture dishes were used for the LB/amp50 plates. The ampicillin
sodium salt was acquired from Fisher Biotech and a 20 mg/mL stock solution
was prepared by dissolving ampicillin sodium salt (2%) in water. The ampicillin
stock solution was filtered with a Star LB™ 0.22 µm filter. Corning® 0.22 µm
polyethersulfone filters were used to sterilize the LB/amp50 media. The
incubators used for bacterial culturing were the Fisher Isotemp® 200 series and
the Lab-line® Incubator-Shaker incubators. Handling and plate streaking with
glycerol stock, as well as transfer of the liquid cultures, were performed within a
Laconco purifier class II biosafety cabinet. The 10 mL and 20 mL LB
broth/amp50 cultures were grown in Falcon® Blue Max™ 50 mL conical tubes.
The electrophoresis chamber used for the agarose gels was the Small
Horizontal Gel System FB MSU-1 by Fisher Biotech and the gels were visualized
on the Transilluminator FB TIV-88 UV Box by Fisher Biotech. The E-C Apparatus
Corporation EC 105 electrophoresis power source was utilized. Ethidium bromide
was obtained from LKB Instruments Incorporated. The QIAquick PCR Purification
Kit and QIAprep Spin Miniprep kit were acquired from Qiagen. Invitrogen® DNA
Dipsticks™ were used for quantitation of DNA samples. Eppendorf Centrifuge
5810 R and Centrifuge 5417 C were utilized for centrifugation steps.
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DNA primers were prepared by Sigma-Genosys and Invitrogen. The
VentR® DNA Polymerase, T4 DNA ligase, and Buffer B were purchased from
New England Biolabs. The Wizard® Plus Maxipreps DNA Purification System,
PCR Nucleotide Mix, Buffer D, Buffer H, acetylated BSA, 1 kb DNA ladder, and
the Bam HI, and Sal I restriction endonucleases were acquired from Promega
Corporation. Ampliwax PCR Gem 100 was obtained from Perkin Elmer. The PCR
thermocycler used was the Ericomp Inc. Twinblock™ System Easycycler Series.
VWR Scientific Products Standard Heatblock and Model 1162 water bath were
used. The E. coli cells were Epicurian Coli BL21-Gold competent cells by
Stratagene. The BL21(DE3)RIL/pRK793 cells were obtained from Science
Reagents.
All biochemical reagents were purchased from Sigma, Fischer Scientific,
and VWR. Molecular Weight Standard Mixture was obtained from Sigma.
Coomassie® Plus-200 Protein Assay Reagent and TPCK Trypsin were obtained
from Pierce. Advanced Protein Assay Reagent was obtained from Cytoskeleton.
Glutathione agarose beads were purchased from Sigma. DTT and IPTG were
obtained from Inalco Spa. SnakeSkin™ Pleated Dialysis Tubing and Slide-ALyzer™ Dialysis Cassettes were obtained from Pierce. Amicon™ Ultra-15
Centrifugal Filter Devices were obtained from Millipore. Mini-Protean® III
Electrophoresis Cell from BioRad was used for PAGE analysis. HiTrap™ QHP
column was obtained from Pharmacia Biotech. The liquid samples were loaded
into the chromatographic columns (both for isolation and purification) with the
help of Dynamix® peristaltic pump. OLIS-CD spectropolarimeter was used for
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CD measurements. Beckman Coulter™ DU® 530 UV/VIS spectrophotometer was
used to read the absorbance. Corning PH meter 430 and VWR symPHony
electrode were used for pH measurements. Hamilton Gastight Syringes from
Hamilton

were

used

for

ITC

experiments.

ThermoVac

and

VP-ITC

Microcalorimeter from MicroCal™ Incorporated were used for ITC experiments.
Wizard® plus maxiprep DNA purification kit (Promega) was used for the
purification of plasmid DNA.
2.8.1.1 Preparation of solid and liquid media. The agar plates were prepared
by dissolving Lenox LB (Difco) broth (2%), agar (1.5%) and deionized water. The
mixture was autoclaved for 30 min at 121-124 ºC. Once the temperature of the
media reached 50 ºC, ampicillin stock solution (20 mg/mL) was added to obtain a
final ampicillin concentration of 50µg/mL. Ampicillin stock solution was prepare
by dissolving ampicillin sodium salt (2%) in deionized water followed by filtering
through Star LBTM 0.22 µm filter to remove any potential contaminants.
The agar solution was then pipetted into Corning® 100 mm tissue culture
dishes and allowed to solidify at room temperature. Once solidified plates were
inverted, labeled and stored at 4 ºC.
TB (Terrific Broth)/amp50 media was prepared by dissolving Bacto Terrific
Broth (4.76%), glycerol (0.4%) in deionized water. To this solution 20 mg/mL
ampicillin stock was added to yield a final ampicillin concentration of 50 µg/mL.
Finally,

media

was

sterilized

by

filtering

through

Corning® 0.22

polyethersulfone filters and stored in autoclaved bottles at room temperature.

µm
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2.8.2 Methods
2.8.2.1 Expression of fusion protein. A glycerol stock solution of E .coli BLRGold cells, containing the gene that encodes for the desired GST fusion, was
used to streak LB/amp50 plates and incubated for 12 h at 37 ºC. An isolated
colony of moderate size was picked out and used to inoculate 10 mL of
TB/amp50 broth in 50 mL Falcon tube, and left to grow with shaking for
approximately 8 h. This culture was then placed in an autoclaved 1 L flask
containing 90 mL of fresh TB/amp50 nutrient media, and incubated in the same
manner for 2 h. The culture was then split in half, and 450 mL of the fresh
TB/amp50 media was added to each. These cultures were incubated in 2x2 L
flasks, with shaking at 37 ºC for approximately 3 h, until the optical density at 600
nm (OD600) value reached 1.2. At this point the expression of fusion protein was
induced by IPTG (isopropyl-1-thio-β-D-galalctoside), used at a final concentration
0.8 mM. The incubation was allowed to continue at 30 ºC with shaking for an
additional 5 h. The culture was transferred into 250 mL centrifuge tubes and
spun down at 3220xg for 20 min at 4 ºC. The supernatant was decanted and the
harvested bacterial pellets were stored at -80ºC.
2.8.2.3 Bacterial cell resuspension and lysis. The bacterial cell pellets were
resuspended in ice-cold PBS buffer (Phosphate Buffered Saline) containing 1%
Triton-X and 10mM β-mercaptoethanol. The Branson 250 Sonifier (Branson
Ultrasonics Corporation) was used to lyse the cells by sonication. During
sonication (3.2 mm probe, instrument set at 50% duty cycle and output control 5)
that lasted for 55 s, cells were kept on ice. The sample was then centrifuged at
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10,000xg for 20 min at 4 ºC to pellet the cell debris. The supernatant was
decanted into a 50 mL Falcon tube. A clear cell lysate was obtained, and kept at
4 ºC.
2.8.2.4 Glutathione agarose beads (GST-affinity) column preparation.
Approximately 0.75 mL of glutathione agarose beads (Sigma) were placed in a
50 mL Falcon tube and allowed to swell in 10 volumes of 1xPBS ice-cold buffer
for 1 h. The beads were than centrifuged at 10,000xg for 10 min, the supernatant
discarded, and 5 mL of 1xPBS added to the bead slurry. Pre-swelled beads were
then transferred to a glass column (20 mm diameter, 150 mm length). The
glutathione bead column was then washed with ten times the volume of 1xPBS
and stored in 10 mL of the same buffer (4 ºC).
2.8.2.5 Isolation of fusion protein. Prepared glutathione-bound agarose beads
column was washed with 10 volumes of ice-cold PBS buffer. Cell lysate was
loaded onto the column at a rate of 5 mL/min, using Dynamix Peristaltic pump,
followed by repeated washing with 10 volumes of PBS. The fusion protein was
eluted with 50mM Tris-HCl, 5 mM reduced glutathione, pH 8.0. This extraction
procedure was repeated till all the fusion protein was isolated from the cell lysate
(determined by Coomassie plus-200 protein assay and SDS-PAGE analysis).
2.8.2.6 SDS-PAGE analysis. In order to determine the effectiveness of the
fusion protein extraction, protein samples were analyzed by 20% SDS-PAGE. 20
µL aliquots were combined with 10 µL of sample buffer (12.5% Tris-HCl (pH 6.8),
10% glycerol, 10%(w/w) sodium dodecylsulfate (SDS), 5% β-mercaptoethanol,
15%(w/v) bromophenol blue and 47.5% deionized water). Molecular weight
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marker (MW) was prepared by taking 20 µL of molecular weight standard
(Sigma) and 5 µL of sample buffer. All samples were placed in a boiling water
bath for 3 min (except for the MW; this period was 2 min). The samples were
loaded on the gel, and run in the mini Protean III Electrophoresis Cell (BioRad)
for approximately 50 min. at 200 V. The gel was then stained in Coomassie blue
stain (50% methanol, 0.05% Coomassie brilliant blue, 10% acetic acid, 40%
deionized water) for 15 min. The gel was then left overnight in destaining solution
(5% acetic acid, 0.5% methanol, 85% deionized water). The gel was scanned
using a CanoScan D1250 U2F scanner.
2.8.2.7 Determination of fusion protein concentration. The Coomassie plus200 protein assay was used to determine GST fusion protein concentration. The
spectrophotometer was auto-zeroed and measurements taken with deionized
water as reference. According to the protocol provided (Pierce), a 50 µL aliquot
of each fusion protein sample was added to 1.5 mL of Coomassie Plus-200
protein reagent in a 2.0 mL microtube. A blank was prepared by mixing 50 µL of
elution buffer with reagent. Contents of the tubes were gently mixed by inverting,
and the absorbance measured at 595 nm. The results obtained were compared
against a standard curve prepared by performing the Coomassie plus 200
Protein assay on diluted samples of 200 50 µg/mg Bovine Serum Albumin (BSA)
stock.
2.8.2.8 Trypsin cleavage of fusion protein. Different trypsin to protein ratios
were used for different fusion protein samples. For GST-PDZ1 and GST-PDZ2,
the ratio used was 1:1400(w/w), and for GST-PDZ1-2 it was 1:7000 (w/w) of
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trypsin (TPKC-trypsin, Pierce) to fusion protein. Trypsin working buffer (20 mM
Tris-HCl, 200 mM NaCl, 1 mM EDTA, pH 7.4) was added, if required, to bring the
final trypsin concentration to 1 µg/mL (from 1 mg/mL trypsin stock solution). The
cleavage reactions were allowed to proceed for 2 h and 2.5 h for PDZ1 and
PDZ1-2, respectively.
In order to stop the trypsin cleavage reaction, immobilized Soybean
Trypsin Inhibitor on beaded agarose (Pierce) was added. The inhibitor was made
into a 50:50 v/v slurry according to the Pierce protocol. One milligram of the
trypsin inhibitor in a slurry can stop 4.5 mg of trypsin. Twice the theoretical
amount was added. The contents of the tube were mixed by inverting for 2 min at
room temperature, and then left for 5 min on ice. The procedure was repeated
two more times. The cleaved product was then filtered through a 0.45 µm nylon
Bio Express syringe filter to remove the immobilized inhibitor. The cleaved
sample was placed in Snake Skin 3500 MWCO dialysis bag (Pierce) and
dialyzed into 1 L of 20 mM MES, 10 mM NaCl, 1 mM DTT, pH 6.0. Thr dialysis
buffer was changed twice.
2.8.2.9 GST removal. A GST affinity column was used to remove GST from
dialyzed cleavage mixture. GST was bound to the glutathione agarose beads,
while PDZ proteins were collected in the flow-through. The column was prewashed with 10 column volumes of ice cold PBS, and trypsin cleavage samples
were loaded at the rate of 5mL/min, collecting the flow in 50 mL Falcon tubes on
ice. The column was washed and the bound GST eluted with 50 mM Tris-HCl, 5
mM reduced glutathione pH 8.0. The GST removal procedure was repeated
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twice. The efficiency of GST removal after a second passage through the column
was visualized by SDS-PAGE. The samples were further dialyzed in MES buffer
(20 mM MES, 10 mM NaCl, 1 mM DTT, pH 6.0) for PDZ1 and MES buffer (20
mM MES, 10 mM NaCl, 1 mM DTT, pH 5.9) for PDZ1-2.
2.8.2.10 Purification of protein with ion exchange chromatography. Dialyzed
protein samples were purified by ion exchange chromatography. The Hi-trap Q
column (Amersham Pharmacia) was pre-washed with 5 column volumes of start
buffer (20 mM MES, 10 mM NaCl, 1 mM DTT), followed by 5 volumes of
regeneration buffer (20 mM MES, 1 M NaCl, 1 mM DTT), and then again 5
column volumes of start buffer. Previously dialyzed protein samples were then
loaded into the Q column at a rate of 5 mL/min, using the Dynamax peristaltic
pump. The column was washed with 5 column volumes of start buffer, and the
bound protein was then eluted with 20 mM MES, 10 mM NaCl, 1 mM DTT, pH
6.0 or pH 5.9 (depending on the protein of interest) with varying ionic strength
buffer. The elutions were conducted with an overall volume of 3 column volumes
(15mL) of 25, 35, 45, 50, 55, 60, 65, 70, 75, and 80 mM NaCl for PDZ1, and 25,
40, 50, 70, 80, 90, 100, 110, 120, 140, 150, 200, and 250 mM NaCl for PDZ1-2.
The column was then regenerated by washing with 5 column volumes of
regeneration buffer, and 10 column volumes of start buffer. All the elutions were
collected in 50 mL Falcon tubes on ice. 20 µL aliquots of all the elution fractions
were analyzed by 20% SDS-PAGE. The elution fractions that contained protein
of interest were dialyzed into final MES buffer (20 mM MES, 10 mM NaCl, pH
6.0) for PDZ1 and PDZ2 and (10 mM sodium phosphate, pH 6.0) for PDZ1-2.
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2.8.3 Concentrating sample and determining protein concentration.
Dialyzed

protein

samples

(dialysis

buffer

changed

three

times)

were

concentrated using Millipore Ultrafree-15 Centrifugal Filter Device MWCO 5000.
The filter was rinsed with dialysis buffer, used for the sample for 10 min at
2000xg, at 4 °C. The samples were added in 50 mL portions, and then
concentrated by centrifuging at the same speed until a satisfactory concentration
for ITC experiments was obtained.
A final protein concentration was defined by UV measurements at λ = 280
nm. Extinction coefficients for individual PDZ domains were obtained from
calculations based on the protein sequence. Two quartz cuvettes (path length of
1 cm) were used for the measurements. Sample dialysis buffer was used as a
reference in the measurements and to auto-zero the instrument.
2.8.3.1 Advanced Protein Assay. The absorbance was measured at 590 nm for
this assay. Advanced Protein Assay Reagent (ADV01) was used as a reference
and to auto-zero the instrument. The samples were gently mixed, transferred to
disposable cuvettes, and the absorbance was measured with a UV-VIS
spectrophotometer. Each 15 µL of protein sample was added to 1.5 mL ADV01,
and the absorbance was read and concentration calculated based on correlation
1.0 OD590 = 30 µg/mL of reagent, per cm of path length.
2.8.3.2 Coomassie plus-200 protein assay. For the final protein sample, the
Coomassie plus-200 Protein Assay was used. The same protocol described in
2.3.2.7 was employed, with the only difference being that the dialysis buffer was
used instead of reduced glutathione solution.
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2.8.4 Characterization of PDZ1, PDZ2 and PDZ1-2 proteins of PSD-95.
2.8.4.1 ESI mass spectroscopy. PDZ1, PDZ2 and PDZ1-2 tandem protein
samples, whose purity were assessed by SDS-PAGE, were placed in 0.5 mL
Slide-A-Lyzer dialysis cassettes (3500 MWCO) and dialyzed in 0.1 %
trifluroacetic acid (TFA) in deionized water, volume of buffer 600 mL. The dialysis
buffer was changed twice. The sample was taken out of the dialysis cassette and
submitted for electrospray ionization mass spectroscopy (ESI-MS) analysis
(Central Instrumentation Facility, WSU).
2.8.4.2 Plasmid DNA preparation for sequencing. Glycerol stocks of E. coli
bearing the individual GST fusion were used to streak a single LB/amp50 plate,
which was then incubated at 37 °C overnight. One colony was chosen to
inoculate 10 mL of TB/amp50 media in a 50 mL falcon tube incubated with
shaking for 10 h at 37 °C. Only 2 mL of the prepared culture was centrifuged at
20,800xg for 5 min to pellet the cells. The supernatant was removed, and a
Qiagen Spin Miniprep Kit was used to extract the plasmid.
2.8.4.3. Quantitation of GST-PDZ plasmids and DNA sequencing. The DNA
DipStick Kit was used to determine DNA concentration in the sample. Plasmid
preparation sample dilutions (1:1; 1:10; and 1:100) were spotted on the DNA
DipStick membrane and developed accordingly. Based on comparison of the
color intensities to the standard chart on the DNA DipStick Quick Reference
Card, the concentration was estimated to be >500 ng/µL, sufficient for analysis.
The result showed the DNA concentration to be 100 ng/mL or more. 20 µL of the
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plasmid DNA sample and 10 µL of PGEX5 primer (1 µM) were sent to the
sequencing facility in the Biological Sciences Department of WSU.
2.8.5 Subcloning PDZ4 of MUPP-1.
2.8.5.1 Isolation of donor plasmid. The template DNA for MUPP-1 PDZ4 was
isolated from cells containing plasmid pcDNA-MUPP1. The gene that encodes
for the whole rat MUPP-1 protein was constructed into plasmid DNA of the host
cells. Glycerol stock of E. coli was used to streak a single LB/amp50 plate, which
was then incubated at 37 °C overnight. One colony was chosen to inoculate 10
mL of TB/amp50 media in a 50 mL falcon tube, incubated with shaking for 10 h at
37 °C. Only 2 mL of the prepared culture was centrifuged at 20,800xg for 5 min
to pellet the cells. The supernatant was removed, and a Qiagen Spin Miniprep Kit
was used to extract the plasmid.
2.8.5.2 Quantification of the MUPP-1 donor plasmid. The DNA DipStick Kit
was used to determine the DNA concentration in the sample. Plasmid
preparation sample dilutions (1:1; 1:10; and 1:100) were spotted on DNA
DipStick membrane and developed accordingly. Based on comparison of the
color intensities to the standard chart on the DNA DipStick Quick Reference
Card, the concentration was estimated to be >500 ng/µL.
2.8.5.3 Polymerase chain reaction of the MUPP-1 plasmid.
Primers were designed to hybridize to sequences flanking the PDZ4 encoding
region for amplification. The lyophilized forward (4.6 nmol) and reverse primer
(4.8 nmol) (obtained from Invitrogen) were resuspended in sterile TE buffer (pH
8.0) to make a 100 µM stock. From these stocks, working solutions (20 µM) were
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prepared by dilution. Two separate reaction mixtures were prepared and Hot
Start PCR was used.

Solution 1

Solution 2

Sterile deionized water (63
µL)

Sterile deionized water (6
µL)

Forward primer (5 µL)

10 x Thermo buffer (1 µL)

Reverse primer (5 µL)

Vent Polymerase (1 µL)

10 x Thermo buffer (9 µL)

Plasmid DNA (2 µL)

nucleotide bases (8 µL)
Total volume (90 µL)
Total volume (10 µL)
Table 2.2 PCR reaction conditions
Each component of the Solution1 was added to a PCR microtube (50 µL)
and an Ampliwax PCR Gem 100 wax bead was placed on the top of the liquid.
The wax was melted by placing the PCR microtube in a 80 °C heat block for 5
min, and then it was transferred on ice to allow the wax layer to solidify. On the
top of the layer, Solution2 was carefully pipetted, and the tube was then placed in
the Thermocycler. A second reaction was prepared exactly as the previous one,
but with an increased concentration of MgSO4 (from 2 µM to 4 µM), while
keeping the overall volume constant.
The thermocycler was programmed for 3 cycles. Cycle 1-5 min at 94 °C
for 1 repetition, cycle 2-10 seconds at 94 °C, 30 seconds at 45 °C, and 1 min at
72 °C for 25 repetitions, cycle 3 was set for 10 min at 72 °C for one repetition.
2.8.5.4 Agarose gel analysis of PCR product. A 1% agarose gel was prepared
by mixing 0.5 g agarose powder with 50 mL 1xTBE buffer (prepared by dilution
from 5 mL of 10xTBE buffer: 0.9M Tris base, 0.9M Boric acid, 0.025M EDTA (pH
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8.0) and 45 mL of deionized water). The mixture was heated in a water bath for
approximately 20 min, until the agarose was completely dissolved (solution
became clear). After cooling for a few minutes, 2.5 µL of ethidium bromide (10
mg/mL) was added to yield a final concentration of 0.5 µg/mL, and then the
mixture was poured into a gel casting frame, with a comb inserted in it. After the
gel solidified (15-20 min), the comb was removed and the gel placed into the
electrophoresis apparatus and covered in 300 mL of 1xTBE buffer with 15 µL
same ethidium bromide stock solution, final concentration being 0.5 µg/mL.
Samles were prepared as follows using 10 X Loading buffer-(20% w/v) Ficoll
400, 0.1M Na2EDTA (pH 8), 1.0% (w/v) SDS, 0.25% (w/v) Bromophenol blue,
0.25% (w/v) Xylene cyanol and 1 X TBE buffer.
sample
LANE1
LANE2
LANE3

1X TBE

10X Loading
buffer
1 µL

Promega 1kB DNA
8 µL
ladder
PCR reaction (2 µM
8 µL
1 µL
MgSO4)
PCR reaction (4 µM
8 µL
1 µL
MgSO4)
Table 2.3 Gel analysis of PCR products

The samples (10 µL) of each were loaded into the wells and the gel was
run at 82 V for 1 h. Lane 2 showed a band at approximately 300 bp, as expected.
The increased concentration of MgSO4 didn’t result in any band at lane 3. The
calculated size of the PCR product was 303 bp, which corresponds to the band
visualized under the UV light.
2.8.5.5 Purification and quantification of the PCR product sample. Qiagen
PCR Purification Kit was used to purify the PCR product. The DNA DipStickTM Kit
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was used to quantitate the purified sample. PCR product samples that were
undiluted, (1:5), (1:10) diluted were spotted on a DipStickTM membrane and
developed accordingly. Concentration estimated to be10 ng/µL.
2.8.5.6 Double restriction enzyme digest of PCR product sample. The PDZ4
PCR product was cleaved using Bam HI and Sal I restriction enzymes to form
complementary ends for ligation into the GST plasmid. Double digest reaction set
up was as follows: purified PCR product (20 µL), 10 X Buffer D (4 µL), acetylated
BSA (0.4 µL), sterile deionized water (13.6 µL), Bam HI (1 µL) and Sal I. The
reaction was mixed in a microtube and incubated for 2 hours at 37 °C.
2.8.5.7 Preparatory agarose gel of the restriction digest (PCR of PDZ4). A
1% agarose gel was prepared as described previously (2.1.3) except different
comb with larger wells was used to accommodate the increased sample volume.
After the gel was solidified, comb was removed and the gel placed into the
electrophoresis apparatus and covered with 300 mL of 1 X TBE buffer, Ethidium
bromide final conc. 0.5 µg/mL. To the overall volume of 40 µL of restriction
digest 5 µL of 10 X Loading buffer and 5 µL of 1 X TBE were added. The sample
was run on the gel along with molecular weight marker (2 µL 1 kb DNA ladder, 2
µL of 10 X Loading buffer, 16 µL 1 X TBE buffer) at 82 V for approximately 1
hour. Gel was then taken out from the chamber and placed on the UV
illumination box. The band containing PDZ4 DNA was cut out and weighted.
2.8.5.8 Preparation of PDZ4 DNA for ligation. The Geneclean II kit Bio 101
was used with the TBE modifier to dissolve the gel slice and remove
contaminants.
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2.8.5.9 Quantification of the purified, digested PDZ4 DNA sample. Once
again DNA DipStickTM Kit was used to determine DNA concentration in the
sample. Purified, digested samples that were undiluted and (1:10) were spotted
on DNA DipStickTM membrane and developed according to the protocol. When
the membrane dried, color intensities were compared to the standard chart.
Concentration was estimated to be 100 ng/µL.
2.8.5.10 Plasmid prep of GST/PDZ3 vector. A plate LB/amp50 was streaked
with glycerol stock of E. coli cells which contained GST/PDZ3 vector and the
plate was incubated overnight. Single, isolated colony was picked out and used
to inoculate 10 mL of TB/amp50 media, followed by incubation at 37 °C with
shaking for 8 h. Then 500 µL of the culture was used to inoculate 500mL of fresh
TB/amp50, and the growth was continued overnight (37 °C, shaking).
The culture was spun down in 250 mL centrifuge tube at 3220 x g for 20
min, to pellet the cells. Supernatant was discarded and Wizard® Plus Maxiprep
purification system from Promega was used to extract the plasmid from cells.
2.8.5.11 Restriction digest of the GST/PDZ3 plasmid. GST/PDZ3 plasmid has
also unique restriction sites Bam HI and Sal I (as previously 1.5). Therefore,
double restriction digest was performed on GST/PDZ3 to remove PDZ3 insert
and create complementary ends for the ligation of the PDZ4 (MUPP-1) into GST
plasmid. Double restriction digest reaction was set up in the following order:
sterile deionized water (5 µL) 10 X Buffer D (10 µL), acetylated BSA (1 µL),), at
this point everything was mixed thoroughly by pipetting, and then enzymes were
added Bam HI (2 µL) and Sal I (2 µL). 1.5mL microcentrifuge tube containing
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reaction mixture was incubated at 37 °C, for 2 hours, and then it was immediately
analyzed by agarose gel.
2.8.5.12 Preparatory agarose gel of the restriction digest product-GST
vector. Again 1% agarose gel was prepared with large wells as previously
described (section 2.1.6) and to the restriction digest sample 10 x Loading buffer
(5 µL) and 1 x TBE (5 µL) were added. The sample was run on the gel along with
a molecular weight marker (2 µL of 1kb DNA ladder, 2 µL 10 x Loading buffer,
16µL 1 x TBE buffer) at 82 V for 55 min. The gel was placed on the UV
illumination box, under minimum UV exposure and least possible time to
minimize DNA damage. Using sharp razor agarose piece (digested plasmid) was
cut out and placed into 2 x 1.5 mL microcentrifuge tubes.
2.8.5.13 Preparation of plasmid for ligation and quantification of the
purified plasmid. For the extraction and purification of DNA sample, again
QIAquick Gel Extraction Kit was used (according to the protocol). The DNA
DipStickTM Kit was used to determine the concentration of the DNA in the
sample. Purified, digested plasmid samples that were undiluted, 1:1, 1:5 diluted
were spotted on the DipStickTM membrane and developed. After comparing the
color intensities on the membrane to the standard chart, results showed DNA
concentration of 100 ng/µL.
2.8.5.14 Ligation reaction of the GST-plasmid with the PDZ4 DNA using
FAST-LINK DNA Ligation Kit. The formula shown below was used to determine
the amounts of PDZ4 DNA and GST plasmid DNA for the ligation reaction.
ng insert =

(ng vector) x (kb size of insert)  moles insert 
 moles vector 
kb size of vector
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According to the Fast-Link protocol, insert to vector ratios (2:1), (5:1) and
(10:1) are most likely to give positive results, that’s why three different ligation
reactions were prepared at the time.
Fast-Link DNA Ligation Kit from Epicentre® was used containing Fast-Link
DNA Ligase, 10 X Fast-Link ligation buffer and ATP. Based on protocol, final
ligation reactions were set up according to Table 2.4.
component
10 x FastLink ligation
buffer
10mM ATP
Vector DNA
Insert DNA
Sterile
deionized
water

(2:1)
1.5 µL

(5:1)
1.5 µL

(10:1)
1.5 µL

1.5 µL
2.0 µL
0.4 µL
8.6 µL

1.5 µL
2.0 µL
1.0 µL
8.0 µL

1.5 µL
2.0 µL
2.0 µL
7.0 µL

Fast-Link
DNA ligase

1.0 µL

1.0 µL

1.0 µL

Total
volume

15.0 µL

15.0 µL

15.0 µL

Table 2.4 Fast-Link ligation conditions
Actual incubation time at room temperature was 20 min instead of the
suggested 5 min, since length of incubation can be extended with no deleterious
effects. All three different ligation reactions were then transferred into heat block
at 70 °C for 15 min to inactivate the Fast-Link DNA ligase, a very important step,
since failure to inactivate ligase may decrease transformation efficiencies.
2.8.5.15 Chemical transformation of E. coli cells. The Epicurian Coli BL-21
Gold competent cells were transformed with DNA plasmid from ligation reactions
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previously described. The protocol followed was the one provided in the
Instruction Manual for the transformation of BL-21 Gold competent cells, from
Stratagene®. After thawing the competent cells on ice, three aliquots 3 x 100 µL
were placed in 3x15 mL pre-chilled falcon tubes. The whole amount of each
ligation reaction mixture (15 µL) was added to the falcon tubes accordingly. The
tubes were then incubated on ice for 30 min. The transformation reactions were
then heat-pulsed in a 42 ° C water bath for 20 seconds. Since duration of the
heat pulse is critical for optimal transformation efficiencies, an optimum was
observed in the 20-25 s range. Reactions were then incubated on ice again for 2
min. 0.9 mL of SOC media (stored at -80 ° C and allowed to thaw on ice prior to
use) were added to all three samples, and then they were incubated at 37 °C,
with shaking for 1 h 15 min. Transformed cells were concentrated by centrifuging
at 10,000xg for 10 min. 750 µL of media was removed, and the cells were
resuspended in 250 µL of the media that was left. Aliquots (3 x 15 µL) of each
transformed cells were spread evenly onto LB/amp50 plates using sterile
spreaders. The plates were placed upside-down in the incubator for 30-45 min,
until the media was dried and then flipped and incubated for 37 °C overnight.
2.8.6

Isothermal

titration

calorimetry

(ITC)

experiments.

Calorimetry

experiments were performed with a VP-ITC titration calorimeter (Microcal, Inc.,
Northampton, MA). The protein samples were extensively dialyzed for at least 24
hours in the experimental buffer prior to experiments. The peptides used in the
study were dissolved into the same dialysis buffer as that of the protein samples
in each experiment. The pH of both solutions was measured at room temperature
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using the pH-meter. The instrument was calibrated using three standard
solutions of pH 4.0, 7.0 and 10.0 before measurements. The pH of peptide
sample was corrected to perfectly match that of the protein sample. Differences
of less than 0.02 pH units were considered a perfect match. The standard buffer
for the calorimetry experiments was 10 mM sodium phosphate, pH 7.0 in case of
PDZ1-2. Different buffer conditions were also tried for PDZ1-2 (20 mM MOPS, 10
mM NaCl, pH 7 or 20 mM HEPES, 10 mM NaCl, pH 7). For the different proteins
tested in this study various buffer conditions were used 20 mM MES, 10 mM
NaCl, pH 6.0 for PDZ1, PDZ2 and PDZ3 titrations. The standard experimental
temperature was 25 °C. Solutions were degassed for 15-45 minutes under
vacuum, without stirring, at a temperature a few degrees less than that of the
experiment using the ThermoVac instrument.
For a typical titration, 65−150 µM samples of the PDZ protein were placed
in the 1.4 mL reaction cell while 1.0−4.0 mM peptides were loaded into the 290
µL injection syringe. The c value, defined by Wiseman et. al. to be the product of
the association constant for the reaction, K, and the macromolecule
concentration, M, varied from 1 to 500. Each titration experiment consisted of a
first (1 or 2 µL) injection (which was not used in data fitting) followed by 5 or 10
µL injections performed at 3 minutes intervals. The stirring speed used was 270
rpm and the reference power 10 µcal/sec. Heats of dilution were measured in
blank titrations by injecting the peptides into the buffer used in the particular
experiment. These results were used to correct the binding heats. This correction
could sometimes be performed by taking the average of the last 5 microinjections
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at the end of titration. Also, control experiments were performed by injecting the
buffer into the buffer and the PDZ protein into the buffer.
2.8.6.1 Analysis of the ITC Data The data from each titration experiment were
collected by the ORIGIN software (version 5.0, MicroCal Inc.). Thermodynamic
parameters were determined by non-linear least-squares fitting for One Set of
Sites, Two Set of Sites and Sequential Binding Sites model (all being standard
model analysis in the Origin software used).
2.9 Results.
2.9.1 Subcloning of PDZ4 domain MUPP-1 into pGEX-2T vector. Primers for
the PCR reaction were designed according to the known sequence of MUPP-1 in
the pcDNA plasmid. This plasmid was used as a template for the polymerase
chain reaction. Primers were designed to hybridize the sequences flanking the
PDZ4 encoding region, in order for it to be isolated and amplified. The PDZ4
product from PCR was then ligated into the GST/PDZ4-containing plasmid in
which the PDZ3 domain of PSD-95 was removed by restriction digest. Bam HI
and Sal I restriction sites in the PDZ3 sequence were utilized for the removal of
the PDZ3 domain from the plasmid. Recognition sites for these two enzymes
therefore must be engineered into the PCR primers, so complementary ends
could be created for ligation of the PDZ4 (MUPP-1) fragment into the donor
plasmid.
When designing PCR primers, two other issues were taken into account.
First, before the actual restriction, endonuclease recognition site series of short
oligonucleotides were added in order to increase cleavage efficiency. Second,
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primer lengths were increased by 9 extra oligonucleotides on both the forward
and reverse PCR primers, outside the actual gene for PDZ4 (MUPP1), in order to
ensure the accuracy of the obtained sequence. The DNA sequences for both
forward and reverse primer are shown below. Primers were obtained from
Invitrogen.
PDZ4FOR

5’- CGC GGA TCC ATG GGA ATT AAC TAT GAA ATA G -3’

PDZ4REV

5’- A CGC GTC GAC TCA GGT GGG TGG CAC AG – 3’

The PCR was run using the “hot start“ protocol, in which the primers and
the nucleotide bases were separated from the polymerase and the template by a
thin wax layer. The actual composition of the reactions and the set up of the
thermocycler are described in detail in the experimental section (section 2.2.5).
Both the PCR product (calculated length 303 bp) and the GST vector
(approximately 5 kb length), were digested using restriction enzymes. Bam HI
and Sal I cut the sequence in such way that it leaves ‘sticky ends’ and facilitates
insertion of the desired fragment.
The Fast-Link DNA Ligation Kit (Epicentre) was used as described in
detail in the experimental section (2.2.5.14). After chemical transformation of
competent cells, 15 µL aliquots of each of transformed cells were spread evenly
onto LB/amp50 plates and left for overnight growth. Only a single colony was
spotted on a plate that had (5:1) ratio of ligated transformants. The colony was
used to inoculate 10 mL of TB/amp50 media. After incubation and subsequent
extraction of the plasmid, it was sent for DNA sequencing. Results confirmed that
it had the right insert (PDZ4), and that the subcloning was successful.
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2.9.1.2 GST-PDZ4 expression and purification. This was a rather challenging
task of expressing and characterizing PDZ domain of MUPP-1 (Multi PDZdomain Protein), a structurally uncharacterized protein consisting of 13 PDZ
domains, with no obvious catalytic activity, for which no binding studies had been
performed. The protein domain chosen (PDZ4 of MUPP-1) needed to be
produced in higher quantities, and to do so the well-established glutathione-Stransferase (GST) Gene Fusion System (Amersham Pharmacia) was selected.
The GST tag from Schistosoma japonicum has been successfully used to
express a significant number of proteins [150]. It has the advantage of relatively
easy isolation from the other proteins expressed in the cells by using its
glutathione substrate in the affinity column. The high affinity of GST for
glutathione is important in the purification of this protein (and those fused to it)
from the mixture of proteins expressed in the bacterial cells.
Expression of PDZ4 in the E. coli cells in the form of a GST fusion showed
that it was mostly present in the insoluble inclusion bodies of the bacterial isolate.
In an attempt to generate soluble protein, chemical lysis of the cells containing
GST-PDZ4 fusion protein (using B-PER® bacterial protein extraction reagent
from Pierce) was employed. The approach was intended as a milder way to
break the bacterial cell membranes, in order to avoid any ‘precipitating’
processes and to access a higher concentration of the protein in the soluble
form. Unfortunately, no soluble protein was harvested. However, the results are
not surprising; in a comparative study done in the lab for a known protein
expressed in high yield when sonication was used to rupture the cells, B-PER®
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bacterial protein extraction gave poor results (Dorina Saro Ph.D. dissertation,
WSU). A possible explanation lies in the composition of the reagent that contains
a mild, nonionic detergent in 20 mM Tris-HCl (pH 7.5) buffer.
A refolding procedure was also applied to the GST-PDZ4 from the
inclusion bodies, but was not successful in isolating the protein in a properly
folded form. The reason for this is likely related to the fact that the mixture of
reduced and oxidized glutathione (which is considered a redox shuffling agent for
disulfide bond formation [151]) is also a substrate for the GST tag of the fusion
protein, so it cannot produce the correctly folded protein.
2.9.2 Expression and purification of recombinant PDZ1-2 of PSD-95
Although considerable effort was spent on expressing and characterizing
individual PDZ domains (constructs PDZ1 and PDZ2), the main focus of this
research study is the tandem PDZ1-2 domain. To the best of our knowledge this
dual domain was never expressed in this fusion vector. Previous attempts made
in the group resulted in the fragmented polypeptide, not a fully functional protein.
The E. coli bacterial cells that were chemically transformed with pGEX-2T
vector encoding the GST-PDZ (PDZ1, PDZ2 or PDZ1-2) fusion protein were
used for overexpression of this protein. The vector is constructed in such a way
that the gene that encodes for the GST enzyme (26 kDa protein) is fused to the
N-terminal of PDZ protein. There is an engineered thrombin cleavage site in
between the GST and the PDZ sequence that is used for proteolytic separation
of these proteins. pGEX-2T vector contains an ampicillin resistance gene that
allows the growth of the transformed bacterial cells in ampicillin containing
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media. The protein expression from a pGEX plasmid is under the control of the
tac promoter, which is induced using the lactose analog isopropyl β-Dthiogalactoside (IPTG).
The expression and purification of PSD-95 PDZ proteins (PDZ1, PDZ2
and PDZ1-2 tandem) were successful and provided high purity samples as
determined by SDS-PAGE analysis. However, in terms of final protein amounts
and stability, considerable differences were observed. In particular, in the case of
PDZ2 by itself, the required concentration of the protein for binding studies by
ITC couldn’t be achieved.
The plasmid PGEX-2T, used for the expression of GST-fusions, was
engineered with the thrombin cleavage site LVPRGS on the C-terminal of GST.
This serine protease cleaves after Arg or Lys residues in the sequence P4-P3Pro-Arg ↓ P1’-P2’ where P3 and P4 are hydrophobic amino acids and P1’ and
P2’ are nonacidic amino acids. In the experiment, however, trypsin (a less
specific protease) was used for cleavage reaction. Assuming that trypsin would
have cleaved the fusion after any arginine or lysine residue, different results for
mass spectra analysis of individual PDZ domains were expected.
2.9.2.1. Expression and characterization of individual PDZ1 and PDZ2 and
PDZ1-2 dual domain. For PDZ1 the yield of the fusion protein was
approximately 120 mg/mL of bacterial culture, as determined by Coomassie®
plus-200 Protein Assay (Bradford assay). After cleavage and further purification
as described in detail in the experimental part, approximately 15 mg of protein
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was isolated (value obtained based on three assays UV measurements (λ =
280nm), Advanced Protein Assay and Coomassie plus-200 Protein Assay).
The determined molecular weight for trypsin-cleaved PDZ1 by ESI-MS
was 10,067±1.55 Da, which was 109 units less than calculated value of 10,176
Da based on thrombin cleavage (95 amino acid residues).
PDZ2 fusion protein yields for GST-PDZ2 were slightly lower than for
GST-PDZ1, approximately 100 mg of protein per liter of bacterial culture
(Coomassie® plus-200 Protein Assay). However, final purification provided a very
low yield of pure PDZ2 (high purity sample as confirmed by SDS-PAGE) of only
approximately 4.5 mg. Even an attempted concentrating of the sample still gave
a very low concentration. When such samples were utilized for ITC binding
studies against several of the high affinity peptides, the obtained data could not
be processed. Saturation of the protein was reached within a few microinjections
of a highly concentrated ligand. Therefore, the obtained results could not be
interpreted. Further studies should focus on stability of the PDZ2 under the
conditions tested.
The determined molecular weight for trypsin cleaved PDZ2 by ESI-MS
was 10,111.98±2.71 Da, which was the same as the calculated value based on
thrombin cleavage (97 aa).
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PDZ1
PDZ2

amino acid
residues

MW
(calculated)

95
97

10,176
10,111.96

MW
(mass.
spec)
10,067
10,111.98

Yield fusion
(mg/L
culture)
120
100

Final protein
(mg/L
culture)
15
4.5

Table 2.5 Protein yield and mass for PDZ1 and PDZ2.
Expression and purification of the PDZ1-2 dual domain actually provided
the highest quantities when compared to results from single PDZ domain
expression attempts. As determined by the Bradford assay, approximate yields
were 200 mg from 1 L of cell culture.
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4

5

6

7

Figure 2.5 Separation steps for isolation of fusion protein, approximately 46 kDa
from soluble cell lysate. Lanes: 1, molecular weight marker; 2, soluble cell lysate;
3, cell pellet after lysis; 4-6, fusion protein extractions I, II, III, respectively; 7, last
load.
A major concern of the PDZ1-2 dual domain, with regard to the five amino
acid linker region between PDZ1 and PDZ2, was that the attempted cleavage
with trypsin (protease of choice) would result in ‘over-cleaving’ and separate the
two domains. This was based on the previous results obtained in the laboratory.
However, optimization of the cleavage reaction finally resulted in a protocol

93
utilizing 1:7000 trypsin to protein ratio, and a reaction time of 2.5 h at room
temperature.
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3

4

5

6

Figure 2.6 Showing trypsin cleavage, reaction for 2,5h, (1:7000) trypsin to
protein ratio used. Lanes: 1, molecular weight marker; 2, fusion protein; 3-6,
reaction aliquots taken out after 1 h,1.5 h, 2 h, 2.5 h, respectively.
In the Figure 2.6 shown above are the results from trypsin cleavage
reaction (1:7000), determined after series of analytical scale cleavages with
varying enzyme to protein ratios and incubation times.

Figure 2.7 Final purification of PDZ1-2. MW- Molecular weight markers. Final
PDZ1-2 purified samples in lanes marked f1 and f2, which corresponds to ion
exchange fractions of 100mM and 150 mM of NaCl.
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Final separation is shown in Figure 2.7. Gels in this figure contain the
elutions from the ion exchange column. The GST portion, approximately 27 kDa,
began eluting with the start buffer, at an ionic strength of 10 mM. The PDZ1-2
dual domain eluted in later fractions at higher ionic strengths of 100 and 150 mM
NaCl. The isolated PDZ1-2 domain is shown in lane labeled f1 and f2.
2.9.3. Energetics of binding of separate PDZ1 and PDZ2 with peptides
derived from their natural ligands. The initial design of peptides mimicking
natural binding partners for the first two PDZ domains, was mainly focused on
already reported results for protein-protein interactions of PSD-95.
The first in hand was PDZ1 and peptides based on binding sequences of
best known binders were tested by ITC in 20 mM MES, 10 mM NaCl, pH 6
buffer. Figure 2.8 shows a typical isotherm (top panel) of titration of a peptide into
a solution of PSD-95 PDZ1. The binding reactions are exothermic, and integrated
heats of reaction for the data in Figure 2.8 (top panel) are shown as a binding
curve in Figure 2.8 (bottom panel).
A non-linear least-square fit of the binding curve gives the stoichiometry
(n), equilibrium dissociation constant (Kd), and the change in enthalpy (ΔH) for
binding interaction. These parameters (ΔH and Kd) were used to calculate the
free energy of binding, ΔG, and change in entropy, ΔS, using equations (1) and
(2). The solid line shown in the Figure 2.8 (bottom panel) is the best fit for one of
the reaction performed at 25 °C. Three different peptide sequences
corresponding to C-terminus of natural binding partners were tested against the
PDZ1.The ITC results are summarized in the Table 2.6 and Table 2.7.

95

Figure 2.8 A representative thermogram of binding of PDZ1 with the
AKAVETDV peptide in MES buffer pH 6 at 25 °C.
Among the natural binders of PDZ1 of PSD- 95, the first series of peptides
studied by ITC were synthesized based on C-terminal sequence of K+ channels
of the Shaker type Kv1 family. The first two peptides, comprising 8 amino acid
residues, were designed to probe the molecular recognition of binding. The Cterminal ends with Thr-Asp-Val; having Thr at -2 and Val at position 0 is
consistent with the Class I PDZ domain binding preferences. The last two
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ligands, an octapeptide and a hexapeptide, are derived from the NMDA receptor
NR2b subunit. This is one of the most well studied interactions of PSD-95 and is
critical for a number of neuronal functions, such as synaptic transmission and
synaptic plasticity. The best binder was proven to be that possessing the Kv1.4
sequence, with a Kd of 5.93 µM, and which was slightly enthropically driven with
ΔH of -4.42 kcal/mol. The potassium ion channel Kv1.3-derived sequence
exhibited almost two times less binding affinity for PDZ1, with a Kd of 13.9 µM,
with favorable enthalpy and similar contributing entropy.
Association with the octameric C-terminal NR2b subunit peptide was
weaker than expected, with Kd = 11.2 µM, and the interaction is primarily driven
by a favorable change in entropy, TΔS = 3.88 kca/mol. Surprisingly, the
hexapeptide had diminished signal, and no thermodynamic parameters could be
calculated.

Peptide

Kd

∆H

-TΔS

ΔG

n

c*

AKAVETDV

(µM)
5.93 ± 0.02

(kcal/mol)
-4.42 ± 0.14

(kcal/mol)
-2.71 ± 0.14

(kcal/mol)
-7.13 ± 0.01

1.09 ± 0.03

17

IKKIFTDV

13.9 ± 0.5

-3.51 ± 0.12

-3.11 ± 0.14

-6.62 ± 0.02

1.25 ± 0.01

7

LSSIESDV

11.2 ± 0.7

-2.87 ± 0.04

-3.88 ± 0.01

-6.75 ± 0.04

0.84 ± 0.13

9

SIESDV

no detectable binding
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Table 2.6 Thermodynamic parameters for peptides based on potassium channel proteins (Kv1.x)
Kv1.4 and Kv1.3 and on NMDA receptor (NR2a subunit).

KKKETEV

Kd

∆H

-TΔS

ΔG

(µM)

(kcal/mol)

(kcal/mol)

(kcal/mol)

10.9

-3.02

-3.75

-6.77

n

c*

1.63

9

Table 2.7 Thermodynamic parameters for peptides based on consensus sequence for PDZ3.
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Peptide
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Of all the three protein domains, PDZ2 was proven to be the least stable.
The quantities of isolated pure protein were too low, and insufficient for ITC
studies. Protein was dialyzed into 20 mM MES, 10 mM NaCl, pH 6, conditions
that were observed to stabilize the PDZ1. In numerous attempts, during ITC
titrations protein sample would precipitate in the cell. A huge shift in baseline
could be observed, and it was impossible to integrate the data. Randomly, it was
possible to collect a whole data set and thermogram of a single experiment was
shown below (Figure 2.9).

Figure 2.9 Thermogram of PDZ2 titration with AKAVETDV peptide.
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When treated with a Single Binding Site model from Origin software this
data set gave an n value of 0.5. Normally this would point to a binding
stoichiometry wherein two peptides associate to each equivalent of protein. This
in itself would be unlikely based on what is presumed about the binding behavior
of individual PDDZ domains. In this case, however, there are experimental
concerns such that this value is more likely attributable to an inadequate protein
concentration estimate, or is indicative of the protein sample not being entirely in
its native, folded state.
PDZ2 was not pursued in further experiments; this was due to such poor
yields at the end of the long purification, which could not be improved through
optimization efforts, and because of its poor stability (protein precipitates after 2
days at 4 °C).
2.9.4. Energetics of binding of the PDZ1-2 dual domain.
PDZ1-2 data was collected in 10 mM sodium-phosphate buffer, pH 7 at 25 °C.
For data processing all three models provided by Origin software were used
(One Set of Sites, Two Set of Sites and Sequential Binding Sites). The best
model fitting, as judged by the χ2 value, was achieved using the Single Site
binding model. This provided a stoichiometry of n = 1 (Table 2.8). This was not
expected, based on the presence of two binding sites in the PDZ1-2 dual
domain. Consequently, the thermodynamic data was hard to interpret from a
biochemical perspective, and further studies were focus on obtaining the
structure of tandem PDZ1-2 of PSD-95.

Peptide

Kd
(µM)

∆H
(kcal/mol)

-TΔS
(kcal/mol)

ΔG
(kcal/mol)

n

c*

AKAVETDV

3.86 ± 0.08

-4.25 ± 0.33

- 3.13 ± 0.31

-7.38 ± 0.01

1.12 ± 0.01

14

KAVETDV

4.81 ± 1.93

-4.41 ± 0.09

-2.88 ± 0.18

-7.29 ± 0.27

1.03 ± 0.05

21

AVETDV

2.81 ± 0.21

-4.60 ± 1.08

-2.57 ± 1.12

-7.56± 0.04

1.11 ± 0.14

41
100

Table 2.8 Tables thermodynamic parameters for peptides based on natural binding sequences of Kv1.4.
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2.9.5 Binding of PDZ1-2 to modified cyclic peptide ligands.
CN2180 is one of several modified peptides designed to bind to PDZ3 of
PSD-95, part of a larger program to develop novel cellular probes to investigate
the in vivo roles of various PDZ domain-mediated interactions. CN2180 is a
nontraditional form of cyclic peptide in which the ring bridges two side chains
residues via a β-alanine linkage (Figure 2.10), and the sequence based on that of
the CRIPT protein (KNYKQTSV), a known binder of PDZ3. Based on a simpler
cyclic peptide structure that itself had been shown to exhibit good binding to
PDZ3 [128], CN2180 contains two additional N-terminal residues and a myristic
acid moiety to promote membrane permeability (Figure 2.10).

Figure 2.10 Chemical structure of the N-myristylated cyclic peptide CN2180.
Although CN2180 was originally designed to bind PDZ3, screening (with a
N-biotinylated version of CN2180) against a membrane-bound array of 96
different PDZ domain constructs demonstrated that significant binding also
occurred with PDZ1-2 (Dr. C. Rupasinghe, Ph.D. dissertation). This screen was
based on the binding of ligand to solid-phase immobilized protein, and thus might
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not have represented a true solution interaction. With the prospects of identifying
a new binding ligand for PDZ1-2, as well as the newly discovered
neuroprotective activities that CN2180 has exhibited (unpublished results, DJ
Goebel, CN Rupasinghe and MR Spaller), there were compelling reasons to
conduct a calorimeteric binding study of the system.
Experimentally, these studies proved more onerous than the earlier ones
utilizing linear peptide. The previous ITC data for the PDZ1-2 dual domain was
collected using final dialysis buffer conditions of sodium phosphate (10 mM, pH
7), which was proven to stabilize the protein. Numerous attempts were made to
dissolve CN2180 under these conditions. ITC experiments were carried out
varying the concentration of peptide, even at very low values (0.5 mM), only to
observe diminished signal and precipitate at the end of the titration. Different
buffer compositions were also tried (10 mM MOPS; 10 mM HEPES) at pH 7, and
for all of them CN2180 was insoluble. In an attempt to match the conditions of
previously obtained data for PDZ3 of PSD-95 binding to the same ligand (where
Kd = 8µM), following purification PDZ1-2 sample was dialyzed against the same
final buffer (20 mM, 10 mM NaCl, pH 6). These final conditions yielded titration
curves suitable for subsequent analysis (Figure 2.11).
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Figure 2.11 ITC thermogram and integrated data with fitted curve for
PDZ1-2 titration with CN2180.
Calorimetric binding analysis was performed in the same manner with the
previously described work. Data was treated with all three models: One Set of
Sites, Two Set of Sites and Sequential Binding Sites. After applying the Single
Binding Model, it became clear that the stoichiometric n value is 2, meaning that
both binding sites on the tandem PDZ1-2 are fully occupied. However, fitting of
the data improved significantly if Sequential Binding Sites model was
implemented, as judged by χ2 values. Therefore, it is clear that the Sequential
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binding Sites Model gives the best description of the experimental data (Table
2.8).
Thermodynamics of the

Thermodynamics of the

first binding site

second binding site

Kd

ΔH
(µM) (kcal/mol)

-TΔS
(kcal/mol)

ΔG
(kcal/mol)

Kd
ΔH
(µM) (kcal/mol)

-TΔS
ΔG
(kcal/mol) (kcal/mol)

6.09

-0.37

-6.83

-7.20

9.00

-1.16

-5.73

-6.89

±3.13

±0.09

±0.25

±0.34

±0.95

±0.21

±0.27

±0.48

Table 2.8 Thermodynamics for CN2180 binding to PDZ1-2.
The data reflect the outcomes of three independent measurements. It is
apparent that CN2180 populates both binding sites in PDZ1-2 tandem with the
fairly good binding affinity for each domain (Kd1 = 6 µM and Kd2 = 9 µM). Although
two different values are obtained, the model fitting does not allow a specific
assignment to be made as to which is that of PDZ1 or PDZ2. These values are
comparable to the previously obtained result for PDZ3 (Kd1 = 8 µM), and thus
make this compound a reasonably effective inhibitor of the PSD-95 interaction
with the NMDA receptor (NMDAR).
2.9.5.1 CN2180 and PDZ1-2. A key organizing protein in the postsynaptic
density of the excitatory synapses is PSD-95. Especially important is the role it
plays in coupling NMDAR to intracellular proteins and signaling enzymes [152,
153]. It has been known that through its second PDZ domain (PDZ2), PSD-95
binds the COOH-terminus, tSXV motif of NMDAR NR2 subunits as well as
neuronal nitric oxide synthase (nNOS) [91, 153] This binding couples NMDAR
activity to the production of nitric oxide (NO), a signaling molecule that mediates
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NMDAR-dependent excitotoxicity [154]. Previous studies have shown that
NMDAR activity is not suppressed by genetically disrupting PSD-95 in vivo [155]
or by suppressing its expression in vitro [156]. Complete PSD-95 deletion
dissociates NMDAR activity from production of NO and suppresses excitotoxicity
[156].
NMDARs mediate ischemic brain injury [157], but targeting them has been
proven deleterious in humans and animals [158-160] Targeting PSD-95, which is
downstream of the NMDAR and would not be expected to impact other NMDAinduced pathways, therefore represents an alternative therapeutic approach for
diseases that involve excitotoxicity. Genetic mutation or reducing expression
levels of PSD-95 is therapeutically impractical; therefore an attractive alternative
approach would be perturbing its interaction with NMDARs in order to suppress
excitotoxicity and ischemic brain damage. This might be achieved by intracellular
introduction of ligands that bind to PDZ2 of PSD-95. In this case, CN2180 has
proven to be a strong lead compound, based on its potential inhibiting of all three
PDZ domains of PSD-95. Because CN2180 is myristylated, it is more
bioavailable than a non-modified peptide, and its diffusion and uptake capacity by
neurons in intact tissues should be enhanced.
In a follow up study, CN2180 was tagged with fluorescein (FITC) to yield
CN3205, and administered via intravitreal injection at the maximal effective dose
to monitor its rate of diffusion of the retinal ganglion cells (unpublished results,
CN Rupasinghe, DJ Goebel, MR Spaller). This is a common approach since
NMDA-induced neuronal cell death has been extensively studied in the retina.
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Results showed that as early as 1 hr following injection, uniform fluorescent
staining was noted in the inner half of the retina, and that by 2 hrs, intensely
stained vacuoles could be seen within select cells in the ganglion cell layer
(GCL). Although further testing needs to be done in order to determine to what
extent these cells express PSD-95, the fact that diffusion and localization of the
modified peptide into putative NMDA-receptive cells occurs within a 2 hour time
frame indicates that this preincubation period is sufficient for testing the
neuroprotective

properties

of

these

compounds

against

NMDA-receptor

mediated cell death.
With the impressive biological properties of CN2180 now documented, the
calorimetric results serve as an absolutely essential step towards fully
characterizing this compound. The solution data make it clear that CN2180 is
capable of binding both PDZ1 and PDZ2, and in so doing provide evidence for a
mechanism by which the observed activity takes place. Although other possible
cellular binding sites cannot be absolutely ruled yet, the combination of the ITC
data, in conjunction with the absence of binding to other non-PSD-95 PDZ
domains on the 96 domain array, strongly suggest that PSD-95 is indeed the in
vivo target.
2.9.5.2 In vivo retinal cell death model. NMDA-induced neuronal cell death has
been extensively studied in the retina [161, 162]. Our laboratory conducted
studies in collaboration with Dr. Goebel, WSU. Relying on previously published
data [161] it was proven that following a moderate insult (20 nmol NMDA injected
intravitreally) only 70-85% of the retinal ganglion cells and a significant number of
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amacrine cells are lost. Extensive research in the past few years in the Goebel
laboratory improved this in vivo NMDA-toxicity model and also led to
development of several quantitative assays to monitor biochemical, physical and
energy dependent/independent pathways that are believed to be linked to the cell
death pathway [163]. This includes measuring PARP-1 activation (believed to be
linked to the process of necrosis), loss of plasma membrane selectivity (a
process directly linked to necrosis), DNA cleavage using TUNEL labeling,
endogenous ATP pools as well as ganglion cell survival. This system offers
several advantages to in vitro systems, with the most significant of them being
that we can monitor the cell death process in an intact, living animal.
In their previous work, Goebel et al have established a baseline for all of
the above assays using NMDA-treated and control eyes; they have been able to
assess putative neuroprotective compounds using this model and have recently
reported that inhibition of PARP-1 activity, using the potent inhibitor PJ-34,
abolished NMDA-induced PARP-1 activation in the retina, blocked NMDAinduced loss of endogenous ATP and provided some neuroprotection to retinal
ganglion cells. However, this blockade did not attenuate NMDA-induced loss of
membrane selectivity or prevent TUNEL labeling [163].
A different set of experiments has shown that blockade of CaMKII-αB
completely abolishes NMDA-induced TUNEL labeling and did provide significant
neuroprotection of retinal ganglion cells; however, this treatment had no effect in
blocking PARP-1 activation nor loss of membrane selectivity of neurons in the
ganglion cell and Inner nuclear layers of the retina (Goebel et al, manuscript in
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preparation). Collectively, these studies clearly indicate that the pathway leading
to cell death is complex and that it can no longer be confined to the classification
of being necrotic or apoptotic.
All the results presented in the following (chapter 2.3.6.2) represent the in
vivo work done in Dr. Goebel’s laboratory. Only finalized data representations
were outlined as a strong indication of CN2180 biological potential.
2.9.5.2.1 CN2180 and CN2097 reduce NMDA-induced poly(ADP-ribosyl)ation
(PAR) in a dose-dependent manner. Two compounds were tested in this study;
myristylated peptide CN2180 (detailed description given in paragraph 2.3.6. of
this dissertation) and its poly-Arg derivative (CN2097), designed to enhance its
diffusion and uptake capacity by neurons in intact tissues. These two compounds
were individually administered into the vitreal chamber of the left eye of male
Spague-Dawley rats at designated doses 2 hours prior to the retina being
exposed to a second injection containing an excitotoxic dose (20 nmol) of the
glutamate agonist N-methyl-D-aspartate (NMDA) in the presence of the
corresponding dose of the peptide (CN2180 or CN2097). The companion eye
(right eye of each animal) served as either the positive or negative control.
Four hours following NMDA insult, the animals were decapitated (to
eliminate any potential anesthetic influence on the results of the assay) and
retinas were individually homogenized and processed for the detection of
poly(ADP-ribosy)lation (an indicator of enhanced PARP-1 activity) as previously
described [163].
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Results show that both CN2080 and CN2097 reduce NMDA-induced
poly(ADP-ribosy)lation (PAR) of large molecular weight proteins. Dose-response
data shows that although both compounds did lower PAR-formation, the poly-Arg
derived peptide (CN2097) was roughly 10 times more effective than the
myristylated compound (CN2180).

Interestingly, a myristylated randomized-

cyclic peptide (of the same size; CN3500) administered at the optimal effective
dose determined for CN2180 and CN2097, showed no significant decline in
NMDA-induced PAR-formation.
The obtained data is a clear indication that the decline in NMDA-induced
PAR-formation is KNYKKTEV peptide-dependent, and that competitive binding to
the PDZ domain of PSD-95 (or related proteins) containing this domain, aids in
diminishing NMDA-induced PARP-1 activation.

This is consistent with the

understanding that PSD-95 is linked to nNOS (neuronal nitric oxide synthetase),
which generates nitrous oxide (NO) within the neuron. It has been hypothesized
that NO hyperstimulates PARP-1 activation in response to NO-free radical
induced DNA-strand breaks [164] and that this response leads to the loss of
plasma membrane permeability properties (i.e. necrosis) [163, 165].
2.9.5.2.2 CN2180 and CN2097 attenuate NMDA-induced loss of plasma
membrane selectivity. Same method as described in the previous chapter was
employed to assess NMDA-induced loss of plasma membrane selectivity (LPMS)
following NMDA insult in the presence of CN2180 or CN2097 and compared with
NMDA-treatment alone or with retinas treated with the non-specific peptide
CN3500 followed by NMDA insult as a control. LPMS is visualized by the ability
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of ethidium bromide to pass through the affected neuron’s plasma membrane
and stain the cell. This process has been shown to be an NMDA-dependent
process, as retinas treated with buffer alone, or those that were untreated are not
responsive to neuronal ethidium bromide staining [163].
Retinas pre-exposed to CN2180 or CN2097 subsequently were subjected
to NMDA insult. These samples showed a significant reduction in the density of
ethidium bromide-stained cells in the ganglion cell layer (GCL), as compared with
retinas treated with NMDA alone. This decrease in ethidium bromide staining
density was shown to be dose dependent, and peptide-specific as the
myristylated randomized cyclic peptide (CN3500), given at the same dose, had
no effect in blocking NMDA-induced LPMS. Consistent with the PAR data above,
the poly-Arg peptide (CN2097) provided almost complete blockade of ethidium
bromide staining in the GCL and inner nuclear layers, whereas the myristylated
peptide given at its maximum dose only partially attenuated LPMS.
Presented data support the hypothesis that NMDA-induced cell death is
mediated by the NMDA-receptor’s linkage to PSD-95 and shows, for the first
time, that disconnection of the NMDA-receptor from PSD-95, through competitive
binding of the peptide-ligand(s) with the PDZ-domain of PSD-95 (or similar
protein), renders the NMDA-receptive neurons insensitive to NMDA-induced
LPMS (necrosis).
2.9.5.2.3 CN3205-FITC localizes to select subpopulations of retinal neurons
that reside in the ganglion cell layer (GCL) and inner nuclear layer of the
retina. Another cellular probe was developed by tagging the myristylated peptide
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CN2180 with fluorescein (FITC: CN3205) and administered via intravitreal
injection at the maximal effective dose (6 nmol/eye) to monitor its rate of diffusion
into the retina. Results showed 1 hr following injection and after 4 hrs, numerous
cells showed preferential accumulation of the tagged peptide and were intensely
stained in both the GCL and inner nuclear layer (INL) of the retina (Fig 2.12).
Interestingly, this intense staining of the cells (in both layers) appears to be
selective, as there were neighboring cells in both layers that did not fluoresce
above tissue background levels (Fig 2.12). Furthermore, the staining and density
patterns of the cells that accumulated CN3205 showed strong similarities to
those neurons that are susceptible to NMDA-induced LPMS.
In the Figure 2.12 panel (a) 4 hrs following intravitreal injection of 12 nmol
of CN3205 shows specific uptake into cells located in the ganglion cell layer and
by 6 hrs (b) the staining density of labeled cells appears to parallel the staining of
cells that are susceptible to NMDA-induced excitotoxcity as detected by ethidium
bromide. (c) Detection of CN3205 in ganglion cells was noted as early as 2 hrs
following treatment and shows that the compound is localized to the cytoplasm.
Panel (d) depicts the ability of the peptide to penetrate the retina radial sectioning
of the retina shows that there is extensive staining in cells located in the ganglion
cell layer (GCL) as well as in cells located in the inner portion of the inner nuclear
layer (INL) (arrows).
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Figure 2.12. Uptake of FITC-labeled KNYKKTEV peptide (CN3205) in the retina
Although these findings are preliminary and will require further
investigation to determine whether the stained cells are NMDA-receptive, and
more importantly express PSD-95, the fact that diffusion and localization of the
modified peptide into putative NMDA-receptive cells occurs within a 2 hour time
frame indicates that this preincubation period is sufficient for testing the
neuroprotective

properties

of

these

compounds

against

NMDA-receptor

mediated cell death.
2.9.5.2.4 CN2097 attenuates NMDA-induced loss of retinal ganglion cells.
Based on the data presented, there is a strong indication that disruption of the
PDZ binding disconnects NMDA-receptor activation from initiating the cell death
signal for the short term (up to 4 hours following insult). However, it was still not
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clear whether this short-term protection was transient or if it does provide longterm neuroprotection. To assess this, a series of animals were treated in such a
way that the left eye received the optimal dose (3 nmol) of CN2097 followed by
NMDA treatment 2 hours later and the right eye received NMDA alone or left
untreated. Two weeks following insult each animal was surgically administered
the retrograde tracer fluorogold. Retinas were harvested and photographed.
Fluorogold (FG)-labeled cells densities were then determined at each eccentricity
and then compared with the densities obtained from the companion eye (for full
methodology [163]).

Figure 2.13. Representative fluorogold labeling of retinal ganglion cells sampled
from the same region of the retina at 1-2 mm from the optic nerve head are
shown.
First panel (Fig. 2.13) shows the NMDA treated retina (20 nmol) and a
dramatic reduction in ganglion cell density of surviving ganglion cells is visible. In
the second panel retinas were pretreated with 3 nmol CN2097 for 2 hrs followed
by 20 nmol NMDA w/ 3 nmol CN2097 (3nmol CN2097/NMDA) and show a
dramatic increase in ganglion cell density which was essentially indistinguishable
from the regional density of the untreated retina (Untreated labeled) third panel
on Fig 2.13.
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Preliminary results from 2 retinal pairings show that CN2097 provides
significant neuro-protection against NMDA-induced ganglion cell loss (Fig. 2.13
and 2.14). In comparing cell densities from the CN2097/NMDA-treated retinas
with those obtained from retinas that were untreated little differences at each
eccentricity were observed between the two treatment conditions (Fig. 2.13 and
2.14).

Figure 2.14 Effect on CN2097 pre and post insult was induced (NMDA)
Figure 2.14 represents retinal pairings (n=2), where one eye was
pretreated with 3 nmol CN2097 and 2 hrs later treated with 20 nmol /NMDA were
compared with companion retinas treated with NMDA-alone show that CN2097
offers almost full protection against NMDA-induced ganglion cell loss when
compared with the densities found in untreated retinas (n=4).
Although the full analysis of these experiments are still forthcoming,
indications from the two retina pairs analyzed here indicate that the competitive
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binding of CN2097 to the PDZ-binding domain does offer almost complete
protection against NMDA-induced ganglion cell loss and indicates that the
interaction of the NMDA receptor subunits to a PDZ containing protein (PSD-95)
is the initiator of the cell death signal that mediates both necrosis and apoptoticlike pathways.
2.10 Discussion
The primary focus of this dissertation is exploring the nature of PDZ
interactions, with the special interest in domain organization and multiplicity. As
stated before, although modular in design, PDZ domains are often linked in
groups within a multi-PDZ protein. Our work has confirmed previously reported
data that the first two PDZ domains in the PSD-95 of the MAGUKs subfamily are
immediately adjacent to each other and form a protease-resistant unit. The
functional significance of such linkages is still uncertain, although it has been
studied extensively lately.
2.10.1 PDZ1 and PDZ2 domain binding characteristics Our first aim was
examining the postulated ability of the combined PDZ1-2 of PSD-95 to show
significantly different binding specificity for C-terminal sequences than did the
individual PDZ1 and PDZ2 domains [166]. We possessed both domains (rat
ortholog sequence) expressed in E. coli and purified. PDZ1 and PDZ2 belong to
Class I based on their preferred binding partner, and we recognized that there
may be similar recognition properties based on this fact alone when testing the
binding of our peptide ligands.
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To evaluate binding to the short peptide ligands, we employed isothermal
titration calorimetry (ITC). ITC has been successfully used to characterize the
binding interactions in the case of protein domains like Src homology 2 (SH2)
and Src homology 3 (SH3). ITC presents great advantages over other methods
(see Chapter I), as it characterizes the molecular interactions with the native,
unmodified form of macromolecules in solution. It allows the measurement of
thermodynamic parameters; namely, the change in enthalpy (ΔH), binding
constant (Kd), and stoichiometry (n) from a single experiment. The change in
Gibbs free energy (ΔG) and change in entropy (ΔS) can be calculated using
equations (1) and (2) respectively. ITC is a method of choice extensively used for
binding studies of PDZ3 of PSD-95 and published in our lab, Saro et al.[136, 167]
Lacking structural information for our PDZ1/PDZ2 system, which is
abundant for PDZ3, we have relied on yeast two-hybrid results published earlier
and well-described interactions with the NMDA receptor. A series of short peptide
ligands, corresponding to the C-termini of endogenous binding partner proteins,
were designed and tested against each individual domain. PDZ1 showed
characteristic binding parameters, similar to PDZ3 reported for its natural binding
partners [167]. Among the natural binders of PDZ1 of PSD-95, the first series of
peptides studied by ITC were synthesized based on C-terminal sequence of K+
channels of the Shaker type Kv.1 family. The first two peptides (8 amino acid
residues) were designed to probe the molecular recognition of binding. The Cterminal ends with Thr-Asp-Val ; and having Thr at -2 and Val at position 0 is
consistent with the Class I PDZ preferences. The last two peptides (8-mer and 6-
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mer) are derived from the NMDA receptor NR2b subunit. This is one of the most
well-studied interactions of PSD-95, and is critical for a number of neuronal
functions such as synaptic transmission and synaptic plasticity. The best binder
proved to be that derived from the Kv1.4 sequence, with Kd of 5.93 µM, and with
a slightly enthropically driven of -4.42 kcal/mol. Potassium ion channel Kv1.3 had
almost two times reduced binding preference for PDZ1, Kd of 13.89 µM, with
favorable enthalpy and similar contributing entropy (Table 2.6 and 2.7).
Interaction with the octapeptide derived from the C-terminus of the NR2b
subunit was weaker than expected at Kd of 11.2 µM, and the interaction is
primarily entropic at 3.88 kcal/mol. Surprisingly, the hexapeptide sequence
exhibited a diminished signal, and no thermodynamic parameters could be
calculated. Results for all the natural PDZ1 binders show the changes in the
enthalpy (∆H) and in the entropy (∆S) for the binding of the peptides to the PDZ3
protein were favorable, reflected in an enhanced, i.e., negative change, in Gibbs
free energy (∆G) for the interaction. These findings are consistent with binding
affinities for PSD-95, and comparable to the extensively studied PDZ3 [168]
interactions with its natural binding partners.
PDZ2, on the other hand, was unstable during titration and would
precipitate in the cell. After extensive trials, only a few complete datasets were
collected due to these problems. These showed a binding stoichiometry of 0.5,
which clearly denotes a problem with the samples; we hypothesized that the
protein is poorly folded and all binding sites are not fully functional (Fig. 2.9).
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Since our primary focus was on PDZ1-2 we have discussed individual domain
data merely in a context of control experiments.
2.10.2. PDZ1-2 dual domain binding characteristics. The PDZ1-2 dual domain
had expressed well and demonstrated an increased stability as compared to the
single domains. Binding thermodynamics of the peptide ligands based on the
potassium ion channel Kv1.4 sequence provided some interesting functional
insight.
Sequence truncation of peptide binders (from 8 to 6 residues) did not
diminish binding affinity, which would indicate that the maximum contribution of
binding is found in the residues of the hexapeptide. Results (Table 2.8) were
comparable to data for the single PDZ1 domain. The dual domain showed an
increased affinity of Kd = 3.86 µM for the AKAVETDV peptide, as opposed to Kd
= 5.93 µM for PDZ1. Changes in ∆H and in ∆S for the association of the peptides
with the domain had roughly similar values, although binding entropy was very
unfavorable (TΔS = -3.13 kcal/mol) indicating a substantial loss of degrees of
freedom upon binding (Fig. 2.15).
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Figure 2.15. Binding energetic of PDZ1-2 domain to its natural derived peptides.
When integrating the ITC data, each of three models were applied (the
One Set of Sites (OSS), the Sequential Binding Sites (SBS), and the Two Sets of
Sites (TSS) models, each as implemented in the Origin program). In addition to
assessing whether the assumptions of each model made biochemical sense, the
chi-squared (χ2) value was used as the primary criterion for the data fit. OSS
yielded the best fitting of the binding isotherm, which appeared contradictory at
first, since there are two binding sites in the domain. Taking into account all our
data presented, we can only conclude that these two binding sites are not equally
exposed or properly folded. Our results are in good agreement with published
work by Cierpicki et al.[169] investigating the dual PDZ domain of syntenin. Their
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crystallographic data showed that peptide binds to a single binding pocket. No
electron density was observed for the lower affinity domain. Their NMR titration,
however, showed that peptides bind to both PDZ1 and PDZ2, although the
magnitudes of the associated chemical shift changes differ significantly. The data
are consistent with fast exchange kinetics and relatively weak affinities [169].
At this point, it is worth mentioning that although ITC represents a very
powerful technique with all its numerous advantages (outlined in Chapter 1) it is
often hard to deconvolute the heat signal. Therefore, any interaction beyond the
simplified 1:1 binding stoichiometry is challenging, especially since the relevant
literature is very scarce. Work presented on dual domain binding, such as
presented in this dissertation, is unique in the field. At the same time it was clear
that without the proper structural information on PDZ1-2 tandem of PSD-95, it
would be extremely difficult to progress with binding studies. Our efforts toward
solving the structure of the dual domain are discussed in detail in Chapter 3 of
this dissertation.
2.10.3. PDZ1-2 dual domain binding to modified cyclic peptide ligand
(CN2180). In an ongoing effort to develop new cellular probes for in vivo
investigations on the nature of protein-protein interactions, our lab has chosen
PSD-95 as a target of interest. This is due to the extensive biological information
available, and especially due to its important roles in the functioning of the postsynaptic density of neuronal cells.

Initially designed to bind PDZ3, modified

ligand CN2180 was developed and synthesized by Chamila Rupasinghe in the
Spaller lab. CN2180 is a cyclic peptide based upon KNYKQTSV, in which the
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ring bridges two side chains residues via β-alanine linkage (Figure 2.7). An
elaboration of a simpler cyclic peptide structure that itself had been shown to
exhibit good binding to PDZ3 [128], CN2180 contains two additional N-terminal
residues and a myristic acid moiety to promote membrane permeability.
However, screening (with a N-biotinylated version of CN2180) against a
membrane-bound array of 96 different PDZ domain constructs demonstrated that
comparable or enhanced binding occurred with the PDZ1-2 dual domain of PSD95.
In light of the exquisite results that we were observing for the biological
activity of CN2180 and its derivatives (in collaboration with Dr. Goebel, WSU), in
parallel we have tested in vitro binding to the dual domain PDZ1-2 by ITC. After
applying the OSS curve fitting, it became clear that the stoichiometric n value is
2, meaning that both binding sites on the tandem PDZ1-2 are fully occupied.
However, fitting of the data improved significantly if SBS model was implemented
(details Appendix C), as judged by χ2 values. Therefore, it is clear that the
Sequential binding Sites Model gives the best description of the experimental
data.
CN2180 populates both binding sites in the PDZ1-2 tandem, with fairly
good binding affinity for each domain (Kd1 = 6 µM and Kd2 = 9 µM). Although two
different values are obtained, the model fitting does not differentiate between the
binding sites. These values are comparable to the previously obtained result for
PDZ3 (Kd1 = 8 µM), and thus make this compound a reasonably effective inhibitor
of the PSD-95 interaction with the NMDA receptor (NMDAR).
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2.10.3.1. In vivo validation of CN2180 activity. Thermodynamic validation of
CN2180 binding to PDZ1-2 represents a strong support of the in vivo tests
carried out in rat retinal model. CN2180 peptide and its polyArg counterpart
(CN2097) showed strong activity in the NMDA-induced stressed neurons.
Decline in NMDA-induced PAR-formation is KNYKKTEV peptide-dependent, and
that competitive binding to the PDZ domain of PSD-95 (or related proteins)
containing this domain, aids in diminishing NMDA-induced PARP-1 activation.
This is consistent with the understanding that PSD-95 is linked to nNOS
(neuronal nitric oxide synthetase), which produces NO within the neuron. Also,
results shown indicate that NMDA-induced cell death is mediated by the NMDAreceptor’s linkage to PSD-95 and connect this finding, for the first time, that
disconnection of the NMDA-receptor from PSD-95, through competitive binding
of the peptide-ligand(s) with the PDZ-domain of PSD-95 (or similar protein),
renders the NMDA-receptive neurons insensitive to NMDA-induced necrosis.
More extensive analysis of these experiments is still forthcoming, although
indications from the two retina pairs analyzed here clearly point out that the
competitive binding of CN2097 to the PDZ domain-binding domain does offer
almost complete protection against NMDA-induced ganglion cell loss and
indicates that the interaction of the NMDA receptor subunits to a PDZ containing
protein (PSD-95) is the initiator of the cell death signal that mediates both
necrosis and apoptotic-like pathways.
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2.11 Conclusions
The central purpose of this dissertation research was to investigate
multiplicity in PDZ domain binding, and our system of choice was a biologically
critical and abundant protein in the cytoplasm of neuronal cells, PSD-95. Since
the broader goal of our laboratory was exploring the nature of PDZ interactions,
both monovalent and multivalent, we had independently expressed three
separate constructs: PDZ1, PDZ2 and PDZ1-2. A series of peptide ligands
derived from the C-terminus of natural binding partners were synthesized and
tested against all three proteins. In the case of PDZ1, association of these
peptide ligands is driven by dominant favorable enthalpic contributions to the
binding free energy. The interactions are usually entropically favorable. The
reported assoiciation constant are in good agreement with the previously
published fluorescence data [170].
PDZ2 did not express well in recombinant form from bacteria, and it was
likely misfolded, and therefore the resulting ITC binding data with peptide ligands
was inconclusive. Future efforts in this area should perhaps focus on using the
full-length (uncut) GST-PDZ fusion for binding studies. Although GST fusion
proteins can dimerize, the alternative would be the preparation of other types of
fusion protein, such as with maltose-binding protein (MPB) or NusA and use
these for the binding studies.
The dual domain PDZ1-2 showed strong binding preferences toward the
same ligands, although a stoichiometry of n=1 clearly points out that only one
binding pocket equivalent is occupied. In the case of a very strong binding to
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modified peptide CN2180, the stoichiometry of n=2 indicated favorable
orientation and occupancy of both binding sites of the domains. We should not
rule out, however, the possibility of CN2180 binding to a remote site on the
surface of tandem domain, although there is no biochemical evidence in the
literature relating to PDZ domains that would suggest this. A lack of structural
information for the intact dual domain in complex with ligands encouraged our
efforts to crystallize and solve PDZ1-2 tandem structure, further discussed in
detail (Chapter 3). CN2180 showed very promising biological activity and efforts
are ongoing in this direction.
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CHAPTER 3
PRELIMINARY STRUCTURAL STUDIES OF THE TANDEM PDZ1-2 DOMAIN
PROTEIN OF PSD-95
PSD-95 is one of the key proteins in the postsynaptic density. Although, its
individual domains have been structurally characterized, PDB deposition for dual
PDZ1-2 is only modeled. Also, ITC data was very difficult to interpret without true
structural insight. In this Chapter we report for the first time successful
crystallization of dual PDZ1-2 of PSD-95. This study was carried out in
collaboration with Dr. Ladislau Kovari, WSU. The work is featured in a
manuscript that is in preparation.
3.1. PDZ domain protein crystallography
X-ray crystallography represents a very powerful method used to
determine the three dimensional structures of the major biomacromolecules,
namely, proteins, DNA and RNA and their complexes. The information provided
by a crystal structure is fundamental in explaining the biological function of
macromolecules. Obtaining detailed pictures of large molecules at the molecular
and atomic level was practically impossible before employing the technique of
single-crystal X-ray crystallography [55, 171, 172]. This method utilizes diffraction
of X-rays from many identical molecules in an ordered array of a crystal. It is
important to point out that proteins mostly retain their fold, and therefore their
function, in the crystal form, therefore obtaining high resolution structures helps
in our understanding of proteins’ biological functions in terms of their binding
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properties and thermodynamics. A detailed explanation of the technique is
provided in Chapter 1 of this dissertation.
3.1.1. PDZ domain structures. There have been a considerable number of PDZ
domain structures, currently on the order of 200, deposited in the Protein Data
Bank (PDB). This includes those solved by either X-ray crystallography or NMR;
at least 120 of them were obtained by the former technique. The vast majority of
these are structures of just the PDZ domain substructure subcloned from their
larger parent protein, which indicates that this class of domain is relatively stable
under laboratory conditions and well suited for structural studies. It also indicates
that even though they might possess a similar three-dimensional fold, there exist
many differences in each particular PDZ domain in both the free or complexed
forms as revealed by these structures. Most importantly, these structures have
contributed tremendously to our understanding of the biological role of these
relatively small protein modules.
3.1.1.1 The general structural form of the PDZ domain. The numerous entries
in the PDB databank illustrate vast interest in these PDZ proteins, but also
underlie the importance of understanding protein domain organization in general.
Most importantly, these studies helped in formulating the rules of peptide (protein
binding partner) recognition, which is essential for their biological function. One of
the first studies that revealed the molecular recognition events taking place in the
PDZ mediated complex formation involved solving the X-ray crystallographic
structure of PDZ3 of PSD-95 complexed with a nonapeptide ligand derived from
the PDZ3 binding partner, CRIPT protein [88].
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The crystal structure (Figure 3.1) of PDZ3 comprises six β strands (βA-βF)
and two α-helices (αA and αB), which fold in an overall six-stranded β sandwich.
Four residues of the ligand’s C-terminal region have been shown to interact with
the peptide-binding groove between the βB strand and αB helix as an antiparallel
β strand extending one of the β sheet. The C-terminal hydrophobic residue valine
at the “0” position of the peptide binds to the hydrophobic pocket created in the
PDZ domain by several hydrophobic residues, which are Leu323, Phe325,
Ile327, and Leu379 [88]. The tight contact of the side chain of valine with the
hydrophobic pocket explains the preference for the sequence having a
hydrophobic residue at the “0” position. Another critical interaction is the
hydrogen-bonding interaction of the hydroxyl group of the “-2” threonine with N3
of His372 (first residue of the αB helix). The side chain of the “-1” Ser residue is
shown pointing away from the interacting surface.

Molecular Basis of Peptide Recognition by PDZ
1071
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Figure 3.1 Stereo view of the peptide binding site demonstating protein –
Figure 4. Chemical Interactions Involved in Peptide Binding
peptide interactions [88].
(A) Stereo view of the peptide-binding site demonstrating protein–
peptide interactions via hydrogen bonds (dashed white lines) and
the location of the Val 0 side chain in the hydrophobic pocket.
Oxygen atoms are shown in red and nitrogen atoms in blue. The
green sphere shows a well-ordered water molecule linking the carboxylate group to Arg-318. The picture was drawn with MOLSCRIPT
and Raster3D.
(B) Schematic view of the contacts identified in the crystal structure
of the complex. Dashed lines represent hydrogen bonds, and the
two closest atom-to-atom distances between the Val 0 side chain
and all atoms in the hydrophobic pocket of the PDZ domain are
drawn as solid black lines. The Val 0 side chain makes numerous
other Van der Waals contacts within the range of 3.9 to 4.3 Å;
however, for clarity they are not indicated in this diagram. The fixed
orientation of the arginine guanidinium head group via hydrogen
bonds with backbone carbonyl groups is also shown.

The peptide (yellow) inserts between the β strand and β helix and forms

an antiparallel sheet with βB. The connecting loop between αB and βB is
involved in binding the peptide C-terminus and therefore is designated the
carboxylate-binding loop.˚

More recently, crystal structure of the same protein at higher resolution

was solved by Dorina Saro in Spaller lab. Two different structures of PDZ3
complexed with hexapeptides KKETWV and KKETPV were deposited, with PDB
codes 1TP5 and 1TP3, respectively. The method employed in both cases was
that of molecular replacement (details in Chapter 1). Figure 3.2 depicts the
domain in association with KKETWV (shown in dark blue) and its position
between β strand and β helix.

sequence Glu-Thr-Asp-Val-COO!) with PDZ-2 from
PSD-95 in which the histidine residue (corresponding
to position 372) is conserved (Kim et al., 1995). The

peptide residue at position !1, on the other hand, has
been shown to be functionally unimportant and is poorly
conserved among the C-termini of membrane proteins
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Figure 3.2 Ribbon diagram showing PDZ3 complexed with KKETWV,
PDB code 1TP5. Ligand shown in dark blue. Image generated by Protein
Workshop.
Crystals of PDZ3 soaked with KKETWV peptide diffracted at high
resolution, 1.54 Å. The structure of the PDZ3/KKETWV complex represents the
highest resolution structure of the PDZ3 of PSD-95 available, and one of the
highest resolution structures of all PDZ domains solved to date. These structures
reveal the specific interactions that play an important role in the PDZ3 recognition
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of these ligands. Even though these peptides have similar sequences and
identical residues at the critical “0” and “-2” positions, they still bind to PDZ3
domain with different thermodynamic properties and this is a result of the
structural differences in each complex formation.
Structural studies have also discovered important biological functions of
these domains. The differences in C-terminal peptide recognition between class I
and II PDZ domains became clear with the information from the complex
structures of PDZ domains of each class [88, 120, 173, 174]. The recognition of
internal sequences by some PDZ domains were also revealed from structural
data [121, 122]. The effect of chaperoning and intermolecular interaction of PDZ
domains with each other [122, 174-176] is one aspect of PDZ function known
from the structural data. Novel structural features of PDZ domains, like the
presence of alternative binding pocket [177], or novel mode of peptide
recognition by a PDZ domain [178], have also become clear from analysis of
crystallographic and NMR structural information. Diverse biological functions of
PDZ domains were discovered from structural studies as well. One example of
this is the study of DegS stress sensor PDZ domain that recognizes misfolded
proteins and activates the proteolytic activity of this enzyme [179]. To further
explain this behavior, the function of PDZ domains in DegP (or also known as
HtrA) protease might be very similar, as described by Krojer et al. [180],
indicating a possible general mechanism of recognition and binding of misfolded
proteins by PDZ domains.
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Interestingly, the most precise crystal structure of a protein known so far is
the PDZ2 domain of syntenin protein. This structure is defined at ultra-high
resolution of 0.87 Å with crystallographic refinement values of R = 7.5% and Rfree
= 8.7% [181]. These refinement values are typically much higher for protein
structures (in the range of 20 to 25% for well-refined structures)[182] and closer
to the small molecule refinement, “bridging the gap” [181] between the two fields.
Being an ultra-high resolution structure, the model of PDZ2 of syntenin also
shows important features of protein structures like the flexibility of the peptide
bond, and the presence and stereochemistry of weak C−H---O hydrogen bonds
[181].
3.1.1.2 Dual or tandem PDZ domains. An important question for which the
answer remains largely unknown and that we have tried to address is the manner
of binding action for multiple PDZ domains. Specifically, this entails the form
involving two vicinal PDZ domains, which are referred to as tandem or dual
domains. Such tandem forms may be critical for the biological activity of the
protein in which they are found. Examples include neuronal nitric oxide synthase
(nNOS) [183] and the cystic fibrosis transmembrane conductance regulator
(CFTR) protein [110, 184, 185].
In the case of PDZ1-2 from PSD-95, which is a focus of this dissertation
research, isothermal titration calorimetry data yielded results that were difficult to
interpret. Using different experimental conditions, it appeared that only one
peptide ligand was binding to the dual PDZ1-2 domain. These finding were
discussed in detail in Chapter I. Also, thermodynamic experiments have their
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own limitations and could not answer some important questions: how do tandem
domains bind to similar targets, and where does the difference in specificity come
from? These questions are best answered by structural methods using a tandem
PDZ1-2 domain as a target to crystallize in both the free and ligand bound forms.
Postsynaptic density protein-95 (PSD-95; also known as synapse
associated protein 90(SAP 90))[85] found in high concentrations at the post
synaptic densities of dendritic spines. All the members of this family consist of
three PDZ domains, followed by one SH3 domain and one guanylate kinase
homology (GK) domain Figure 3.3.

Figure 3.3 Domain organization of PSD-95 protein.

Interestingly enough, a NMR structure of tandem PDZ1-2 domain of PSD95 was previously published [186]. However, this was not a true solution
structure, but the result of modeling the two domains together, each of which had
been solved independently. The PDZ1 domain NMR structure was also
previously solved and deposited in the PDB (codes 1iu0 and 1iu2). Relying on
other experimental results, PDZ2 domain was modeled. A mechanism of binding
was hypothesized, and modeled as well. This study is the first to characterize the
three-dimensional structure of a tandem (supramodular) array of PDZ domains.
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Previously, the same group has solved the free structure of PDZ2 and deposited
in the PDB (PDB code 1qlc) [187].
Although these modeled results are intriguing, it is unclear why an effort
was not made to solve a true NMR structure of dual domain? One can only
speculate that it was attempted, but for unreported reasons was not successful.
In the absence of an explanation from the reporting group, it is not unreasonable
to suppose that the NMR methodology did not yield solvable information on the
actual tandem construct. Thus, there remains a large hole in our understanding
of how the PDZ12 dual domain of PSD-95 is truly structured. The availability of
this structure would add considerably to our understanding of the endogenous
binding interactions that PDZ12 engages in. Besides helping to shed light on this
fundamental character of PDZ12, it would also greatly aid efforts to design novel
inhibitors that could specifically and simultaneously target both domains. As
described in Chapter 2 there are profound biological—and potentially
therapeutic—effects associated with small peptides that target PDZ1 and PDZ2.
Therefore, a significant effort was expended in attempts to solve the structure of
the first two PDZ domains of PSD-95 protein by X-ray crystallography.
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3.2 Materials and Methods
3.2.1 Materials Crystallization plates were obtained from Nextal Biotechnologies
Inc. (Qiagen). For fast setup of crystallization conditions screw-in, greaseless
crystallization supports were used that also provide easier setup and crystal
recovery. The EasyXtal Tool is supplied as an empty 24 well plate with a capacity
of 1 mL of solution per well and 24 EasyXtal CrystalSupports. For initial
screening of crystallization conditions the Wizard™ I&II (Emerald Biosystems)
was used. Wizard™ I&II screens provided full 96 unique formulations of the
random sparse matrix for the crystallization of biological macromolecules. A
Leica GZ7 microscope was used to check the plates after set up and to observe
the crystallization process. Diffraction data were collected from several crystals
on a Rigaku/MSC FRD generator/R-AXIS HTC image plate system. Silicon
Graphics and Monarch Computer Systems Unix box were used for computer
calculations.
3.2.2 Methods
3.2.2.1 PDZ1-2 protein expression and purification The PDZ1-2 dual domain
of PSD-95 was expressed and purified as described in section 2.3.2.1 of Chapter
2.
3.2.2.2 Crystallization of dual PDZ1-2 protein The PDZ1-2 samples were
dialyzed into the final dialysis buffer (10 mM sodium phosphate, pH 8.0). The
sample was then concentrated up to 15 mg/mL using Amicon centrifugal filter
devices 3000 MWCO (Millipore) and stored at 4 °C until needed. Preliminary
crystallization trials were performed using Wizard™ I&II. The hanging-drop
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vapor-diffusion technique was utilized. For initial screening, concentrated PDZ1-2
protein (1 µL) was mixed with an aqueous buffer containing precipitant (1 µL).
The cover slip with the prepared droplet was inverted over the same precipitant
aqueous solution (0.7 mL) in the well, and after the set up the plates were
incubated in the dark under controlled temperature (22 ºC) and humidity
conditions. After 1-2 weeks micro crystals were observed in three out of 96
conditions; these were from Wizard™II crystallization screens listed below:

Solution 1: 10% (w/v) PEG-3000 , 100mM acetate( pH 4.5) , 200mM Zn(OAc)2
Solution 19: 1.6 M NaH2PO4/0.4 M K2HPO4, 100mM phosphate-citrate (pH 4.2)
Solution 40: 20% (w/v) PEG-3000, 100mM imidazole (pH 8.0) ,200mM Zn(OAc)2

These conditions were repeated, but now with varying protein to
precipitant ratios (1:1, 1:2, 1:3, 1:4) and with the same ratios for precipitant to
protein. Chemicals were purchased from following vendors: PEG-3000 (Fluka),
Zn(OAc)2, NaH2PO4, K2HPO4, imidazole, acetic acid, sodium acetate, citric acid
(Sigma). Controls were run alongside with final dialysis buffer.
Microcrystals were observed only in the drops formed with 10% (w/v)
PEG-3000, 100 mM acetate (pH 4.5), 200mM Zn(OAc)2. These were further
optimized resulting in good size crystals (0.2-0.4) mm obtained by mixing 4 µL of
high purity protein sample (15 mg/mL) with 1 µL of precipitant. Crystals formed
within one week. Hexagonal PDZ1-2 crystals were stable for approximately three
months in mother liquor, but started to degrade afterwards. These crystals were
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directly flash-frozen in liquid nitrogen and preliminary test showed very good
diffraction. Therefore, it was concluded that the presence of PEG-3000 was
sufficient and no additional cryoprotectant was needed.
3.2.2.3 PDZ1-2 data collection Diffraction data were collected from a single
crystal on a Rigaku/MSC FRD generator/R-AXIS HTC image plate system at
WSU Medical School. The temperature during data collection was -180 °C due to
continuous liquid nitrogen stream over the crystal. The crystal-to-detector
distance was 150 mm. Copper radiation (1.5418 Å) was used. For a complete
data set, 360 frames with 0.5° oscillation were collected. The exposure time was
3 minutes for each frame. Diffraction data were collected and processed using
Rigaku/MSC CrystalClear software.
3.3 Results
3.3.1 Crystallization properties of the free PDZ1-2 dual domain The
conjoined first two PDZ domains (PDZ1-2) from PSD-95 were overexpressed as
a GST fusion protein and purified using a slightly altered purification protocol.
The 190-amino acid long tandem domain was separated from the GST affinity
tag by trypsin cleavage. After further purification the isolated PDZ1-2 protein
appeared very stable when stored at 4 ºC, even though it was highly
concentrated (up to 15 mg/mL).
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The crystallization setup using optimized conditions (10% (w/v) PEG3000, 100mM acetate (pH 4.5), 200mM Zn(OAc)2) as explained in detail in
(3.2.2.2), provided for well shaped crystals as shown in Figures 3.4 and 3.5.

Figure 3.4 PDZ1-2 dual domain crystals in a 5 µL hanging drop (crystal
diameter 0.4 mm).
Figure 3.4 is a photograph of a one week old crystals in the 5 µL drop. Nicely
shaped hexagonal crystals, well dispersed in mother liquor can be easily
separated. No skin formation on the drop also made the process of mounting the
crystal much easier. Crystals were flash-frozen without the additional
cryoprotectant.
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Figure 3.5 Single PDZ1-2 crystal. Hexagonal crystals grew in a week in 10%
(w/v) PEG-3000, 100 mM acetate (pH 4.5), 200 mM Zn(OAc)2. (crystals 0.4 mm).

3.3.2 Data collection. The crystals formed were of very good quality and stable
while flash-freezing in liquid nitrogen. Upon assessing crystal diffraction quality
by collecting initial frames, obtained diffraction pattern was very good and
estimated a resolution was high. Therefore, the same crystal was left in the X-ray
beam for the complete data set collection (360 frames, 0.5º oscillation and 3
minutes exposure time per frame). A typical diffraction pattern of PDZ1-2 dual
domain protein is shown in Figure 3.6.
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Figure 3.6 Diffraction pattern-single frame of free tandem PDZ1-2. Exposure
time 3 minutes.
3.3.3 Data reduction. The crystal of PDZ1-2 dual domain protein diffracted at
good resolution (2.6 Å). A complete data set of 360 frames were collected, 0.5º
oscillation angle and exposure time of 3 minutes per frame. This data set was
collected using a Rigaku/MSC FRD generator/R-AXIS HTC image plate system.
Data collection and initial processing were conducted using CrystalClear for
Rigaku. CrystalClear incorporates the concept that data acquisition and data
processing should be combined. Further data reduction was performed utilizing
MOSFLM software. MOSFLM processes diffraction images and gives a MTZ file

140
as an output, which contains reflection indices with their intensities and standard
deviations. This MTZ file is then used by other programs of the CCP4 program
suite for data reduction, scaling and merging. Table 3.1 lists the parameter
values after processing data with SCALA from the CCP4 package. These results
indicate that PDZ1-2 dual domain form cubic crystals that belong to the P23
space group. This is a high symmetry space group, which, unfortunately, has
historically proven to be a problem when attempting to solve the structure using
the molecular replacement method.

Table 3.1 Data collection statistics for the dual PDZ1-2 protein domain

Resolution range (Å)
Unit –cell parameters (Å)

29.09 – 2.60

(2.74 – 2.60)

a = b = c = 87.2667 Å
α = β = γ = 90°

Space group

P23

Rmerge

0.112

No. of total reflections

149876

No. of unique reflections

7052

Completeness (%)

99.9

(100.0)

Average I/σ(I)

29.0

(5.1)

Multiplicity

21.3

(21.4)

Values in () are for the last resolution shell

(0.630)
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3.4 Discussion
A PDZ1-2 dual domain protein that was expressed and purified as
discussed, was successfully crystallized. Purification protocol for this protein was
altered and explained in detail in Chapter I of this report. This modified
purification scheme resulted in a highly pure and stable protein. Crystallization
set-up experiments using optimized conditions (10% (w/v) PEG-3000, 100 mM
acetate (pH 4.5), 200 mM Zn(OAc)2) explained in detail in (section 2.2.2),
provided for well-shaped hexagonal crystals. PDZ1-2 crystallizes in cubic P23
group. Data reduction gave a Rmerge value of 11.2 %, which proves that this was
a high quality data set.
We tried to solve the PDZ1-2 dual domain protein structure using the
molecular replacement method. The rationale for this was that structures of
several PDZ domains are known and can be used as a model for this technique.
The first model used was that of the crystal structure of PDZ3 domain of PSD-95
protein [88], complexed with a peptide ligand. This attempt failed to yield an
acceptable solution, as this model represents only a single PDZ domain and we
are looking for the structure of a dual PDZ domain containing protein. The
structure of another dual PDZ domain protein syntenin was also used in
molecular replacement calculations, but likewise did not result in a clear solution.
[188]
The 1n99.pdb file of PDZ tandem of human syntenin was downloaded
from the PDB and used as the model (Fig 3.7). The file was modified by
removing solvent molecules, and used as a model during calculations. In order to
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ensure that these changes to the template model really occurred, the structure
was inspected using PyMol display software, and in fact it was confirmed to be a
single polypeptide chain.

Figure 3.7 PDZ 1-2 of synthenin. PDB code: 1N99. Image generated with PyMol.
The programs utilized for solving the structure were from the CCP4
package; Refmac 5 was used. The template file was modified with rigid body
refinement at 4 Å. After the first round of Refmac 5 was successful, a rigid body
refinement at 3 Å was performed, followed by restrained refinement at 3 Å. This
round was followed by restrained refinement to the limited resolution. In our case
that was 2.6 Å. The Mtz output file was created, followed by twenty cycles of
ARP/wARP and adding water molecules to the structure resulted in file
10_solvent.pdb. An image from this file is reproduced below in Figure 3.8.
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Figure 3.8 Image of the 10_solvent.pdb. Image generated with PyMol.
This image represents mostly a random coiled structure, but it can be
clearly seen that there are some structured regions. However, this does not
represent a true solution of the PDZ1-2 tandem domain structure, since R = 47.7
and Rfree = 52.8. As these values were very high (more than 50%), this indicates
that the experimental data are not in good agreement with the model. A good
starting point for R/Rfree values is around 40%, and further structure refinement
can bring those values down to acceptable values of 20 – 30%.
Another view of the hypothetical structure denoted 10_solvent.pdb is
depicted in Figure 3.9. The characteristic fold of PDZ domains of six β-strands
and two α-helices can be easily visualized in both domains, although for the
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reasons explained above, this rendering cannot be accepted with confidence as
a true solution structure.

Figure 3.9 Image of the 10_solvent.pdb. Image generated with PyMol.
The reason the molecular replacement calculations failed relate to the
different space groups of the model and our molecule. An alternative way to
solve this problem would be to use AMoRe [189], another molecular replacement
program that has the advantage of transforming both the model and the new
structure into a hypothetical space group and then performing the searches. If
the molecular replacement methods do not work, then the structure can still be
solved by another method, like heavy atom derivative or MAD (multiwavelength
anomalous diffraction).
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The problem with molecular replacement methods not being able to solve
the PDZ1-2 structure, despite the fact that there is good quality diffraction data
available, might be that the PDZ1-2 dual domain crystallizes in a different way
than the previously known structures. So even though structures of separate
PDZ domains are known, their relative orientation in the PDZ1-2 dual domain
might be different and that accounts for significant changes between the model
and the experimental data that the molecular replacement method cannot
resolve.
Since PDZ12 of PSD-95 is a novel unsolved protein, never crystallized
before, further efforts to solve the structure should focus on using methods other
then molecular replacement. One way is producing heavy metal derivatives.
Anomalous scattering methods can be used to calculate phases based on the
advantage that a heavy-atom can absorb X-rays of specified wavelengths. Also,
multiwavelength anomalous dispersion (MAD) phasing can be used as an
alternative to solving the phase problem in crystallography. For this purpose
selenomethionine derivatives can be used. In this strategy, the protein is
expressed in media that contains selenomethionine as the only source for amino
acid methionine.
GSEYEEITLERGNSGLGFSIAGGTDNPHIGDDPSIFITKIIPGGAAAQDGRL
RVNDSILFVNEVDVREVTHSAAVEALKEAGSIVRLYVMRRKPPAEKVMEIK
LIKGPKGLGFSIAGGVGNQHIPGDNSIYVTKIIEGGAAHKDGRLQIGDKILAV
NSVGLEDVMHEDAVAALKNTYDVVYLKVAKPSNA
Figure 3.10. Sequence of PDZ1-2 with highlighted methionines.
As a result selenium is incorporated as a heavy atom containing amino
acid in the protein that can be further purified and crystallized as the wild type. If
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that is successful, than data collection using synchrotron radiation with multiple
wavelengths can result is solving the phase problem and the crystal structure of
the protein.
3.5 Conclusions
In this thesis chapter, crystallization of a new protein construct, PDZ1-2 of PSD95 is reported. Identifying the conditions required to grow crystals is a major step
forward in efforts to solve this tandem domain by X-ray methods. Significant
efforts were made to solve the structure using the molecular replacement
method, but due to specific space group that protein crystallizes in, thus far
solved models of similar proteins could not be implemented. However, producing
a seleno-methionine derivative would gain a diffractable crystal and would enable
to solve the structure of the protein.
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CHAPTER 4
CHARACTERIZING BINDING PROPERTIES OF Fe(II) BINDING TO
FRATAXIN
Further exploring the idea of multivalency and applying ITC as a true
solution method for assessing affinity of protein–mediated interactions; another
project was carried out in collaboration with Dr. Timothy Stemmler’s lab at WSU
Medical School. The study provided greater in depth understanding of cellular
processes, this time on the example of metal binding to the iron chaperoneFrataxin. The work presented in this chapter has been published in Biochemisty,
2006.
Friedreich’s ataxia (FRDA) is caused by deficiency in the protein frataxin.
FRDA is as an autosomal recessive cardio and neurodegenerative disorder that
affects approximately 1 in 50 000 people, as reported by independent studies
[190-192]. At this rate, it is believed to be the most common autosomal-recessive
neurodegenerative disease of Caucasians [193]. Frataxin is nuclear-encoded
protein subsequently localized in mitochondria at the matrix side of the inner
membrane [194, 195]. Cells depleted of frataxin will have progressive
mitochondrial accumulation of iron. However, iron deposits are biologically
unavailable, which leads to further decrease of metal activities – its role in ironsulfur cluster enzymes, oxidative damage to mitochondria [196, 197]. Clinical
picture

of

iron

deficiency

in

humans

manifests

through

hypertrophic

cardiomyopathy, degeneration of sensory neurons in the dorsal root ganglia, and
diabetes mellitus [195].
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4.1 Mitochondrial iron metabolism Transition metals play a key role in
regulatory, structural and catalytic properties of the cell [198]. Metal content in
prokaryotic cells of iron, zinc and calcium is very similar and ranges around 0.1
mM [198]. The concentration of iron in mitochondria of yeast cells is the same as
for prokaryotes, which is consistent with its role within the organelle. Iron is
required for two major pathways in the mitochondria: iron-sulfur (Fe-S) cluster
and heme assembly. These cofactors are found in key proteins like aconitase
(Krebs cycle), complex I of the respiratory chain (electron transport) that require
Fe-S clusters [199] or cytochromes, membrane proteins that utilize heme.
However, redox ability of the transition metals, iron and copper in particular can
generate toxic organic and oxide based radicals [200]. Maintaining iron
concentration within the mitochondria is crucial for cell survival.
Iron is found ubiquitously in all living systems, although both metal
deficiency and metal overload are destructive to cells. Through its protein
controlled mechanisms organisms have evolved, so that iron import can be
quickly enhanced or suppressed, or finally stored for the future use [201]. In
humans, Fe obtained from diet is reduced and acidified by the low pH
environment of the stomach and potion is transported for production of heme and
Fe-S clusters. More than 2/3 of Fe found in the body is incorporated into
hemoglobin in developing erythroid precursor cells or in mature red blood cells
[202]. Such an abundance of heme prosthetic group is absolutely necessary for
controlling O2 concentration, availability and reactivity. As previously outlined, Fes clusters are another Fe containing prosthetic groups that help control cell
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viability by taking part in electron transfer events, substrate binding and
activation, iron and sulfur storage, regulation of gene expression and enzyme
activity [203].
4.2 Heme bisynthesis. Heme is an iron-containing tetra-pyrrole ring system. The
heme biosynthetic pathway was described in detail during 1950’s and 60’s [204].
Heme biosynthesis consists of eight sequential steps [205], four of which (step 1
and steps 6-8) occur in mitochondria, while the other steps occur in the
cytoplasm. The final step is the insertion of ferrous ion into porphyrin ring by
enzyme ferrochelatase to yield a functional heme prosthetic group [206]. In
prokaryotes, ferrochelatase is found within the cytoplasm or embedded in the
cytoplasmic membrane [207], as in eukaryotes enzyme is part of the inner
mitochondrial membrane. In was revealed that ferrochelatase can chelate divers
divalent metal ions, most prominently Zn2+ [208].
4.3 Iron-sulfur cluster biosynthesis Fe-S clusters are ancient and complex
prosthetic group. They are absolutely crucial in electron transport, catalysis, gene
regulation and iron uptake [209]. In the recent studies various steps of their
biosynthetic pathways have been revealed, but surprisingly research is still
ongoing for in depth understanding of particular processes.
Iron sulfur cluster (ISC) assembly in yeast begins with the liberation of
sulfur by the cysteine desulfurase, Nfs1 [210]. Nfs1 is an enzyme that contains
pyridoxal phosphate (PLP) as cofactor, through which it forms Schiff base with
free cysteine. This is followed by a nucleophilic attack on the cysteine-PLP
complexby the active site thiolate, releasing alanine [211]. Most recently a small
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protein Isd11 is identified, believed to act as an adaptor between Nfs1 and
scaffold proteins thus helping stabilize the complex and promote sulfur release
[212-214]. In the next step, sulfur is transferred to the cluster assembly scaffold
proteins, ~ 28 kDa protein dimer constructed of Isu1 (and/or) 2, usually through
heterotetrameric complexes of the scaffold and the desulfurase [211, 215-217]
This protein–controlled mechanism prevents toxic effect of iron while enabling
bioavailability for delivery to the Isu.
4.4 Disruption of iron homeostasis and Friedreich’s ataxia Friedreich’s ataxia
(FRDA) is a disease related to the disruption of cellular iron homeostasis [201].
First described by a physician Nicholaus Friedreich, FRDA is an autosomal
cardio and neurodegenerative disorder, and it is the most prevalent inherited
ataxia. FRDA affects 1 in 50,000 people and is caused by deficiency of the
protein frataxin (Ftx). The void of Ftx leads to progressive iron accumulation and
a deficiency in heme and Fe-S clusters, resulting in loss of cell viability and
eventually patient death. The patients with FRDA (96%) have extensive
trinucleotide repeat expansions in the first intron of the gene encoding Ftx, while
small some patients have frataxin point mutations [218]. The expanded GAA
repeat adopts abnormal DNA structures that impair Ftx transcription; longer the
repeat, the more profound is the frataxin deficiency and the earlier the onset and
greater the intensity of the disease [219-221].
Early symptoms of the disease like loss of coordination, muscle weakness
and scoliosis usually begin between ages 5 to 15 years. About 20% of patients
develop diabetes mellitus. Disease is progressive and death occurs during early
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thirties and mostly (91%) involves cardiomyopathy. At present, there is no cure
for Friedreich’s ataxia. The treatment is limited to 3 possible approaches [222].
One strategy involves antioxidants targeted to mitochondria and recent trials
include idebenone (proven to delay cardiac dysfunction in mice) and drugs like
VitQ and MitoQ. Second approach uses iron chelators to protect from peroxide
induced toxicity (deferoxamine). At last, third approach uses DNA sequence
specific polyamides and histone deacetylase inhibitors that reverse gene
silencing [222].
4.5 Role of frataxin in the mitochondria Frataxin is a nuclear encoded protein
localized in the mitochondria. This protein is highly conserved from prokaryotes
to eukaryotes and amino acid sequence identity of yeast frataxin (Yfh1)
compared to bacterial (CyaY) is 28.1% and to human (Hftx) is 37.8%. Frataxin is
abundant in tissues with high metabolic rate such as kidneys, liver, brown fat
neurons and heart [195]. Initial studies of frataxin’s role in maintaining iron
homeostasis were done on yeast homolog (Yfh1)[223]. Deletion of frataxin gene
results in accumulation of mitochondrial Fe deposits [223], followed by aconitase
and general Fe-S cluster protein deficiencies [196, 224]. The presence of zinc
suppresses iron accumulation phenotypes in yeast [225]. Cells depleted of Yfh1
were hypersensitive to H2O2, iron and copper levels [223, 224]. However, it was
also noted that after reintroducing Yfh1 expression under depleted conditions,
recovery and export of original mitochondrial iron deposits was promoted.
Therefore, it was proposed that frataxin has a role of directly controlling
mitochondrial iron efflux [226].
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Frataxin’s ability to directly bind iron was first identified in the yeast system
[227]. The same property has been confirmed for bacterial and human orthologs
[228-233]. Initial hypothesis was that the iron binding in the yeast system induces
frataxin to oligomerize under unique solution conditions. Numerous reports after
that have proven that oligomerization is not essential when protein act as a
chaperone, but it might be necessary when protein participates in helping control
ROS production under iron overload conditions [234]. Metal to protein
stoichiometries, measured for monomeric bacterial, yeast and N-terminally
truncated human frataxin show these proteins will tightly bind 2, 2 and 7 Fe(II)
atoms, respectively [230, 231, 233]. Iron dissociation constants, measured for
bacterial (CyaY), yeast (Yfh1) and N-terminally truncated human frataxin (HsFtx)
give average Kd values of 3.8, 3.0 and 55.0 µM, respectively [230, 233].
However, the exact role of frataxin is still unclear. Initially, it was believed
to be an iron regulator, since metal accumulation occurs as a result of its
depletion [226]. It was also shown that frataxin is involved in energy conversion
and ATP synthesis [235], also protecting aconitase [4Fe-4S]2+ clusters against
disassembly and inactivation [236, 237]. Frataxin is involved in the in vivo
production of heme [238-240] and Fe-S clusters [216, 241, 242].
In order to characterize binding affinity of monomeric yeast frataxin to
ferrous ion, isothermal titration calorimetry was used. The research conducted is
a collaboration project with Dr.Stemmler’s group (WSU, Medical School). In order
to better understand how frataxin binds iron, besides ITC measurements, nuclear
magnetic resonance (NMR) spectroscopic analysis was used to further identify
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amino acids affected by the presence of iron.

Finally, X-ray absorption

spectroscopic (XAS) studies were used to determine the oxidation and spin-state
of iron bound to frataxin, as well as help provide structural detail of the binding
event [233].
ITC experiments performed so far were done using yeast frataxin (Yfh1),
wild type protein. Since, there is a high sequence homology and structural
similarities between protein family members, these results provide additional
direct insight into general properties that dictate how frataxin orthologs bind iron.
Besides wild type protein, additional mutant proteins were used. Mutations were
engineered in order to knock out the assumed binding points for ferrous ion.
This project was worth more than 80 ITC experiment. Unfortunately, for a
lot of them good curve fitting was impossible to achieve.

Working under

anaerobic conditions, with the presence of a reducing agent requires extreme
caution; since iron solution readily oxidizes. Experiments were very lengthy due
to a long equilibration period between injections.
4.6 Structure of frataxin Human, yeast and bacterial frataxin orthologs have
their structures deposited in PDB [243-248]. All frataxin variant share structural
similarity, as expected based on the high sequence overlap. Frataxin structure is
comprised of two terminal α-helices that make one plane, five antiparallel βstrands that build a second plane of the protein and a sixth β-strand (even
seventh in case of HsFtx) that intersects the planes to give an overall planer α-β
sandwich structural motif (Fig. 4.1).
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Figure 4.1. Top: ribbon diagram of yeast, human and bacterial frataxin. Middle:
electropotential plots for proteins in same orientation. Bottom: electropotential
plots for proteins rotated -90 degrees around the y-axis compared to top display.
Structure figures made using solution structures of Yfh1 (PDB ID# 2GA5), HsFtx
(PDB ID# 1LY7) and CyaY (PDB ID# 1SOY) frataxins.

As a illustration of the structure similarities between orthologs, RMSDs of HsFtx
versus CyaY and Yfh1 in regions of secondary structure are 1.34 and 0.65
respctively [201]. Very interesting property of frataxin structure is a large number

155
of Asp and Glu residues in the N-terminal region. These residues are primarily
located in the α1 and β1 regions of the protein [201]. In the electrostatic potential
plots (Fig 4.1), these conserved acidic residues form negatively charged surface
that covers almost a quarter of frataxin’s total accessible surface [244].
Carboxylate Asp and Glu serve as ligands for metal binding, so it is believed to
be the case for frataxin as well.
4.7 Mapping iron binding sites of yeast frataxin NMR spectroscopy was used
to identify frataxin amino acids perturbed by the presence of ferrous iron under
solution conditions that stabilize the monomeric protein. The goal was to locate
the region of the monomeric protein affected by the presence of iron with the
intent to determine which amino acids may be directly involved in iron binding
[233]. Subsequently, these residues will be subjected to mutations in order to
further investigate the nature of Fe binding. Ferrous iron titrations performed
anaerobically with the
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N labeled frataxin orthologs show distinct alterations in

α1 and β1 amino acid NMR resonances. General trends in amide resonance
perturbations upon addition of iron can be divided into two categories: amide
resonances that significantly line broaden (often beyond detection) and amide
chemical shifts that are shifted in the presence of metal. Yfh1 resonances
broadened by addition of up to 2 iron atoms include alpha-1 residues Asp28,
Asp31, His32 and Asp35, the β1 residue Glu61 and the β2 residue Glu61 (Fig
4.2).
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Figure 4.2 Mapping binding sites on the frataxin. A) Apo-protein structure with
helix-1 amino acid side chain atoms from line broadened amide resonances in the
yeast frataxin NMR iron titration. Expanded view to the right of arrows. B) Apoprotein structure with β-sheet amino acid side chain atoms from line broadened
amide resonances in the yeast frataxin NMR iron titration and D50. PDB accession
number 2GA5.
Amide resonances for additional α1, β1 and β2 residues undergo chemical shift
perturbations in the presence of iron [233, 245]. Ferric iron titrations were
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performed on CyaY with similar results to those obtained from ferrous iron
binding.
Characterizing the metal-ligand coordination geometry and electronic
properties of bound iron provide additional insight into the metal binding ability of
the monomeric frataxin orthologs. X-ray absorption spectroscopy (XAS) provides
a powerful tool for characterizing structural and electronic properties of metals
bound to proteins in solution [249].This technique has been used to characterize
iron bound to Yfh1. Analysis of the iron 1s→3d transitions in the X-ray absorption
near edge structure (XANES) portion of the XAS spectrum are consistent with
ferrous iron existing in the high-spin state and coordinated in a highly centrosymmetric metal-ligand coordination geometry when bound to monomeric HsFtx
and Yfh1 [201, 233]. Structural analysis of the Fe(II)-ligand coordination
geometry for monomeric Yfh1 and HsFtx from the extended x-ray absorption fine
structure (EXAFS) portion of the XAS spectrum are consistent with iron bound in
a highly symmetric 6 coordinate ligand environment. Ligands coordinating Fe(II)
are exclusively oxygen and/or nitrogen based, in agreement with α1 and β1 Asp,
Glu and His residues identified in the multiple NMR titrations as residues that
possibly interact with iron. Additional ligands to the protein bound metal surely
also come from water or hydroxide ions. There is no evidence for any
metal•••metal interaction for the ferrous iron bound to monomeric frataxin, even
when up to 2 metals are bound to Yfh1.
4.8 Results-ITC measurement of Fe binding to yeast frataxin ITC
measurements were performed to determine the metal binding affinity and
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maximum metal to protein stoichiometry of monomeric yeast frataxin.
Experiments were performed at 30 °C on a VP-ITC titration microcalorimeter
(Micro Cal Inc.). Protein and aqueous ferrous ammonium sulfate solutions were
prepared anaerobically in 20 mM HEPES (pH = 7.0) and 10 mM MgSO4.
Experiments were designed to keep a ca. 20 fold excess of iron in the syringe
and data were collected at three independent protein concentrations (100 µM, 70
µM and 50 µM) corresponding to aqueous iron solutions of 2.5 mM, 1.4 mM and
0.8 mM, respectively.

Protein samples were loaded anaerobically into the

sample chamber and after an initial 2 µL iron solution injection, 29 additional
injections of 10 µL each were titrated into the protein sample. Spacing between
injections was 10 minutes and the stirring speed of the syringe was held constant
at 500 rpm. All experiments were repeated in triplicate on independent protein
and iron samples Isothermal titration calorimetry (ITC) measurements were
performed to measure the to ensure data reproducibility. The Origin 5.0 software
package supplied by Micro Cal Inc. was used for data analysis. Origin 5.0 uses
non-linear least squares curve fitting algorithm to determine the stoichiometric
ratio, dissociation constant and change in enthalpy of the reaction.
4.8.1 Yeast Frataxin Binds Two Iron Atoms at Micro-Molar Affinity. ITC was
used to provide insight into monomeric yeast frataxin’s iron binding affinity and
the maximal number of ferrous iron atoms that the protein can bind.

ITC

measurements were performed anaerobically under solution conditions that
stabilized the monomeric iron loaded protein. Changes in heat resulting from
iron binding are displayed in µcal/sec on the raw ITC data (Figure 4.3A). These
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data show a single strong exothermic reaction that follows exponential behavior
in the early injection points. Heats at the end of the titration equal those obtained
from Fe(II) alone, indicating metal binding is complete following the early titration
points. Initially, data sets were treated using a model with one set of binding
sites (Origin 5.0). The calculated stoichiometry from the fitted curve provided for
an average of 1.4-1.6 iron atoms per monomeric frataxin.

However, upon

analyzing the diagram, it was apparent that complete saturation is achieved for a
2:1 Fe(II) to protein ratio. Considering also the nature of binding sites in yeast
frataxin, an advanced curve fitting of two sets of binding sites was employed.
The theoretical curve for this model resulted in a better fit to the original data
represented in the metal binding isotherm (Figure 4.3B), and used to determine
the protein’s metal binding affinity. After curve fitting analysis, binding affinities
for both sites was determined to be in the micromolar range (Kd1 = 3.0 ± 0.4 µM
and Kd2 = 2.0 ± 0.2 µM). These results indicate the two metal binding sites are
independent, although they have nearly identical binding affinities.
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Figure 4.3. Raw isothermal titration calorimetry (A) and binding isotherm
data (B) for ferrous iron to yeast frataxin. Grey line in panel (A) shows
baseline and in panel (B) shows the simulated fit to the binding isotherm data.
Data were collected anaerobically at 30 °C in 20 mM HEPES (pH 7.0) and 10
mM MgSO4. These data were collected by injecting small aliquots of a 0.8 mM
ferrous iron solution into a 50 µM Yfh1 sample. Spacing between injections was
10 minutes. Syringe stirring speed was kept at 500 rpm [233].
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4.8.2 Binding Affinity of Mutated Yeast Frataxin Homologs In order to
investigate the role of individual residues involved in iron binding, different
mutations were made to the original sequence. Work on the double mutants was
done in collaboration with Andrew Dancis group at University of Pennsylvania. Nterminal double mutant (H32A/D35A), showed binding of two iron atoms, per
molecule of protein. Binding isotherm is shown in figure 4.4.

Figure 4.4 Binding of frataxin double –mutant to Fe(II).
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These results are easily interpreted if the original NMR structure is
examined [233]. There are a lot of residues in helix-1 being perturbed by the
presence of iron (shown in red on Figure 4.4), which implies that there are more
residues that can facilitate metal binding instead of H32 and D35.
4.9 Discussion
Frataxin has been hypothesized to play a variety of roles in helping
maintain cellular iron homeostasis, most of which involve direct binding to iron.
Frataxin facilitates in vivo heme and Fe-S cluster production and the monomeric
protein binds to enzyme partners that complete the assembly of these ironcontaining cofactors, suggesting monomeric protein may play a direct role in both
processes by acting as the iron chaperone [238, 239]. Since a single iron atom is
transferred during heme and Fe-S cluster assembly, it seems further unlikely that
frataxin oligomers would participate as the source of metal during delivery. Given
this rationale, having a structural and biochemical understanding of iron bound to
monomeric frataxin would help propel the general understanding of how frataxin
functions towards controlling iron bioavailability in the cell.
Frataxin's metal binding affinity is similar to those seen for the copper
chaperones suggesting a common theme in cellular metal delivery if frataxin is in
fact acting as an iron chaperone. The micromolar dissociation constants
measured for yeast frataxin, with respect to ferrous iron (Kd's of 2.0 and 3.0 µM),
resembles those obtained for the human and bacterial orthologs (Kd's of 55.0 and
3.8 µM, respectively). Ferrous iron binding affinities measured for ferrochelatase
are also within the micromolar range indicating frataxin's metal binding affinity is
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closely matched by its protein partner that receives metal. It is therefore
reasonable to suggest frataxin can act as an iron chaperone during Fe-cofactor
production.
4.9 Conclusions
All three structurally characterized frataxin orthologs bind multiple iron
atoms with a micromolar binding affinity when the protein exists in the monomeric
state, which is consistent with a functional role of monomeric protein being
involved in iron binding and delivery. The weak nature of the protein's metal
binding affinity (Kd's of 2.0 and 3.0 µM) and the ligand environment utilized by the
protein when binding metal would be consistent with frataxin acting as an iron
chaperone; the protein must be able to form a favorable interface with its protein
partners and also easily release the metal. Additional structural characterization
will be critical to help elucidate how frataxin binds iron and docks with its protein
partners to promote metal delivery.
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CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS
Our understanding of multivalent effects in biological molecular recognition
has been extensively broadened by emerging new research involving
biochemical studies that seek to address the topic. Whether this pertains to the
binding of two or more peptide ligands to a single or dual domain protein, or the
binding of multiple metal ions to a protein, there are common themes that unite
the two. Conceptually, there are binding theories and data treatments that can be
applicable to both. Operationally, what is also unfortunately in common is the
degree of experimental difficulty that often accompanies studying such systems.
But such investigations are necessary if we not only want to understand the
fundamental molecular recognition properties of these types of systems, but also
want to apply that knowledge to the discovery and development of cellular
probes and therapeutic agents that take multivalency into account. This could
yield ligands that have higher affinity, and improved selectivity, for a given
biomolecular receptor. The projects outlined in this dissertation, encompassing
the peptide-protein interactions of PDZ domains, and the iron-binding interactions
of frataxin, are steps towards understanding multivalency for both fundamental
knowledge and biomedical application.
5.1 Protein-Peptide Interactions: PDZ Domains
Regarding the first project area, PDZ domains have proven to be an ideal
subject for exploring multivalency, given the incidence of the phenomenon as
reported in the literature, especially in proteins involved in critical cellular
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processes. This domain family often appears in proteins situated at neuronal
synapses, and involved in organizing transduction complexes, clustering
membrane receptors, and maintaining cell-polarities [96, 250-252]. These
properties of PDZ domains have been extensively discussed in Chapter 1 of this
dissertation. In these proteins, PDZ domains are usually present in multiple, but
not identical, copies. The protein that we have centered our research upon, the
tandem (PDZ1-2) domain of the N-terminal region of postsynaptic density
protein-95 (PSD-95), is connected by a five-residue peptide linker between the
two domains [186]. Our choice for such a spatially proximal domain may allow
our studies to contribute to understanding other domain constructs so configured.
For example, a four amino acid residue linker is observed in tandem repeats in
mammalian syntenins [253] and also in X11s (also known as Mints) [254].
Besides these dual repeats, clustering of the first three (PDZ123) and second
three (PDZ45) domains has been observed in GRIP (glutamate receptorinteracting protein) and ABP (AMPA receptor-binding protein) [255-257].
Evidence is emerging which indicates that tandem PDZ repeats show distinct
target-binding properties from the individual PDZ domains or from a simple sum
of the two PDZ domains in the repeats [137, 185, 186, 258-260], although the
molecular basis of such supramodular properties remains largely unclear.
The research efforts in our laboratory yielded monovalent [136, 167] and
cyclic [128] peptides that provided insight into nature of interaction of a single
PDZ domain (PDZ3 of PSD-95). In brief, we found that relative short peptides,
with exposed C-termini, are capable of binding to PDZ domains with dissociation
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constants in the low micromolar range, provided they possess certain sequence
motifs. Further on, this knowledge led us to validation of a PDZ domain-directed
molecular probe that functions within human cells [130]. Based on this efforts
homobivalent ligands were designed and probed against the PDZ3 [261] and
proven was the formation of the ternary complex.
The above-mentioned results provided us with the chemical tools to tackle
the problem of the dual PDZ1-2 domain, although immediately it became clear
that the nature of the questions we would ask were based on exactly how we
constructure our bivalent participants; the possibilities for the two-binding site
architecture is outlined in the schematic Fig 5.1. Our initial focus was to pursue
studies that would correlate with cases (3) and (4) in that diagram.

Fig 5.1 Protein domain-ligand combinations for bivalent interactions.
Reprinted by permission.
Based on the previous experience in the group, in the reported
dissertation studies we continue to rely on the extensively used technique of ITC,
which had been applied towards linear [131, 167] and macrocyclic [128, 129]
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ligands for the third PDZ domain (PDZ3) of the PSD-95. These studies benefited
greatly from the advantages of ITC, a pure solution method that provides for
each of the thermodynamic binding parameters, as well as the stoichiometry of
the interaction. We have employed the same approach to our protein domains
PDZ1, PDZ2 and PDZ1-2 tandem.
Challenging the individual PDZ1 and PDZ2 and dual domains with short
peptides derived form the C-terminal region of the domains’ natural binding
partners, we found that only one of the domains remains functional when
expressed separately. Binding of PDZ1 and tandem PDZ1-2 we were able to
characterize, whereas PDZ2, despite extensive efforts, could not be stabilized
under solution conditions to yield a valid binding curve. The PDZ1-2 dual domain
of PSD-95 therefore functions in the same manner as hypothesized for PDZ1-2
of GRIP1 [262] or PDZ4-5 of the same protein [263]. We suggest that PDZ2
induces the folding of PDZ1, stabilizing its structure. The two domains can pack
closely to each other and form a compact supramodule, which is the case in
GRIP1 [263]. Alternatively, they might be partially restrained to promote
synergistic target binding, as in the case of syntenin [176]. Our ITC data for the
binding of PDZ1-2 to natural binding partners supports the hypothesis that PDZ2
binding groove is distorted and probably cannot bind C-terminal peptides, which
is in good agreement with the published work for syntenin [169].
At the same time, in an ongoing effort to develop new cellular probes for in
vivo investigation of multiprotein assembly, we studied modified ligand CN2180
(designed and synthesized by Dr. Chamila Rupansinghe) which targets the
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tandem PDZ1-2 of PSD-95. This cyclic peptide showed striking biological activity,
which was thoroughly described in section 2.9.5.1 of Chapter 2. Our in vitro
testing by ITC of the same peptide after integrating the binding isoterm, yielded a
stoichiometry of n=2, indicating that both binding sites are fully occupied. Affinity
for the interaction is Kd1 = 6 µM and Kd2 = 9 µM, for each domain. These values
are comparable to the previously obtained result for PDZ3 (Kd1 = 8 µM), and thus
make this compound a reasonably effective inhibitor of the PSD-95 interaction
with the NMDA receptor (NMDAR).
Although two different values are obtained, the model fitting does not
differentiate between the binding sites. Although ITC is a very powerful
technique, it is often hard to deconvolute the heat signal. Therefore, based on
this data we cannot make the final determination on the precise mode of PDZ1-2
binding; this will have to await for more structural information to be obtained.
In terms of progress on that structural front, we have successfully
crystallized a new protein construct, PDZ1-2 of PSD-95. Identifying the
conditions required to grow crystals is a major step toward the goal of solving the
structure of this tandem domain by X-ray methods. Significant efforts were made
to solve the structure using the molecular replacement method, but due to
specific space group that protein crystallizes in, thus far solved models of similar
proteins could not be implemented. We are confident that producing a selenomethionine derivative of PDZ1-2 would gain a diffractable crystal and would
enable us to eventually solve the structure of the protein. Further on, these
protein crystals should be co-crystallized with ligands already tested by ITC.
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These results should be valuble in revealing the mode of protein-protein
interactions mediated by PSD-95.
5.2 Protein-Metal Interactions: Frataxin
Exploring the phenomenon of mutivalency and its possible applications,
we have looked into the nature of protein-metal interaction on the example of
frataxin binding to ferrous ion. This project provided valuable knowledge on
possibilities of ITC when analyzing more complexed interactions beyond
standard 1:1 host-ligand titration.
Iron deficiency still represents one of the medical concerns of the modern
world. It has been speculated that nearly 9 milion people are iron deficient in the
United States. Iron deficiency is associated with pregnancy problems and
impaired cognitive development in the newborns. On the other side, excess iron
(ca. ten times the nutritional need) causes severe mitochondrial dysfunction that
is associated with several prominent neurodegenerative, hematological and other
related disorder [222, 264]. Iron dysregulation is proposed to be important in the
pathophysiology of human brain diseases during Parkinson’s, FRDA, and
Alzheimer’s [222]. Another iron overload disorder, hemochromatosis leads to
severe health consequences characterized by diabetes, cirrhosis of the liver and
bronze pigmentation of the skin [222]. Therefore, a deeper understanding of iron
metabolism and characterization of proteins involved in iron homeostasis is
essential to tackle these diseases.
It has been proposed that the cellular iron metabolism can be divided into
three sequential steps. First is the synthesis of proteins that are modulated by
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iron levels in the cell. Second is the regulation of the activities of the proteins that
transport iron in and out of the cell, store cytoplasmic iron and direct iron to
various cellular compartments. Third is the compartmental trafficking of soluble
ionic iron for activation of essential cofactors. The protein that is the center of our
research efforts is implicated in the third biochemical activity.
Frataxin is a nuclear encoded protein targeted to the mitochondrial matrix.
This protein is essential for the effective regulation of cellular iron homeostasis.
Inability to produce frataxin leads to mitochondrial iron accumulation and loss of
cell viability. This results in a severe neurodegenerative disease, Friedreich’s
ataxia, that affects 1 in 50, 000 humans. Frataxin is essential for the cellular iron
control and is believed to serve as an iron chaperone that delivers mitochondrial
Fe(II) to the enzymes ferrochelatase and the ISU apparatus for completion of
heme and Fe-S cluster biosynthesis.
ITC measurements were performed to measure the metal binding affinity
and maximum metal to protein stoichiometry of monomeric yeast frataxin. The
micromolar dissociation constants measured for yeast frataxin, with respect to
ferrous iron (Kd's of 2.0 and 3.0 µM) were obtained from ITC titrations. The weak
interaction is consistent with the hypothesis of frataxin acting as an iron
chaperone. Frataxin must be able to form a favorable interface with its protein
partners and also easily release the metal. Additional structural characterization
will be critical to help elucidate how frataxin binds iron and docks with its protein
partners to promote metal delivery.
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Frataxin has been suggested to play a variety of roles in helping to
maintain cellular iron homeostasis, most of which involve direct binding to iron.
Frataxin facilitates in vivo heme and Fe-S cluster production and the monomeric
protein binds to enzyme partners that complete the assembly of these ironcontaining cofactors, suggesting monomeric protein may play a direct role in both
processes by acting as the iron chaperone [238]. Fluctuations in mitochondrial
iron or Fe-cofactor levels, and the differences in binding affinities between
partners, have been proposed to serve as the trigger for which cofactor assembly
system is delivered iron [231].
Metal binding site(s) on monomeric frataxin must accommodate the
binding of multiple iron atoms. Additional structural characterization will be critical
to help elucidate how frataxin binds iron and docks with its protein partners to
promote metal delivery.
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APPENDIX A
SINGLE AND THREE LETTER CODES FOR AMINO ACIDS
Codes
Amino acids

Single letter

Three letter

Alanine

A

Ala

Arginine

R

Arg

Asparagine

N

Asn

Aspartic acid

D

Asp

Cysteine

C

Cys

Glutamic acid

E

Glu

Glutamine

Q

Gln

Glycine

G

Gly

Histidine

H

His

Isoleucine

I

Ile

Leucine

L

Leu

Lysine

K

Lys

Methionine

M

Met

Phenylalanine

F

Phe

Proline

P

Pro

Serine

S

Ser

Threonine

T

Thr

Tryptophan

W

Trp

Tyrosine

Y

Tyr

Valine

V

Val
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APPENDIX B
GENERAL CHARACTERISTICS OF PDZ1-2 DUAL DOMAIN OF PSD-95

PDZ1-2 sequence
GSEYEEITLERGNSGLGFSIAGGTDNPHIGDDPSIFITKIIPGGAAAQDGRLRV
NDSILFVNEVDVREVTHSAAVEALKEAGSIVRLYVMRRKPPAEKVMEIKLIKG
PKGLGFSIAGGVGNQHIPGDNSIYVTKIIEGGAAHKDGRLQIGDKILAVNSVGL
EDVMHEDAVAALKNTYDVVYLKVAKPSNA
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Protein-mediated interactions that involve multiple ligands in their binding
mechanisms are critical for many cellular functions. The primary focus of this
dissertation research was to investigate such interactions for two proteins, the
PDZ domain and frataxin, involving peptide and metal binding ligands,
respectively. The three component projects of this work comprised (1)
thermodynamic analysis of PDZ domain binding using calorimetry; (2) X-ray
crystallographic structural studies of a PDZ dual domain; and (3) thermodynamic
analysis of frataxin binding to iron. The specific goal of the research conducted
with the PDZ domains was to understand the mechanism of action of
multiple/tandem protein domains. The protein chosen for study was the dual
domain PDZ1-2 of postsynaptic density-95 kDa (PSD-95) protein, a mammalian
neuronal protein. The individual constructs, PDZ1 and PDZ2, were also prepared
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for comparative studies. Challenging the individual PDZ1 and PDZ2 and dual
domains with short peptides derived form the C-terminal region of the domains’
natural binding partners (8-mer to 6-mer) sequences, it was found that only one
of the domains remains functional when expressed separately. Binding of PDZ1
and tandem PDZ1-2 could be characterized, whereas PDZ2 could not be
stabilized under solution conditions to yield a valid binding curve. The use of
bivalent peptides that would bind with 1:1 stoichiometry to the tandem PDZ1-2
domain was problematic due to ligand insolubility. In an ongoing effort to develop
new cellular probes for in vivo investigation of multiprotein assembly, we studied
modified ligand CN2180 which targets the tandem PDZ1-2 of PSD-95. Our in
vitro testing by ITC of the same peptide after integrating the binding isoterm,
yielded a stoichiometry of n=2, indicating that both binding sites are fully
occupied, and dissociation constants for each of the two interaction sites were in
the single digit micromolar range.
In terms of progress on that structural front, the dual PDZ domain protein
construct PDZ1-2 of PSD-95 was successfully crystallized. Identifying the
conditions required to grow crystals is a major step toward the goal of solving the
structure of this tandem domain by X-ray methods. Optimization of the
purification protocol resulted in high purity protein that allowed for increased
volume of protein crystallization attempts. The optimized conditions yielded wellshaped hexagonal crystals for PDZ1-2, which crystallizes in cubic P23 group.
Data reduction resulted in a Rmerge value of 11.2 %. A final structure could not be
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solved by molecular replacement methods, and additional work will be needed to
accomplish this.
In the last project, calorimetry was employed to investigate the binding of
frataxin to iron ions. This protein is essential for the effective regulation of cellular
iron homeostasis. Frataxin, is essential for cellular iron control and is believed to
serve as an iron chaperone that delivers mitochondrial Fe(II) to the enzymes
ferrochelatase and the ISU apparatus for completion of heme and Fe-S cluster
biosynthesis. Monomeric frataxin protein has a high affinity for ferrous ion,
completely saturating at 2:1 iron to protein ratio. The micromolar dissociation
constants measured for yeast frataxin, with respect to ferrous iron (Kd's of 2.0
and 3.0 µM) were obtained from calorimetric titrations. The weak interaction is
consistent with the hypothesis of frataxin acting as an iron chaperone. Frataxin
must be able to form a favorable interface with its protein partners and also easily
release the metal. Although this thermodynamic binding study increases
understanding of the underlying metal-binding behavior, additional structural
characterization will be critical to help elucidate how frataxin binds iron and docks
with its protein partners to promote metal delivery.
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